Axomadol    B-Diol114835980

Fusidic    B-Diol114835980
acid    I-Diol114835980
is    O
a    O
steroid    O
antibiotic    O
that    O
is    O
often    O
used    O
topically    O
in    O
creams    O
and    O
eyedrops    O
but    O
may    O
also    O
be    O
given    O
systemically    O
as    O
tablets    O
or    O
injections    O
.    O

The    O
company    O
launched    O
Fucidin    B-Diol114835980
to    O
be    O
used    O
to    O
treat    O
staphylococcus    O
infections    O

After    O
her    O
successful    O
publications    O
,    O
Barber    O
was    O
hired    O
by    O
the    O
Medical    O
Research    O
Council    O
to    O
study    O
semisynthetic    O
penicillin    O
,    O
cephalosporin    O
,    O
fucidin    B-Diol114835980
,    O
lincomycin    O
,    O
and    O
pristinamycin    O
.    O

Methicillin    O
-    O
resistant    O
Staphylococcus    O
aureus    O
infections    O
may    O
be    O
treated    O
with    O
a    O
combination    O
therapy    O
of    O
fusidic    B-Diol114835980
acid    I-Diol114835980
and    O
rifampicin    O
.    O

This    O
hepoxilin    O
is    O
esterified    O
to    O
sphinganine    B-Diol114835980
in    O
a    O
lipid    O
complex    O
termed    O
EOS    O
(    O
i.e.    O
esterified    O
omega    O
-    O
hydroxyacyl    O
-    O
sphingosine    O
,    O
see    O
Lipoxygenase#Biological    O
function    O
and    O
classification#Human    O
lipoxygenases    O
)    O
that    O
also    O
contains    O
a    O
very    O
long    O
chain    O
fatty    O
acid    O
.    O

PAP    O
is    O
downregulated    O
by    O
sphingosine    B-Diol114835980
and    O
dihydrosphingosine    B-Diol114835980
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
(    O
R)-pantothenate    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
(R)-pantoate    B-Diol114835980
and    O
beta    O
-    O
alanine    O
.    O

Caldarchaeol    B-Diol114835980

:    O
C04AD02    O
Xantinol    B-Diol114835980
nicotinate    I-Diol114835980

Humectants    O
used    O
in    O
cosmetics    O
include    O
triethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
tripropylene    O
glycol    O
,    O
propylene    O
glycol    O
,    O
and    O
PPGs    O
.    O

Triethylene    O
glycol    O
dinitrate    O
(    O
TEGDN    O
)    O
is    O
a    O
nitrated    O
alcohol    O
ester    O
of    O
triethylene    B-Diol114835980
glycol    I-Diol114835980
.    O

Rifaximin    B-Diol114835980
,    O
sold    O
under    O
the    O
trade    O
name    O
Xifaxan    B-Diol114835980
among    O
others    O
,    O
is    O
an    O
antibiotic    O
used    O
to    O
treat    O
traveler    O
's    O
diarrhea    O
,    O
irritable    O
bowel    O
syndrome    O
,    O
and    O
hepatic    O
encephalopathy    O
.    O

Rifaximin    B-Diol114835980
may    O
also    O
be    O
useful    O
.    O

Rifaximin    B-Diol114835980
is    O
approved    O
in    O
the    O
U.S.    O
for    O
treatment    O
of    O
TD    O
caused    O
by    O
ETEC    O
.    O

Typical    O
polyols    O
used    O
are    O
polyethylene    O
adipate    O
(    O
a    O
polyester    O
)    O
and    O
poly(tetramethylene    B-Diol114835980
ether)    I-Diol114835980
glycol    I-Diol114835980
(    O
a    O
polyether    O
)    O
.    O

Other    O
block    O
copolymers    O
also    O
show    O
the    O
shape    O
-    O
memory    O
effect    O
,    O
such    O
as    O
,    O
block    O
copolymer    O
of    O
polyethylene    O
terephthalate    O
(    O
PET    O
)    O
and    O
polyethyleneoxide    B-Diol114835980
(    O
PEO    O
)    O
,    O
block    O
copolymers    O
containing    O
polystyrene    O
and    O
poly(1,4-butadiene    O
)    O
,    O
and    O
an    O
ABA    O
triblock    O
copolymer    O
made    O
from    O
poly(2-methyl-2-oxazoline    O
)    O
and    O
polytetrahydrofuran    B-Diol114835980
.    O

Probiotics    O
have    O
been    O
hypothesized    O
to    O
have    O
therapeutic    O
effects    O
for    O
those    O
affected    O
by    O
acne    O
due    O
to    O
their    O
ability    O
to    O
decrease    O
skin    O
inflammation    O
and    O
improve    O
skin    O
moisture    O
by    O
increasing    O
the    O
skin    O
's    O
ceramide    B-Diol114835980
content    O
.    O

These    O
include    O
several    O
homologs    O
of    O
oxysterol    O
binding    O
protein    O
(    O
OSBP    O
,    O
both    O
in    O
humans    O
and    O
in    O
baker    O
's    O
yeast    O
,    O
as    O
well    O
as    O
ceramide    B-Diol114835980
transfer    O
protein    O
(    O
CERT    O
)    O
-    O
previously    O
known    O
as    O
Goodpasture    O
's    O
antigen    O
binding    O
protein    O
(    O
GPBP    O
)    O
or    O
Collagen    O
type    O
IV    O
alpha-3-binding    O
protein    O
(    O
COL4A3BP    O
)    O
,    O
and    O
Nir2/RdgB.    O
The    O
significance    O
of    O
this    O
was    O
enhanced    O
by    O
the    O
linked    O
finding    O
in    O
a    O
proteomics    O
study    O
published    O
in    O
Nature    O
(    O
journal    O
)    O
,    O
where    O
all    O
three    O
of    O
proteins    O
in    O
baker    O
's    O
yeast    O
with    O
FFAT    O
motifs    O
(    O
Osh1/Swh1    O
,    O
Osh2    O
and    O
Opi1    O
)    O
were    O
in    O
protein    O
complexes    O
that    O
contain    O
Scs2    O
,    O
the    O
baker    O
's    O
yeast    O
homolog    O
of    O
VAPA    O
and    O
VAPB    O
.    O

CerS4    O
synthesizes    O
ceramides    B-Diol114835980
containing    O
C18    O
-    O
22    O
fatty    O
acids    O
in    O
a    O
fumonisin    O
B1-independent    O
manner    O
.    O

CerS5    O
robustly    O
synthesizes    O
ceramide    B-Diol114835980
,    O
which    O
is    O
often    O
considered    O
to    O
be    O
an    O
important    O
pro    O
-    O
apoptotic    O
ceramide    O
.    O

Instead    O
,    O
IMTG    O
metabolites    O
,    O
such    O
as    O
diacylglycerol    O
and    O
ceramide    B-Diol114835980
are    O
responsible    O
for    O
the    O
insulin    O
resistance    O
.    O

A    O
ganglioside    O
is    O
a    O
molecule    O
composed    O
of    O
a    O
glycosphingolipid    O
(    O
ceramide    B-Diol114835980
and    O
oligosaccharide    O
)    O
with    O
one    O
or    O
more    O
sialic    O
acids    O
(    O
e.g.    O
n    O
-    O
acetylneuraminic    O
acid    O
,    O
NANA    O
)    O
linked    O
on    O
the    O
sugar    O
chain    O
.    O

Based    O
on    O
the    O
research    O
of    O
Peter    O
M.    O
Elias    O
it    O
is    O
made    O
up    O
of    O
ceramide    B-Diol114835980
,    O
free    O
fatty    O
acids    O
and    O
cholesterol    O
,    O
and    O
is    O
designed    O
to    O
treat    O
atopic    O
dermatitis    O
,    O
a    O
type    O
of    O
eczema    O
.    O

The    O
ceramide    B-Diol114835980
-    O
dominant    O
,    O
physiological    O
-    O
lipid    O
based    O
formulation    O
could    O
represent    O
an    O
effective    O
stand    O
-    O
alone    O
or    O
ancillary    O
therapy    O
for    O
many    O
pediatric    O
patients    O
with    O
atopic    O
dermatitis    O
.    O

The    O
stratum    O
corneum    O
is    O
primarily    O
composed    O
of    O
lipophilic    O
cholesterol    O
,    O
cholesterol    O
esters    O
and    O
ceramide    B-Diol114835980
.    O

It    O
is    O
unclear    O
if    O
moisturizers    O
that    O
contain    O
ceramide    B-Diol114835980
are    O
more    O
or    O
less    O
effective    O
than    O
others    O
.    O

For    O
example    O
glycosphingolipids    O
become    O
ceramides    B-Diol114835980
and    O
phospholipids    O
become    O
free    O
fatty    O
acids    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ceramide    B-Diol114835980
and    O
phosphatidylcholine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
sphingomyelin    O
and    O
1,2-diacyl    O
-    O
sn    O
-    O
glycerol    O
.    O

Sphingosine    O
(    O
e.g.    O
sphingomyelin    O
and    O
ceramide    B-Diol114835980
)    O
.    O

Entecavir    B-Diol114835980

Entecavir    B-Diol114835980
,    O
also    O
called    O
ETV    O
,    O
is    O
a    O
guanosine    O
analog    O
used    O
for    O
hepatitis    O
B    O
under    O
the    O
trade    O
name    O
Baraclude    O
.    O

Guanosine    O
analogues    O
:    O
abacavir    O
(    O
ABC    O
)    O
and    O
entecavir    B-Diol114835980
(    O
ETV    O
)    O

Anabolic    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
use    O
can    O
also    O
increase    O
the    O
amount    O
of    O
RBCs    O
and    O
,    O
therefore    O
,    O
impact    O
the    O
hematocrit    O
,    O
in    O
particular    O
the    O
compounds    O
boldenone    O
and    O
oxymetholone    B-Diol114835980
.    O

Oxymetholone    B-Diol114835980

Oxymetholone    B-Diol114835980

There    O
are    O
two    O
chemotypes    O
in    O
"    O
S.    O
chartarum    O
"    O
,    O
one    O
that    O
produce    O
trichothecene    O
mycotoxins    O
including    O
satratoxin    B-Diol114835980
and    O
one    O
that    O
produce    O
atranones    O
.    O

Aplysiatoxin    B-Diol114835980
is    O
a    O
cyanotoxin    O
produced    O
by    O
certain    O
cyanobacteria    O
species    O
.    O

2,3-Butanediol    B-Diol114835980
is    O
a    O
organic    O
compound    O
with    O
the    O
formula    O
is    O
(    O
CH3)2(CHOH)2    O
.    O

2,3-Butanediol    B-Diol114835980

Absinthin    B-Diol114835980
is    O
a    O
naturally    O
produced    O
triterpene    O
lactone    O
from    O
the    O
plant    O
"    O
Artemisia    O
absinthium    O
"    O
(    O
Wormwood    O
)    O
.    O

Examples    O
of    O
amphenicols    O
include    O
chloramphenicol    O
,    O
thiamphenicol    B-Diol114835980
,    O
azidamfenicol    B-Diol114835980
and    O
florfenicol    O
.    O

Melzer's    B-Diol114835980
reagent    I-Diol114835980
(    O
also    O
known    O
as    O
Melzer's    B-Diol114835980
solution    I-Diol114835980
or    O
informally    O
as    O
Melzer's    B-Diol114835980
)    O
is    O
a    O
chemical    O
reagent    O
used    O
by    O
mycologists    O
to    O
assist    O
with    O
the    O
identification    O
of    O
fungi    O
.    O

The    O
basidiospores    O
generally    O
have    O
ellipsoidal    O
,    O
spindle    O
-    O
like    O
(    O
fusiform    O
)    O
,    O
cylindrical    O
,    O
or    O
tear    O
-    O
drop    O
(    O
lacrimiform    O
)    O
shapes    O
;    O
they    O
are    O
thin    O
-    O
walled    O
,    O
hyaline    O
,    O
and    O
do    O
not    O
react    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
.    O

They    O
are    O
nonamyloid    O
,    O
meaning    O
they    O
do    O
not    O
take    O
up    O
iodine    O
when    O
stained    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
.    O

The    O
spores    O
are    O
7–9    O
by    O
5–6.5    O
μm    O
,    O
broadly    O
ellipsoid    O
,    O
smooth    O
,    O
and    O
strongly    O
amyloid    O
(    O
it    O
turns    O
black    O
when    O
treated    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
)    O
.    O

The    O
spores    O
are    O
broadly    O
ellipsoid    O
,    O
amyloid    O
(    O
meaning    O
they    O
will    O
adsorb    O
iodine    O
when    O
stained    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
)    O
,    O
and    O
measure    O
7–10    O
by    O
4–6    O
μm    O
.    O

When    O
stained    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
,    O
the    O
spores    O
turn    O
a    O
light    O
blue    O
color    O
.    O

Clitocybula    O
"    O
spores    O
are    O
smooth    O
,    O
ellipsoid    O
to    O
roughly    O
spherical    O
in    O
shape    O
,    O
hyaline    O
(    O
translucent    O
)    O
,    O
and    O
mostly    O
amyloid    O
(    O
staining    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
)    O
.    O

The    O
spores    O
of    O
"    O
Bjerkandera    O
"    O
are    O
smooth    O
with    O
a    O
short    O
cylindrical    O
shape    O
,    O
thin    O
-    O
walled    O
,    O
and    O
do    O
not    O
react    O
in    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
.    O

Spores    O
are    O
small    O
and    O
smooth    O
,    O
and    O
non    O
-    O
reactive    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
(    O
non    O
-    O
amyloid    O
)    O
.    O

Viewed    O
with    O
a    O
light    O
microscope    O
,    O
the    O
basidiospores    O
are    O
8–10.5    O
by    O
4.5–5.5    O
µm    O
,    O
ellipsoid    O
,    O
smooth    O
,    O
and    O
yellowish    O
in    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
.    O

The    O
spore    O
surface    O
is    O
covered    O
with    O
an    O
almost    O
complete    O
reticulum    O
with    O
narrow    O
ridges    O
up    O
to    O
about    O
1    O
µm    O
high    O
,    O
and    O
irregular    O
warts    O
that    O
stain    O
amyloid    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
.    O

The    O
spores    O
are    O
non    O
-    O
amyloid    O
—    O
unable    O
to    O
take    O
up    O
iodine    O
stain    O
in    O
the    O
chemical    O
test    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
.    O

The    O
genus    O
is    O
otherwise    O
quite    O
variable    O
morphologically    O
;    O
for    O
example    O
,    O
spores    O
range    O
from    O
allantoid    O
(    O
sausage    O
-    O
shaped    O
)    O
to    O
spherical    O
,    O
the    O
surface    O
ornamentation    O
ranges    O
from    O
warted    O
to    O
smooth    O
,    O
and    O
reaction    O
with    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
can    O
be    O
amyloid    O
or    O
inamyloid    O
.    O

They    O
have    O
an    O
apical    O
apparatus    O
(    O
a    O
region    O
at    O
the    O
ascus    O
tip    O
that    O
forms    O
the    O
spore    O
-    O
shooting    O
mechanism    O
)    O
that    O
stains    O
blue    O
in    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
.    O

They    O
are    O
non    O
-    O
amyloid    O
(    O
not    O
taking    O
up    O
iodine    B-Diol114835980
stain    I-Diol114835980
)    O
,    O
and    O
hyaline    O
(    O
translucent    O
)    O
,    O
with    O
dimensions    O
of    O
22–37    O
by    O
10–15    O
µm    O
.    O

The    O
spores    O
are    O
acyanophilous    O
and    O
strongly    O
amyloid    O
,    O
meaning    O
they    O
stain    O
with    O
Methyl    O
blue    O
and    O
Melzer's    B-Diol114835980
reagent    I-Diol114835980
,    O
respectively    O
.    O

Probably    O
the    O
most    O
important    O
chemical    O
compound    O
within    O
hops    O
are    O
the    O
alpha    O
acids    O
or    O
humulones.    B-Diol114835980

Humulone    B-Diol114835980
(    O
α-lupulic    B-Diol114835980
acid    I-Diol114835980
)    O
,    O
a    O
vinylogous    O
type    O
of    O
organic    O
acid    O
,    O
is    O
a    O
bitter    O
-    O
tasting    O
chemical    O
compound    O
found    O
in    O
the    O
resin    O
of    O
mature    O
hops    O
(    O
"    O
Humulus    O
lupulus    O
"    O
)    O
.    O

1%    O
)    O
in    O
the    O
production    O
of    O
cyclohexanedimethanol    B-Diol114835980
,    O
a    O
commodity    O
chemical    O
,    O
during    O
hydrogenation    O
of    O
dimethyl    O
terephthalate    O
.    O

The    O
closely    O
related    O
compound    O
cyclohexanedimethanol    B-Diol114835980
(    O
CAS    O
105    O
-    O
08    O
-    O
8    O
)    O
exhibits    O
low    O
toxicity    O
(    O
3.5    O
g    O
/    O
kg    O
)    O
when    O
fed    O
orally    O
to    O
rats    O
.    O

The    O
only    O
approved    O
medicine    O
to    O
treat    O
EPP    O
is    O
afamelanotide    B-Diol114835980
,    O
developed    O
by    O
Australian    O
-    O
based    O
Clinuvel    O
Pharmaceuticals    O
and    O
approved    O
by    O
the    O
European    O
Commission    O
in    O
December    O
2014    O
for    O
treatment    O
or    O
prevention    O
of    O
phototoxicity    O
in    O
adult    O
patients    O
with    O
EPP    O
.    O

In    O
December    O
2014    O
,    O
afamelanotide    B-Diol114835980
received    O
authorization    O
from    O
the    O
European    O
Commission    O
as    O
a    O
treatment    O
for    O
the    O
prevention    O
of    O
phototoxicity    O
in    O
adult    O
patients    O
with    O
EPP    O
.    O

Afamelanotide    B-Diol114835980

Final    O
products    O
contain    O
20%    O
propylene    O
glycol    O
,    O
1.5%    O
of    O
dipropylene    B-Diol114835980
glycol    I-Diol114835980
and    O
small    O
amounts    O
of    O
other    O
polypropylene    O
glycols    O
.    O

Dipropylene    B-Diol114835980
glycol    I-Diol114835980

2-Methyl-2,4-pentanediol    B-Diol114835980
(    O
MPD    O
)    O

1,4-butanediol    O
and    O
1,5-pentanediol    B-Diol114835980
are    O
important    O
precursors    O
to    O
polyurethanes    O
.    O

The    O
production    O
plant    O
seems    O
to    O
have    O
intended    O
to    O
cut    O
costs    O
by    O
replacing    O
less    O
toxic    O
1,5-pentanediol    B-Diol114835980
with    O
1,4-butanediol    O
.    O

Well    O
-    O
known    O
terpenoids    O
include    O
citral    O
,    O
menthol    O
,    O
camphor    O
,    O
salvinorin    O
A    O
in    O
the    O
plant    O
"    O
Salvia    O
divinorum    O
"    O
,    O
the    O
cannabinoids    O
found    O
in    O
cannabis    O
,    O
ginkgolide    O
and    O
bilobalide    B-Diol114835980
found    O
in    O
"    O
Ginkgo    O
biloba    O
"    O
,    O
and    O
the    O
curcuminoids    O
found    O
in    O
turmeric    O
and    O
mustard    O
seed    O
.    O

any    O
compound    O
(    O
not    O
being    O
Trilostane    B-Diol114835980
or    O
a    O
compound    O
for    O
the    O
time    O
being    O
specified    O
in    O
sub    O
-    O
paragraph    O
(    O
b    O
)    O
above    O
)    O
structurally    O
derived    O
from    O
17-hydroxyandrostan-3-one    O
or    O
from    O
17-hydroxyestran-3-one    O
by    O
modification    O
in    O
any    O
of    O
the    O
following    O
ways    O
,    O
that    O
is    O
to    O
say    O
,    O

3β-HSD    O
is    O
potently    O
inhibited    O
by    O
azastene    O
,    O
cyanoketone    O
,    O
epostane    O
,    O
and    O
trilostane    B-Diol114835980
.    O

Ixempra    O
(    O
ixabepilone    B-Diol114835980
)    O

Notable    O
examples    O
of    O
this    O
strategy    O
are    O
the    O
potential    O
drug    O
ixabepilone    B-Diol114835980
which    O
is    O
an    O
analogue    O
of    O
the    O
natural    O
product    O
epothilone    O
B    O
and    O
carfilzomib    O
which    O
is    O
derived    O
from    O
epoxomicin    O
and    O
eravacycline    O
derived    O
from    O
tetracycline    O
.    O

Sylimarin    B-Diol114835980
has    O
been    O
investigated    O
as    O
a    O
possible    O
treatment    O
,    O
with    O
ambiguous    O
results    O
.    O

Traditional    O
milk    O
thistle    O
extract    O
is    O
made    O
from    O
the    O
seeds    O
,    O
which    O
contain    O
approximately    O
4–6%    O
silymarin    B-Diol114835980
.    O

Silibinin    B-Diol114835980
,    O
a    O
semipurified    O
fraction    O
of    O
silymarin    O
,    O
is    O
primarily    O
a    O
mixture    O
of    O
2    O
diastereoisomers    O
,    O
silybin    O
A    O
and    O
silybin    O
B    O
,    O
in    O
a    O
roughly    O
1:1    O
ratio    O
.    O

Silibinin    B-Diol114835980
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
O    O
-    O
demethylpuromycin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
puromycin    B-Diol114835980
.    O

The    O
process    O
results    O
in    O
translated    O
peptides    O
or    O
proteins    O
that    O
are    O
associated    O
with    O
their    O
mRNA    O
progenitor    O
via    O
a    O
puromycin    B-Diol114835980
linkage    O
.    O

Puromycin    B-Diol114835980
is    O
an    O
analogue    O
of    O
the    O
3’    O
end    O
of    O
a    O
tyrosyl    O
-    O
tRNA    O
with    O
a    O
part    O
of    O
its    O
structure    O
mimics    O
a    O
molecule    O
of    O
adenosine    O
,    O
and    O
the    O
other    O
part    O
mimics    O
a    O
molecule    O
of    O
tyrosine    O
.    O

Another    O
theoretical    O
interaction    O
is    O
with    O
drugs    O
with    O
affinity    O
to    O
the    O
transporter    O
protein    O
ABCG2    O
(    O
also    O
known    O
as    O
BCRP    O
)    O
,    O
such    O
as    O
pitavastatin    B-Diol114835980
,    O
pravastatin    O
,    O
ciprofloxacin    O
,    O
methotrexat    O
,    O
and    O
diclofenac    O
;    O
a    O
study    O
with    O
the    O
latter    O
has    O
shown    O
no    O
clinical    O
relevance    O
.    O

Cytosolic    O
Glycerol-3-phosphate    O
dehydrogenase    O
(    O
GPD1    O
)    O
,    O
is    O
an    O
NAD+-dependent    O
enzyme    O
that    O
reduces    O
dihydroxyacetone    O
phosphate    O
to    O
glycerol-3-phosphate    B-Diol114835980
.    O

Mitochondrial    O
glycerol-3-phosphate    O
dehydrogenase    O
(    O
GPD2    O
)    O
,    O
catalyzes    O
the    O
irreversible    O
oxidation    O
of    O
glycerol-3-phosphate    B-Diol114835980
to    O
dihydroxyacetone    O
phosphate    O
and    O
concomitantly    O
transfers    O
two    O
electrons    O
from    O
FAD    O
to    O
the    O
electron    O
transport    O
chain    O
.    O

Oxidation    O
of    O
cytoplasmic    O
NADH    O
by    O
the    O
cytosolic    O
form    O
of    O
the    O
enzyme    O
creates    O
glycerol-3-phosphate    B-Diol114835980
from    O
dihydroxyacetone    O
phosphate    O
.    O

substrate    O
pages    O
:    O
glycerol    B-Diol114835980
3-phosphate    I-Diol114835980
,    O
dihydroxyacetone    O
phosphate    O

(    O
D    O
)    O
glycerol    O
pathway    O
reducing    O
DHAP    O
to    O
glycerol-3-phosphate    B-Diol114835980
(    O
G3P    O
)    O
by    O
G3P    O
dehydrogenase    O
,    O
followed    O
by    O
dephosphorylation    O
to    O
glycerol    O
by    O
G3Pase    O
.    O
(    O
E    O
)    O
The    O
lower    O
part    O
of    O
glycolysis    O
converts    O
GAP    O
to    O
pyruvate    O
while    O
generating    O
1    O
NADH    O
and    O
2    O
ATP    O
via    O
a    O
series    O
of    O
5    O
enzymes    O
.    O

The    O
mechanism    O
of    O
action    O
by    O
which    O
salinomycin    O
kills    O
cancer    O
stem    O
cells    O
specifically    O
remains    O
unknown    O
,    O
but    O
is    O
thought    O
to    O
be    O
due    O
to    O
its    O
action    O
as    O
a    O
potassium    O
ionophore    O
due    O
to    O
the    O
detection    O
of    O
nigericin    B-Diol114835980
in    O
the    O
same    O
compound    O
screen    O
.    O

The    O
Nigericin    B-Diol114835980
(    O
Nigericin    O
)    O
Family    O

Nidoflor    O
(    O
cream    O
,    O
combined    O
with    O
neomycin    O
sulfate    O
and    O
triamcinolone    B-Diol114835980
acetonide    I-Diol114835980
)    O

Animax    O
(    O
veterinary    O
topical    O
ointment    O
or    O
cream    O
;    O
combined    O
with    O
neomycin    O
sulfate    O
,    O
thiostrepton    O
and    O
triamcinolone    B-Diol114835980
acetonide    I-Diol114835980
)    O

Amcinonide    O
,    O
budesonide    B-Diol114835980
,    O
desonide    O
,    O
fluocinolone    O
acetonide    O
,    O
fluocinonide    O
,    O
halcinonide    O
,    O
and    O
triamcinolone    B-Diol114835980
acetonide    I-Diol114835980
.    O

Triamcinolone    B-Diol114835980
acetonide    I-Diol114835980

It    O
is    O
injected    O
into    O
the    O
heel    O
when    O
treating    O
plantar    O
fasciitis    O
,    O
sometimes    O
in    O
conjunction    O
with    O
triamcinolone    B-Diol114835980
acetonide    I-Diol114835980
.    O

Additionally    O
,    O
intralesional    O
injection    O
with    O
a    O
corticosteroid    O
such    O
as    O
Kenalog    B-Diol114835980
does    O
appear    O
to    O
aid    O
in    O
the    O
reduction    O
of    O
inflammation    O
and    O
pruritus    O
.    O

Etohexadiol    B-Diol114835980
(    O
or    O
ethohexadiol    B-Diol114835980
)    O
is    O
an    O
ectoparasiticide    O
.    O

1,2-Butanediol    B-Diol114835980

Oleandrin    B-Diol114835980
,    O
one    O
of    O
the    O
toxins    O
present    O
in    O
oleander    O
.    O

Scilliroside    O
and    O
other    O
cardiac    O
glycosides    O
like    O
oleandrin    B-Diol114835980

Examples    O
of    O
diterpenes    O
and    O
diterpenoids    O
are    O
cafestol    B-Diol114835980
,    O
kahweol    B-Diol114835980
,    O
cembrene    O
and    O
taxadiene    O
(    O
precursor    O
of    O
taxol    O
)    O
.    O

iopydol    B-Diol114835980
(    O
INN    O
)    O

Zeaxanthin    O
is    O
epoxidized    O
to    O
form    O
violaxanthin    B-Diol114835980
or    O
neoxanthin    O
.    O

Eustigmatophytes    O
contain    O
one    O
or    O
more    O
yellow    O
-    O
green    O
chloroplasts    O
,    O
which    O
contain    O
chlorophyll    O
a    O
and    O
the    O
accessory    O
pigments    O
violaxanthin    B-Diol114835980
and    O
β-carotene    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
N7-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
2'-O    O
-    O
methylguanosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
containing    O
uridine    O
at    O
position    O
54    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
ribothymidine    O
at    O
position    O
54    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
L    O
-    O
tryptophan    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
L-2-methyltryptophan    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tyramine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
N    O
-    O
methyltyramine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
vitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
7-O    O
-    O
methylvitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
xanthotoxol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
O    O
-    O
methylxanthotoxol    O
.    O

A    O
SAM    B-Diol114835980
-    O
dependent    O
"    O
N    O
"-    O
methylation    O
of    O
putrescine    O
gives    O
the    O
"    O
N    O
"-    O
methylputrescine    O
product    O
,    O
which    O
then    O
undergoes    O
oxidative    O
deamination    O
by    O
the    O
action    O
of    O
diamine    O
oxidase    O
to    O
yield    O
the    O
aminoaldehyde    O
.    O

S-Adenosyl    B-Diol114835980
methionine    I-Diol114835980
(    O
SAM    O
)    O
can    O
act    O
as    O
a    O
catalyst    O
for    O
the    O
transfer    O
of    O
methyl    O
group    O
from    O
the    O
sulfonium    O
compound    O
to    O
nucleophile    O
.    O

Vitamin    B-Diol114835980
B12    I-Diol114835980
,    O
or    O
cobalamin    O
,    O
acts    O
as    O
a    O
cofactor    O
for    O
the    O
enzyme    O
methionine    O
synthase    O
(    O
which    O
forms    O
part    O
of    O
the    O
S-adenosylmethionine    B-Diol114835980
(    O
SAMe    O
)    O
biosynthesis    O
and    O
regeneration    O
cycle    O
)    O
.    O

S-Adenosyl    B-Diol114835980
methionine    I-Diol114835980
(    O
SAMe    O
)    O
is    O
available    O
as    O
a    O
prescription    O
antidepressant    O
in    O
Europe    O
and    O
an    O
over    O
-    O
the    O
-    O
counter    O
dietary    O
supplement    O
in    O
the    O
US    O
.    O

One    O
review    O
claimed    O
benefit    O
for    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
in    O
disease    O
models    O
.    O

The    O
alkaloid    O
berberine    O
has    O
a    O
tetracyclic    O
skeleton    O
derived    O
from    O
a    O
benzyltetrahydroisoquinoline    O
system    O
with    O
the    O
incorporation    O
of    O
an    O
extra    O
carbon    O
atom    O
provided    O
by    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
(    O
SAM    O
)    O
via    O
an    O
"    O
N    O
"-    O
methyl    O
group    O
.    O

After    O
oxidation    O
and    O
methylation    O
by    O
SAM    B-Diol114835980
,    O
(    O
"    O
S")-reticuline    O
4    O
is    O
formed    O
.    O

Histamine    O
N    O
-    O
methyltransferase    O
catalyzes    O
the    O
methylation    O
of    O
histamine    O
in    O
the    O
presence    O
of    O
S-adenosylmethionine    B-Diol114835980
(    O
SAM    O
)    O
forming    O
N    O
-    O
methylhistamine    O
.    O

This    O
gene    O
encodes    O
the    O
first    O
enzyme    O
which    O
is    O
found    O
in    O
the    O
cytosol    O
and    O
uses    O
S-adenosyl-L-methionine    B-Diol114835980
as    O
the    O
methyl    O
donor    O
.    O

In    O
the    O
first    O
step    O
of    O
the    O
biosynthesis    O
these    O
two    O
amino    O
acids    O
are    O
combined    O
by    O
the    O
enzyme    O
arginine    O
:    O
glycine    O
amidinotransferase    O
(    O
AGAT    O
,    O
EC:2.1.4.1    O
)    O
to    O
form    O
guanidinoacetate    O
,    O
which    O
is    O
then    O
methylated    O
by    O
guanidinoacetate    O
N    O
-    O
methyltransferase    O
(    O
GAMT    O
,    O
EC:2.1.1.2    O
)    O
,    O
using    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
as    O
the    O
methyl    O
donor    O
.    O

The    O
pathway    O
for    O
the    O
synthesis    O
of    O
creatineArg    O
-    O
Arginine    O
;    O
GATM    O
-    O
Glycine    O
amidinotransferase    O
;    O
GAMT    O
-    O
Guanidinoacetate    O
N    O
-    O
methyltransferase    O
;    O
Gly    O
-    O
Glycine    O
;    O
Met    O
-    O
Methionine    O
;    O
SAH    O
-    O
S-adenosyl    B-Diol114835980
homocysteine    I-Diol114835980
;    O
SAM    O
-    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
.    O

Diphthamide    O
is    O
biosynthesized    O
from    O
histidine    O
and    O
"S"-adenosyl    B-Diol114835980
methionine    I-Diol114835980
.    O

Adequate    O
methionine    O
(    O
which    O
,    O
like    O
folate    O
,    O
must    O
otherwise    O
be    O
obtained    O
in    O
the    O
diet    O
,    O
if    O
it    O
is    O
not    O
regenerated    O
from    O
homocysteine    O
by    O
a    O
B12    O
dependent    O
reaction    O
)    O
is    O
needed    O
to    O
make    O
"S"-adenosyl    B-Diol114835980
methionine    I-Diol114835980
(    O
SAMe    O
)    O
,    O
which    O
is    O
in    O
turn    O
necessary    O
for    O
methylation    O
of    O
myelin    O
sheath    O
phospholipids    O
.    O

Vitamin    O
methylcobalamin    O
and    O
5-methyltetrahydrofolate    O
are    O
needed    O
by    O
Methionine    O
synthase    O
in    O
the    O
Methionine    O
cycle    O
to    O
transfer    O
a    O
methyl    O
group    O
from    O
5-methyltetrahydrofolate    O
to    O
homocysteine    O
,    O
thereby    O
generating    O
tetrahydrofolate    O
(    O
THF    O
)    O
and    O
methionine    O
,    O
which    O
is    O
used    O
to    O
make    O
SAMe    B-Diol114835980
.    O

SAMe    B-Diol114835980
is    O
the    O
universal    O
methyl    O
donor    O
and    O
is    O
used    O
for    O
DNA    O
methylation    O
and    O
to    O
make    O
phospholipid    O
membranes    O
,    O
choline    O
,    O
sphingomyelin    O
and    O
acetylcholine    O
and    O
other    O
neurotransmitters    O
.    O

PFL    O
activase    O
is    O
part    O
of    O
the    O
radical    O
SAM    O
(    O
S-adenosylmethionine    B-Diol114835980
)    O
superfamily    O
.    O

The    O
5    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
,    O
malonyl    O
-    O
CoA    O
,    O
NADPH    O
,    O
H+    O
,    O
and    O
S-adenosyl-L-methionine    B-Diol114835980
,    O
whereas    O
its    O
6    O
products    O
are    O
dihydromonacolin    O
L    O
,    O
CoA    O
,    O
CO2    O
,    O
NADP+    O
,    O
S-adenosyl-L-homocysteine    B-Diol114835980
,    O
and    O
H2O.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
S-adenosyl-L-methionine    B-Diol114835980
,    O
and    O
two    O
products    O
,    O
5'-methylthioadenosine    O
and    O
2-aminobutan-4-olide    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-methionine    B-Diol114835980
and    O
N6-(Delta2-isopentenyl)-adenine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
5'-methylthioadenosine    O
and    O
discadenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-methionine    B-Diol114835980
and    O
nocardicin    O
E    O
,    O
whereas    O
its    O
two    O
products    O
are    O
5'-methylthioadenosine    O
and    O
isonocardicin    O
A.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
S-adenosyl-L-methionine    B-Diol114835980
,    O
and    O
two    O
products    O
,    O
S    O
-    O
methyl-5'-thioadenosine    O
and    O
nicotianamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-methionine    B-Diol114835980
and    O
tRNA    O
uridine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
5'-methylthioadenosine    O
and    O
tRNA    O
3-(3-amino-3-carboxypropyl)-uridine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-methionine    B-Diol114835980
and    O
8-amino-7-oxononanoate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosyl-4-methylthio-2-oxobutanoate    O
and    O
7,8-diaminononanoate    O
.    O

Although    O
the    O
mechanism    O
of    O
methylation    O
of    O
arsenic    O
in    O
humans    O
has    O
not    O
been    O
elucidated    O
,    O
the    O
source    O
of    O
methyl    O
is    O
methionine    O
,    O
which    O
suggests    O
a    O
role    O
of    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
.    O

S-Adenosylmethionine    B-Diol114835980
,    O
a    O
source    O
of    O
methyl    O
groups    O
in    O
many    O
biogenic    O
arsenic    O
compounds    O
.    O

"S"-Adenosyl    B-Diol114835980
methionine    I-Diol114835980
can    O
subsequently    O
methylate    O
the    O
amine    O
of    O
phosphatidylethanolamines    O
to    O
yield    O
phosphatidylcholines    O
.    O

18-deoxy-25-demethyl    O
herboxitriene    O
is    O
then    O
epoxidized    O
by    O
enzyeme    O
HerE    O
on    O
the    O
carbon    O
carbon    O
double    O
bond    O
between    O
C14    O
and    O
C15    O
,    O
oxidized    O
by    O
enzyme    O
HerG    O
on    O
C-18    O
and    O
eventually    O
methylated    O
by    O
enzyme    O
HerF    O
on    O
C25    O
to    O
herboxidiene    O
with    O
the    O
help    O
of    O
cofactor    O
SAM    B-Diol114835980
.    O

The    O
backbone    O
is    O
synthesized    O
through    O
the    O
addition    O
of    O
two    O
carbon    O
units    O
via    O
addition    O
of    O
acetate    O
units    O
from    O
acetyl-CoA    B-Diol114835980
The    O
5    O
methyl    O
groups    O
are    O
added    O
via    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
(    O
SAM    O
)    O
methylation    O
,    O
as    O
opposed    O
to    O
incorporation    O
of    O
propionate    O
(    O
instead    O
of    O
acetate    O
)    O
to    O
the    O
growing    O
compound    O
during    O
biosynthesis    O
.    O

For    O
example    O
,    O
"S"-adenosylmethionine    B-Diol114835980
acts    O
as    O
a    O
methylating    O
agent    O
in    O
biological    O
SN2    O
reactions    O
.    O

The    O
methyl    O
groups    O
transferred    O
to    O
create    O
ADMA    O
are    O
derived    O
from    O
the    O
methyl    O
group    O
donor    O
"S"-adenosylmethionine    B-Diol114835980
,    O
an    O
intermediate    O
in    O
the    O
metabolism    O
of    O
homocysteine    O
.    O

Abbreviations    O
:    O
S-Adenosyl-L-homocysteine    B-Diol114835980
(    O
SAH    O
)    O
,    O
S-adenosyl-L-methionine    B-Diol114835980
(    O
SAM    O
)    O
,    O
DNA    O
methyltransferase    O
(    O
DNA    O
MTase    O
)    O
,    O
Uracil    O
-    O
DNA    O
glycosylase    O
(    O
UNG    O
)    O
.    O

CBS    O
uses    O
the    O
cofactor    O
pyridoxal    O
-    O
phosphate    O
(    O
PLP    O
)    O
and    O
can    O
be    O
allosterically    O
regulated    O
by    O
effectors    O
such    O
as    O
the    O
ubiquitous    O
cofactor    O
S-adenosyl-L-methionine    B-Diol114835980
(    O
adoMet    O
)    O
.    O

This    O
inhibition    O
is    O
alleviated    O
by    O
binding    O
of    O
the    O
allosteric    O
effector    O
,    O
adoMet    B-Diol114835980
,    O
or    O
by    O
deletion    O
of    O
the    O
regulatory    O
domain    O
;    O
however    O
,    O
the    O
magnitude    O
of    O
the    O
effects    O
differ    O
.    O

In    O
analogy    O
with    O
other    O
β-replacement    O
enzymes    O
,    O
the    O
reaction    O
catalyzed    O
by    O
CBS    O
is    O
predicted    O
to    O
involve    O
a    O
series    O
of    O
adoMet    B-Diol114835980
-    O
bound    O
intermediates    O
.    O

This    O
alternative    O
metabolic    O
pathway    O
is    O
also    O
dependent    O
on    O
adoMet    B-Diol114835980
.    O

Allosteric    O
activation    O
of    O
CBS    O
by    O
adoMet    B-Diol114835980
determines    O
the    O
metabolic    O
fate    O
of    O
homocysteine    O
.    O

Mammalian    O
CBS    O
is    O
activated    O
2.5    O
-    O
5-fold    O
by    O
AdoMet    O
with    O
a    O
dissociation    O
constant    O
of    O
15    O
µM.    O
AdoMet    B-Diol114835980
is    O
an    O
allosteric    O
activator    O
that    O
increases    O
the    O
Vmax    O
of    O
the    O
CBS    O
reaction    O
but    O
does    O
not    O
affect    O
the    O
Km    O
for    O
the    O
substrates    O
.    O

A    O
common    O
functional    O
feature    O
of    O
the    O
mutations    O
in    O
the    O
CBS    O
domains    O
is    O
that    O
the    O
mutations    O
abolish    O
or    O
strongly    O
reduce    O
activation    O
by    O
adoMet    B-Diol114835980
.    O

S-Adenosyl-L-methionine    B-Diol114835980

:    O
(    O
1    O
)    O
CDP-choline    B-Diol114835980
+    O
H2O    O
CMP    O
+    O
phosphocholine    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP-choline    B-Diol114835980
and    O
sphingosine    B-Diol114835980
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    O
and    O
sphingosyl    O
-    O
phosphocholine    O
.    O

Solpecainol    B-Diol114835980
is    O
an    O
anti    O
-    O
anginal    O
and    O
anti    O
-    O
arrhythmic    O
agent    O
.    O

It    O
has    O
3    O
cofactors    O
:    O
pyridoxal    O
phosphate    O
,    O
Cobamide    B-Diol114835980
coenzyme    I-Diol114835980
,    O
and    O
Dithiothreitol    B-Diol114835980
.    O

W.    O
Wallace    O
Cleland    O
,    O
University    O
of    O
Wisconsin    O
-    O
Madison    O
biochemist    O
;    O
inventor    O
of    O
Cleland's    B-Diol114835980
reagent    I-Diol114835980

dithiothreitol    B-Diol114835980
reduces    O
the    O
disulfide    O
bridges    O
of    O
proteins    O
.    O

In    O
addition    O
to    O
SDS    O
,    O
proteins    O
may    O
optionally    O
be    O
briefly    O
heated    O
to    O
near    O
boiling    O
in    O
the    O
presence    O
of    O
a    O
reducing    O
agent    O
,    O
such    O
as    O
dithiothreitol    B-Diol114835980
(DTT)    I-Diol114835980
or    O
2-mercaptoethanol    O
(    O
beta    O
-    O
mercaptoethanol    O
/    O
BME    O
)    O
,    O
which    O
further    O
denatures    O
the    O
proteins    O
by    O
reducing    O
disulfide    O
linkages    O
,    O
thus    O
overcoming    O
some    O
forms    O
of    O
tertiary    O
protein    O
folding    O
,    O
and    O
breaking    O
up    O
quaternary    O
protein    O
structure    O
(    O
oligomeric    O
subunits    O
)    O
.    O

This    O
enzyme    O
has    O
at    O
least    O
one    O
effector    O
,    O
Dithiothreitol    B-Diol114835980
.    O

idoxuridine    B-Diol114835980
(    O
INN    O
)    O

In    O
those    O
with    O
herpes    O
of    O
the    O
eye    O
,    O
aciclovir    O
may    O
be    O
more    O
effective    O
and    O
safer    O
than    O
idoxuridine    B-Diol114835980
.    O

Pyrimidine    O
analogues    O
of    O
uridine    O
:    O
Idoxuridine    B-Diol114835980
,    O
Trifluridine    B-Diol114835980

Examples    O
include    O
2-methyl-2-propyl-1,3-propanediol    O
and    O
neopentyl    B-Diol114835980
glycol    I-Diol114835980
.    O

The    O
enzyme    O
adenylosuccinate    O
synthase    O
carries    O
out    O
the    O
reaction    O
by    O
the    O
addition    O
of    O
aspartate    O
to    O
IMP    O
and    O
requires    O
the    O
input    O
of    O
energy    O
from    O
a    O
phosphoanhydride    O
bond    O
in    O
the    O
form    O
of    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
(    O
GTP    O
)    O
.    O

In    O
molecular    O
biology    O
,    O
Adenylosuccinate    O
synthase    O
(    O
or    O
adenylosuccinate    O
synthetase    O
)    O
is    O
an    O
enzyme    O
that    O
plays    O
an    O
important    O
role    O
in    O
purine    O
biosynthesis    O
,    O
by    O
catalysing    O
the    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
(    O
GTP)-dependent    O
conversion    O
of    O
inosine    B-Diol114835980
monophosphate    I-Diol114835980
(    O
IMP    O
)    O
and    O
aspartic    O
acid    O
to    O
guanosine    B-Diol114835980
diphosphate    I-Diol114835980
(    O
GDP    O
)    O
,    O
phosphate    O
and    O
N(6)-(1,2-dicarboxyethyl)-AMP    O
.    O

The    O
Gs    O
alpha    O
subunit    O
of    O
the    O
stimulated    O
G    O
protein    O
complex    O
exchanges    O
GDP    B-Diol114835980
for    O
GTP    B-Diol114835980
and    O
is    O
released    O
from    O
the    O
complex    O
.    O

It    O
also    O
allows    O
high    O
energy    O
molecules    O
to    O
form    O
;    O
3x    O
NADH    O
,    O
FADH2    O
,    O
and    O
GTP    B-Diol114835980
/    O
ATP    O
are    O
all    O
produced    O
by    O
one    O
iteration    O
of    O
the    O
cycle    O
.    O

This    O
gene    O
encodes    O
a    O
mitochondrial    O
enzyme    O
that    O
catalyzes    O
the    O
conversion    O
of    O
oxaloacetate    O
(    O
OAA    O
)    O
to    O
phosphoenolpyruvate    O
(    O
PEP    O
)    O
in    O
the    O
presence    O
of    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
(    O
GTP    O
)    O
.    O

When    O
the    O
50S    O
subunit    O
joins    O
,    O
it    O
hydrolyzes    O
GTP    B-Diol114835980
to    O
GDP    B-Diol114835980
and    O
Pi    O
,    O
causing    O
a    O
conformational    O
change    O
in    O
the    O
IF2    O
that    O
causes    O
IF2    O
to    O
release    O
and    O
allow    O
the    O
70S    O
subunit    O
to    O
form    O
.    O

The    O
biosynthesis    O
of    O
molybdopterin    O
begins    O
with    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
.    O

Substrate    O
-    O
level    O
phosphorylation    O
is    O
a    O
metabolic    O
reaction    O
that    O
results    O
in    O
the    O
formation    O
of    O
ATP    O
or    O
GTP    B-Diol114835980
by    O
the    O
direct    O
transfer    O
of    O
a    O
phosphoryl    O
(    O
PO3    O
)    O
group    O
to    O
ADP    O
or    O
GDP    B-Diol114835980
from    O
another    O
phosphorylated    O
compound    O
.    O

Their    O
work    O
revealed    O
that    O
the    O
addition    O
of    O
guanine    O
,    O
such    O
as    O
in    O
the    O
molecule    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
,    O
to    O
dopamine    O
binding    O
sites    O
could    O
increase    O
the    O
binding    O
affinity    O
of    O
the    O
D4    O
dopamine    O
receptor    O
while    O
decreasing    O
the    O
binding    O
affinity    O
of    O
the    O
D2    O
dopamine    O
receptor    O
.    O

Kinesins    O
are    O
structurally    O
related    O
to    O
G    O
proteins    O
,    O
which    O
hydrolyze    O
GTP    B-Diol114835980
instead    O
of    O
ATP    O
.    O

This    O
enables    O
EF    O
-    O
Tu    O
to    O
bind    O
to    O
a    O
new    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
molecule    O
,    O
release    O
EF    O
-    O
Ts    O
,    O
and    O
go    O
on    O
to    O
catalyze    O
another    O
aminoacyl    O
tRNA    O
addition    O
.    O

Aluminum    O
fluoride    O
complexes    O
are    O
used    O
to    O
study    O
the    O
mechanistic    O
aspects    O
of    O
phosphoryl    O
transfer    O
reactions    O
in    O
biology    O
,    O
which    O
are    O
of    O
fundamental    O
importance    O
to    O
cells    O
,    O
as    O
phosphoric    O
acid    O
anhydrides    O
such    O
as    O
ATP    O
and    O
GTP    B-Diol114835980
control    O
most    O
of    O
the    O
reactions    O
involved    O
in    O
metabolism    O
,    O
growth    O
and    O
differentiation    O
.    O

Guanosine    B-Diol114835980
triphosphate    I-Diol114835980
,    O
an    O
organic    O
chemical    O
and    O
energy    O
carrier    O

This    O
protein    O
recruits    O
a    O
small    O
GTPase    O
called    O
Sar1    O
(    O
think    O
of    O
Sar1    O
as    O
a    O
switch    O
,    O
it    O
is    O
active    O
when    O
bound    O
to    O
GTP    B-Diol114835980
and    O
inactive    O
when    O
it    O
hydrolyses    O
the    O
GTP    O
to    O
GDP    B-Diol114835980
)    O
.    O

Oxaloacetate    O
is    O
later    O
decarboxylated    O
and    O
phosphorylated    O
by    O
phosphoenolpyruvate    O
carboxykinase    O
and    O
becomes    O
2-phosphoenolpyruvate    O
using    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
(    O
GTP    O
)    O
as    O
phosphate    O
source    O
.    O

The    O
citric    O
acid    O
cycle    O
oxidizes    O
the    O
acetyl    O
-    O
CoA    O
to    O
carbon    O
dioxide    O
,    O
and    O
,    O
in    O
the    O
process    O
,    O
produces    O
reduced    O
cofactors    O
(    O
three    O
molecules    O
of    O
NADH    O
and    O
one    O
molecule    O
of    O
FADH2    O
)    O
that    O
are    O
a    O
source    O
of    O
electrons    O
for    O
the    O
"    O
electron    O
transport    O
chain    O
"    O
,    O
and    O
a    O
molecule    O
of    O
GTP    B-Diol114835980
(    O
that    O
is    O
readily    O
converted    O
to    O
an    O
ATP    O
)    O
.    O

Dock11    O
binds    O
and    O
activates    O
nucleotide    O
-    O
free    O
Cdc42    O
via    O
its    O
DHR2    O
domain    O
and    O
has    O
also    O
been    O
reported    O
to    O
mediate    O
positive    O
feedback    O
on    O
active    O
,    O
GTP    B-Diol114835980
-    O
bound    O
Cdc42    O
,    O
although    O
this    O
interaction    O
required    O
a    O
small    O
N    O
-    O
terminal    O
region    O
of    O
Dock11    O
in    O
addition    O
to    O
the    O
DHR2    O
domain    O
.    O

Furthermore    O
,    O
if    O
the    O
bound    O
AdoCbl    O
accrues    O
oxidative    O
damage    O
during    O
normal    O
functioning    O
,    O
"    O
MMAA    O
"    O
protein    O
fosters    O
exchange    O
of    O
the    O
damaged    O
cofactor    O
for    O
a    O
new    O
AdoCbl    O
via    O
a    O
GTP    B-Diol114835980
-    O
reliant    O
pathway    O
.    O

In    O
the    O
activated    O
NMBR    O
/    O
G    O
-    O
protein    O
complex    O
,    O
there    O
occurs    O
an    O
exchange    O
of    O
GTP    B-Diol114835980
for    O
GDP    B-Diol114835980
bound    O
to    O
G-α    O
subunit    O
.    O

The    O
main    O
function    O
of    O
the    O
SEC23A    O
protein    O
is    O
to    O
hydrolyze    O
or    O
break    O
down    O
a    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
(    O
GTP    O
)    O
molecule    O
bound    O
to    O
the    O
SAR1A    O
protein    O
at    O
the    O
start    O
of    O
the    O
COPII    O
pathway    O
.    O

GTP    B-Diol114835980
,    O
CTP    B-Diol114835980
,    O
and    O
UTP    B-Diol114835980
are    O
also    O
nucleotides    O
important    O
in    O
the    O
protein    O
synthesis    O
,    O
lipid    O
synthesis    O
,    O
and    O
carbohydrate    O
metabolism    O
,    O
respectively    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Diol114835980
and    O
beta    O
-    O
L    O
-    O
fucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
L    O
-    O
fucose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Diol114835980
and    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
glucose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GTP    B-Diol114835980
,    O
whereas    O
its    O
two    O
products    O
are    O
AMP    O
and    O
guanosine    O
3'-diphosphate    O
5'-triphosphate    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
GTP    B-Diol114835980
,    O
and    O
two    O
products    O
,    O
diphosphate    O
and    O
P1,P4-bis(5'-guanosyl    O
)    O
tetraphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Diol114835980
and    O
5-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Diol114835980
and    O
5-phosphonooxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Diol114835980
and    O
alpha    O
-    O
D    O
-    O
mannose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Diol114835980
and    O
(    O
5')ppPur    O
-    O
mRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
G(5')pppPur    O
-    O
mRNA    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Diol114835980
and    O
3-phospho    O
-    O
D    O
-    O
glycerate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Diol114835980
and    O
3-phospho    O
-    O
D    O
-    O
glyceroyl    O
phosphate    O
.    O

Every    O
"    O
turn    O
"    O
of    O
the    O
citric    O
acid    O
cycle    O
produces    O
two    O
molecules    O
of    O
carbon    O
dioxide    O
,    O
one    O
equivalent    O
of    O
ATP    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
(    O
GTP    O
)    O
through    O
substrate    O
-    O
level    O
phosphorylation    O
catalyzed    O
by    O
succinyl    O
-    O
CoA    O
synthetase    O
,    O
three    O
molecules    O
of    O
NADH    O
,    O
and    O
one    O
equivalent    O
of    O
FADH2    O
.    O

GTP    B-Diol114835980
.    O

Capsidiol    B-Diol114835980
is    O
a    O
terpenoid    O
compound    O
that    O
accumulates    O
in    O
tobacco    O
"    O
Nicotiana    O
tabacum    O
"    O
and    O
chili    O
pepper    O
"    O
Capsicum    O
annuum    O
"    O
in    O
response    O
to    O
fungal    O
infection    O
.    O

Other    O
members    O
of    O
this    O
class    O
have    O
entered    O
development    O
,    O
such    O
as    O
posizolid    B-Diol114835980
(    O
AZD2563    O
)    O
,    O
ranbezolid    O
(    O
RBx    O
7644    O
)    O
,    O
torezolid    O
(    O
TR-701    O
)    O
,    O
and    O
radezolid    O
(    O
RX-1741    O
)    O
.    O

The    O
yeasts    O
also    O
help    O
keep    O
levels    O
low    O
by    O
consuming    O
diacetyl    O
and    O
reducing    O
it    O
to    O
acetoin    O
and    O
butylene    B-Diol114835980
glycol    I-Diol114835980
.    O

Butanediol    B-Diol114835980
,    O
also    O
called    O
butylene    O
glycol    O
,    O
may    O
refer    O
to    O
any    O
one    O
of    O
four    O
stable    O
structural    O
isomers    O
:    O

Floctafenine    B-Diol114835980
and    O
Glafenine    B-Diol114835980
are    O
a    O
pair    O
of    O
fenamate    O
NSAIDs    O
whose    O
synthesis    O
rely    O
on    O
the    O
Gould    O
–    O
Jacobs    O
reaction    O
.    O

The    O
following    O
standard    O
prostaglandins    O
have    O
the    O
following    O
relative    O
potencies    O
in    O
binding    O
to    O
and    O
activating    O
EP1    O
:    O
PGE2≥PGE1>PGF2alpha    O
>    O
PGD2    B-Diol114835980
.    O

The    O
following    O
standard    O
prostaglandins    O
have    O
the    O
following    O
relative    O
efficacies    O
in    O
binding    O
to    O
and    O
activating    O
EP2    O
:    O
PGI2    B-Diol114835980
PGD2    B-Diol114835980
.    O

Standard    O
prostanoids    O
have    O
the    O
following    O
relative    O
efficacies    O
in    O
binding    O
to    O
and    O
activating    O
EP3    O
:    O
PGI2    B-Diol114835980
PGD2    B-Diol114835980
.    O
Prostaglandin    O
E1    O
(    O
PGE1    O
)    O
,    O
which    O
has    O
one    O
less    O
double    O
bond    O
than    O
PGE2    O
,    O

The    O
FP    O
receptor    O
is    O
the    O
least    O
selective    O
of    O
the    O
prostenoid    O
receptors    O
in    O
that    O
it    O
is    O
responsive    O
to    O
PGD2    O
and    O
to    O
a    O
lesser    O
extent    O
PGE2    O
at    O
concentrations    O
close    O
to    O
those    O
of    O
PGF2α.    O
Standard    O
prostanoids    O
have    O
the    O
following    O
relative    O
efficacies    O
as    O
receptor    O
ligands    O
in    O
binding    O
to    O
and    O
activating    O
FP    O
:    O
PGD2    B-Diol114835980
PGE2    B-Diol114835980
PGI2    B-Diol114835980
.    O

Standard    O
prostanoids    O
have    O
the    O
following    O
relative    O
efficacies    O
as    O
receptor    O
ligands    O
in    O
binding    O
to    O
and    O
activating    O
IP    O
:    O
PGD2    B-Diol114835980
PGE2    B-Diol114835980
.    O

If    O
the    O
correct    O
anticodon    O
binds    O
to    O
the    O
mRNA    O
codon    O
,    O
the    O
ribosome    O
changes    O
configuration    O
and    O
alters    O
the    O
geometry    O
of    O
the    O
GTPase    O
domain    O
of    O
EF    O
-    O
Tu    O
,    O
resulting    O
in    O
the    O
hydrolysis    O
of    O
the    O
GTP    O
associated    O
with    O
the    O
EF    O
-    O
Tu    O
to    O
GDP    B-Diol114835980
and    O
Pi    O
.    O

In    O
molecular    O
biology    O
,    O
Adenylosuccinate    O
synthase    O
(    O
or    O
adenylosuccinate    O
synthetase    O
)    O
is    O
an    O
enzyme    O
that    O
plays    O
an    O
important    O
role    O
in    O
purine    O
biosynthesis    O
,    O
by    O
catalysing    O
the    O
guanosine    B-Diol114835980
triphosphate    I-Diol114835980
(    O
GTP)-dependent    O
conversion    O
of    O
inosine    B-Diol114835980
monophosphate    I-Diol114835980
(    O
IMP    O
)    O
and    O
aspartic    O
acid    O
to    O
guanosine    B-Diol114835980
diphosphate    I-Diol114835980
(    O
GDP    O
)    O
,    O
phosphate    O
and    O
N(6)-(1,2-dicarboxyethyl)-AMP    O
.    O

In    O
an    O
example    O
of    O
feedback    O
inhibition    O
,    O
ATase    O
is    O
inhibited    O
mainly    O
by    O
the    O
end    O
-    O
products    O
of    O
the    O
purine    O
synthesis    O
pathway    O
,    O
AMP    O
,    O
GMP    B-Diol114835980
,    O
ADP    O
,    O
and    O
GDP    B-Diol114835980
.    O

The    O
Gs    O
alpha    O
subunit    O
of    O
the    O
stimulated    O
G    O
protein    O
complex    O
exchanges    O
GDP    B-Diol114835980
for    O
GTP    B-Diol114835980
and    O
is    O
released    O
from    O
the    O
complex    O
.    O

When    O
the    O
50S    O
subunit    O
joins    O
,    O
it    O
hydrolyzes    O
GTP    B-Diol114835980
to    O
GDP    B-Diol114835980
and    O
Pi    O
,    O
causing    O
a    O
conformational    O
change    O
in    O
the    O
IF2    O
that    O
causes    O
IF2    O
to    O
release    O
and    O
allow    O
the    O
70S    O
subunit    O
to    O
form    O
.    O

Substrate    O
-    O
level    O
phosphorylation    O
is    O
a    O
metabolic    O
reaction    O
that    O
results    O
in    O
the    O
formation    O
of    O
ATP    O
or    O
GTP    B-Diol114835980
by    O
the    O
direct    O
transfer    O
of    O
a    O
phosphoryl    O
(    O
PO3    O
)    O
group    O
to    O
ADP    O
or    O
GDP    B-Diol114835980
from    O
another    O
phosphorylated    O
compound    O
.    O

EF    O
-    O
Ts    O
serves    O
as    O
the    O
guanine    O
nucleotide    O
exchange    O
factor    O
for    O
EF    O
-    O
Tu    O
(    O
elongation    O
factor    O
thermo    O
unstable    O
)    O
,    O
catalyzing    O
the    O
release    O
of    O
guanosine    B-Diol114835980
diphosphate    I-Diol114835980
from    O
EF    O
-    O
Tu    O
.    O

This    O
protein    O
recruits    O
a    O
small    O
GTPase    O
called    O
Sar1    O
(    O
think    O
of    O
Sar1    O
as    O
a    O
switch    O
,    O
it    O
is    O
active    O
when    O
bound    O
to    O
GTP    B-Diol114835980
and    O
inactive    O
when    O
it    O
hydrolyses    O
the    O
GTP    O
to    O
GDP    B-Diol114835980
)    O
.    O

In    O
the    O
activated    O
NMBR    O
/    O
G    O
-    O
protein    O
complex    O
,    O
there    O
occurs    O
an    O
exchange    O
of    O
GTP    B-Diol114835980
for    O
GDP    B-Diol114835980
bound    O
to    O
G-α    O
subunit    O
.    O

:    O
ATP    O
+    O
GMP    B-Diol114835980
ADP    O
+    O
GDP    B-Diol114835980

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GMP    B-Diol114835980
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
GDP    B-Diol114835980
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Diol114835980
and    O
5-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Diol114835980
and    O
5-phosphonooxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    B-Diol114835980
and    O
alpha    O
-    O
D    O
-    O
mannose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
GDP    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Diol114835980
and    O
3-phospho    O
-    O
D    O
-    O
glycerate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Diol114835980
and    O
3-phospho    O
-    O
D    O
-    O
glyceroyl    O
phosphate    O
.    O

In    O
addition    O
to    O
CSF    O
,    O
other    O
cytokines    O
such    O
as    O
IL-6    O
,    O
IL-10    O
,    O
VEGF    O
,    O
PGE2    B-Diol114835980
and    O
IL-1    O
have    O
been    O
implicated    O
in    O
the    O
development    O
and    O
regulation    O
of    O
MDSC    O
.    O

Ricinoleic    O
acid    O
specifically    O
activates    O
the    O
EP3    O
prostanoid    O
receptor    O
for    O
prostaglandin    B-Diol114835980
E2    I-Diol114835980
.    O

Prostaglandin    B-Diol114835980
E2    I-Diol114835980

He    O
completed    O
his    O
postgraduate    O
study    O
at    O
the    O
University    O
of    O
London    O
where    O
he    O
was    O
awarded    O
a    O
PhD    O
in    O
Pharmacology    O
for    O
the    O
research    O
investigating    O
the    O
characterisation    O
of    O
interleukin-1-induced    O
prostaglandin    B-Diol114835980
E₂    I-Diol114835980
release    O
in    O
human    O
synovial    O
cells    O
in    O
1988    O
.    O

Prostaglandin    B-Diol114835980
E2    I-Diol114835980
,    O
an    O
abortifacient    O

PGE2    B-Diol114835980

Intravaginal    O
,    O
endocervical    O
or    O
extra    O
-    O
amniotic    O
administration    O
of    O
prostaglandin    O
,    O
such    O
as    O
dinoprostone    B-Diol114835980
or    O
misoprostol    B-Diol114835980
.    O

It    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
reducing    O
body    O
temperature    O
in    O
sleep    O
,    O
and    O
acts    O
opposite    O
to    O
PGE2    B-Diol114835980
.    O

Prostaglandin    O
receptors    O
or    O
prostanoid    O
receptors    O
represent    O
a    O
sub    O
-    O
class    O
of    O
cell    O
surface    O
membrane    O
receptors    O
that    O
are    O
regarded    O
as    O
the    O
primary    O
receptors    O
for    O
one    O
or    O
more    O
of    O
the    O
classical    O
,    O
naturally    O
occurring    O
prostanoids    O
viz    O
.    O
,    O
prostaglandin    B-Diol114835980
D2    I-Diol114835980
,    O
(    O
i.e.    O
PGD2    B-Diol114835980
)    O
,    O
PGE2    B-Diol114835980
,    O
PGF2alpha    O
,    O
prostacyclin    B-Diol114835980
(    O
PGI2    O
)    O
,    O
thromboxane    O
A2    O
(    O
TXA2    O
)    O
,    O
and    O
PGH2    O
.    O

Prostaglandin    O
E2    O
receptor    O
2    O
(    O
53kDa    O
)    O
,    O
also    O
known    O
as    O
EP2    O
,    O
is    O
a    O
prostaglandin    O
receptor    O
for    O
prostaglandin    B-Diol114835980
E2    I-Diol114835980
(    O
PGE2    O
)    O
encoded    O
by    O
the    O
human    O
gene    O
PTGER2    O
:    O
it    O
is    O
one    O
of    O
four    O
identified    O
EP    O
receptors    O
,    O
the    O
others    O
being    O
EP1    O
,    O
EP3    O
,    O
and    O
EP4    O
,    O
which    O
bind    O
with    O
and    O
mediate    O
cellular    O
responses    O
to    O
PGE2    O
and    O
also    O
,    O
but    O
with    O
lesser    O
affinity    O
and    O
responsiveness    O
,    O
certain    O
other    O
prostanoids    O
(    O
see    O
Prostaglandin    O
receptors    O
)    O
.    O

Prostaglandin    O
EP3    O
receptor    O
(    O
53kDa    O
)    O
,    O
also    O
known    O
as    O
EP3    O
,    O
is    O
a    O
prostaglandin    O
receptor    O
for    O
prostaglandin    B-Diol114835980
E2    I-Diol114835980
(    O
PGE2    O
)    O
encoded    O
by    O
the    O
human    O
gene    O
PTGER3    O
;    O
it    O
is    O
one    O
of    O
four    O
identified    O
EP    O
receptors    O
,    O
the    O
others    O
being    O
EP1    O
,    O
EP2    O
,    O
and    O
EP4    O
,    O
all    O
of    O
which    O
bind    O
with    O
and    O
mediate    O
cellular    O
responses    O
to    O
PGE2    O
and    O
also    O
,    O
but    O
generally    O
with    O
lesser    O
affinity    O
and    O
responsiveness    O
,    O
certain    O
other    O
prostanoids    O
(    O
see    O
Prostaglandin    O
receptors    O
)    O
.    O

The    O
FP    O
receptor    O
is    O
the    O
least    O
selective    O
of    O
the    O
prostenoid    O
receptors    O
in    O
that    O
it    O
is    O
responsive    O
to    O
PGD2    O
and    O
to    O
a    O
lesser    O
extent    O
PGE2    O
at    O
concentrations    O
close    O
to    O
those    O
of    O
PGF2α.    O
Standard    O
prostanoids    O
have    O
the    O
following    O
relative    O
efficacies    O
as    O
receptor    O
ligands    O
in    O
binding    O
to    O
and    O
activating    O
FP    O
:    O
PGD2    B-Diol114835980
PGE2    B-Diol114835980
PGI2    B-Diol114835980
.    O

Standard    O
prostanoids    O
have    O
the    O
following    O
relative    O
efficacies    O
as    O
receptor    O
ligands    O
in    O
binding    O
to    O
and    O
activating    O
IP    O
:    O
PGD2    B-Diol114835980
PGE2    B-Diol114835980
.    O

Evans    O
rearrangement    O
in    O
the    O
synthesis    O
of    O
the    O
hormone    O
Prostaglandin    B-Diol114835980
E2    I-Diol114835980
.    O

Mesoxalic    O
acid    O
readily    O
absorbs    O
and    O
reacts    O
with    O
water    O
to    O
form    O
a    O
product    O
commonly    O
called    O
"    O
mesoxalic    O
acid    O
(    O
mono)hydrate    O
"    O
,    O
more    O
properly    O
dihydroxymalonic    B-Diol114835980
acid    I-Diol114835980
,    O
HO-(C    O
=    O
O)-C(OH)2-(C    O
=    O
O)-OH    O
.    O

The    O
particular    O
shade    O
depends    O
upon    O
the    O
amount    O
of    O
fucoxanthin    B-Diol114835980
present    O
in    O
the    O
alga    O
.    O

Their    O
plastids    O
also    O
contain    O
chlorophyll    O
c    O
and    O
carotenoids    O
(    O
the    O
most    O
widespread    O
of    O
those    O
being    O
fucoxanthin    B-Diol114835980
)    O
.    O

The    O
chloroplasts    O
characteristically    O
contain    O
chlorophyll    O
a    O
and    O
chlorophyll    O
c    O
,    O
and    O
usually    O
the    O
accessory    O
pigment    O
fucoxanthin    B-Diol114835980
,    O
giving    O
them    O
a    O
golden    O
-    O
brown    O
or    O
brownish    O
-    O
green    O
color    O
.    O

The    O
brown    O
colour    O
of    O
this    O
seaweed    O
results    O
from    O
the    O
dominance    O
of    O
the    O
xanthophyll    O
fucoxanthin    B-Diol114835980
which    O
masks    O
the    O
other    O
pigments    O
that    O
are    O
present    O
,    O
namely    O
chlorophyll    O
a    O
,    O
chlorophyll    O
c    O
,    O
beta    O
-    O
carotene    O
and    O
other    O
xanthophylls    O
.    O

The    O
2-"C    O
"-    O
methyl    O
-    O
D    O
-    O
erythritol    O
4-phosphate/1-deoxy    O
-    O
D    O
-    O
xylulose    O
5-phosphate    O
pathway    O
(    O
MEP    O
/    O
DOXP    O
pathway    O
)    O
,    O
also    O
known    O
as    O
[    O
non    O
-    O
mevalonate    O
pathway    O
]    O
or    O
mevalonic    B-Diol114835980
acid    I-Diol114835980
-    O
independent    O
pathway    O
,    O
takes    O
place    O
in    O
the    O
plastids    O
of    O
plants    O
and    O
apicomplexan    O
protozoa    O
,    O
as    O
well    O
as    O
in    O
many    O
bacteria    O
.    O

IPP    O
is    O
formed    O
from    O
acetyl-CoA    B-Diol114835980
via    O
the    O
intermediacy    O
of    O
mevalonic    B-Diol114835980
acid    I-Diol114835980
in    O
the    O
HMG    O
-    O
CoA    O
reductase    O
pathway    O
.    O

Mevalonate    B-Diol114835980
is    O
a    O
key    O
intermediate    O
,    O
and    O
mevalonate    O
kinase    O
a    O
key    O
early    O
enzyme    O
,    O
in    O
isoprenoid    O
and    O
sterol    O
synthesis    O
.    O

Mevalonic    B-Diol114835980
acid    I-Diol114835980

ATP    O
+    O
"    O
(    O
mevalonate    B-Diol114835980
ADP    O
+    O
"    O
(    O
R)"-5-phosphomevalonate    O
.    O

Mevalonic    B-Diol114835980
acid    I-Diol114835980

Cholesterol    O
is    O
bio    O
-    O
synthesised    O
from    O
mevalonate    B-Diol114835980
via    O
a    O
squalene    O
cyclisation    O
of    O
terpenoids    O
.    O

Dimethylsphingosine    O
(also    B-Diol114835980
known    I-Diol114835980
as    I-Diol114835980
"'DMS    I-Diol114835980
)    O
is    O
an    O
inhibitor    O
of    O
sphingosine    O
kinase    O
.    O

Dihydroxymethylidene    B-Diol114835980
is    O
a    O
chemical    O
compound    O
with    O
formula    O
C(OH)2    O
.    O

2-Oleoylglycerol    B-Diol114835980

PAS    O
formed    O
part    O
of    O
the    O
standard    O
treatment    O
for    O
tuberculosis    O
prior    O
to    O
the    O
introduction    O
of    O
rifampicin    B-Diol114835980
and    O
pyrazinamide    O
.    O

Its    O
potency    O
is    O
less    O
than    O
that    O
of    O
the    O
current    O
five    O
first    O
-    O
line    O
drugs    O
(    O
isoniazid    O
,    O
rifampicin    B-Diol114835980
,    O
ethambutol    B-Diol114835980
,    O
pyrazinamide    O
,    O
and    O
streptomycin    O
)    O
for    O
treating    O
tuberculosis    O
and    O
its    O
cost    O
is    O
higher    O
,    O
but    O
it    O
is    O
still    O
useful    O
in    O
the    O
treatment    O
of    O
multidrug    O
-    O
resistant    O
tuberculosis    O
.    O

When    O
taken    O
with    O
rifampicin    B-Diol114835980
,    O
the    O
levels    O
of    O
rifampicin    B-Diol114835980
in    O
the    O
blood    O
fall    O
by    O
about    O
half    O
.    O

A    O
preliminary    O
trial    O
of    O
antibiotic    O
therapy    O
with    O
doxycycline    O
and    O
rifampin    B-Diol114835980
at    O
McMaster    O
University    O
had    O
indicated    O
that    O
it    O
was    O
effective    O
in    O
delaying    O
the    O
progress    O
of    O
the    O
disease    O
:    O
"    O
In    O
conclusion    O
,    O
a    O
3-month    O
course    O
of    O
doxycycline    O
and    O
rifampin    O
reduced    O
cognitive    O
worsening    O
at    O
6    O
months    O
of    O
follow    O
-    O
up    O
in    O
patients    O
with    O
mild    O
to    O
moderate    O
AD    O
.    O
"    O

Rifampicin    B-Diol114835980
.    O

Rifampin    B-Diol114835980

Inducers    O
of    O
hepatic    O
microsomal    O
enzymes    O
such    O
as    O
barbiturates    O
,    O
phenytoin    O
,    O
and    O
rifampicin    B-Diol114835980
can    O
reduce    O
the    O
half    O
-    O
life    O
of    O
dexamethasone    O
.    O

The    O
metabolism    O
of    O
NOMAC    O
is    O
dependent    O
on    O
CYP3A4    O
,    O
so    O
inhibitors    O
and    O
inducers    O
of    O
this    O
enzyme    O
such    O
as    O
ketoconazole    O
and    O
rifampicin    B-Diol114835980
,    O
respectively    O
,    O
as    O
well    O
as    O
some    O
anticonvulsants    O
,    O
may    O
pose    O
a    O
clinically    O
significant    O
drug    O
interaction    O
with    O
NOMAC    O
.    O

These    O
horses    O
are    O
typically    O
treated    O
with    O
rifampin    B-Diol114835980
in    O
addition    O
to    O
one    O
of    O
the    O
previously    O
mentioned    O
antibiotics    O
.    O

Currently    O
,    O
a    O
multidrug    O
treatment    O
(    O
MDT    O
)    O
is    O
recommended    O
by    O
the    O
World    O
Health    O
Organization    O
,    O
including    O
dapsone    O
,    O
rifampicin    B-Diol114835980
and    O
clofazimine    O
.    O

The    O
search    O
for    O
additional    O
anti    O
-    O
leprosy    O
drugs    O
led    O
to    O
the    O
use    O
of    O
clofazimine    O
and    O
rifampicin    B-Diol114835980
in    O
the    O
1960s    O
and    O
1970s    O
.    O

The    O
search    O
for    O
more    O
effective    O
anti    O
-    O
leprosy    O
drugs    O
led    O
to    O
the    O
use    O
of    O
clofazimine    O
and    O
rifampicin    B-Diol114835980
in    O
the    O
1960s    O
and    O
1970s    O
.    O

A    O
dermatologist    O
or    O
general    O
physician    O
usually    O
administers    O
combination    O
therapy    O
of    O
drugs    O
used    O
for    O
tuberculosis    O
,    O
such    O
as    O
Rifampicin    B-Diol114835980
,    O
Isoniazid    O
and    O
Pyrazinamide    O
(    O
possibly    O
with    O
either    O
streptomycin    O
or    O
ethambutol    B-Diol114835980
)    O
.    O

Ulipristal    O
acetate    O
is    O
likely    O
to    O
interact    O
with    O
substrates    O
of    O
CYP3A4    O
,    O
like    O
rifampicin    B-Diol114835980
,    O
phenytoin    O
,    O
St    O
John    O
's    O
wort    O
,    O
carbamazepine    O
or    O
ritonavir    O
,    O
therefore    O
concomitant    O
use    O
with    O
these    O
agents    O
is    O
not    O
recommended    O
.    O

rifampin    B-Diol114835980

Rifampin    B-Diol114835980
prophylactically    O

Rifampin    B-Diol114835980

Dapsone    O
and    O
rifampin    B-Diol114835980

Rifampicin    B-Diol114835980

Rifampicin    B-Diol114835980

Rifampin    B-Diol114835980

Chloramphenicol    O
,    O
vancomycin    O
,    O
streptomycin    O
were    O
all    O
found    O
to    O
completely    O
inhibit    O
growth    O
,    O
though    O
it    O
was    O
resistant    O
to    O
rifampin    B-Diol114835980
.    O

Today    O
,    O
the    O
drugs    O
of    O
choice    O
for    O
treating    O
leprosy    O
are    O
dapsone    O
,    O
rifampicin    B-Diol114835980
and    O
clofazimine    O
.    O

In    O
cases    O
where    O
antibiotics    O
have    O
been    O
suggested    O
to    O
affect    O
the    O
efficiency    O
of    O
birth    O
control    O
pills    O
,    O
such    O
as    O
for    O
the    O
broad    O
-    O
spectrum    O
antibiotic    O
rifampicin    B-Diol114835980
,    O
these    O
cases    O
may    O
be    O
due    O
to    O
an    O
increase    O
in    O
the    O
activities    O
of    O
hepatic    O
liver    O
enzymes    O
'    O
causing    O
increased    O
breakdown    O
of    O
the    O
pill    O
's    O
active    O
ingredients    O
.    O

Since    O
then    O
,    O
drugs    O
such    O
as    O
isoniazid    O
and    O
rifampin    B-Diol114835980
have    O
been    O
used    O
.    O

Resistance    O
of    O
"    O
Mycobacterium    O
tuberculosis    O
"    O
to    O
isoniazid    O
,    O
rifampin    B-Diol114835980
,    O
and    O
other    O
common    O
treatments    O
has    O
become    O
an    O
increasingly    O
relevant    O
clinical    O
challenge    O
.    O

In    O
contrast    O
to    O
bacterial    O
RNA    O
polymerases    O
,    O
T7    O
polymerase    O
is    O
not    O
inhibited    O
by    O
the    O
antibiotic    O
rifampicin    B-Diol114835980
.    O

For    O
people    O
with    O
MRSA    O
bacteremia    O
in    O
the    O
setting    O
of    O
vancomycin    O
failure    O
the    O
IDSA    O
recommends    O
high    O
-    O
dose    O
daptomycin    O
,    O
if    O
the    O
isolate    O
is    O
susceptible    O
,    O
in    O
combination    O
with    O
another    O
agent    O
(    O
e.g.    O
gentamicin    O
,    O
rifampin    B-Diol114835980
,    O
linezolid    O
,    O
TMP    O
-    O
SMX    O
,    O
or    O
a    O
beta    O
-    O
lactam    O
antibiotic    O
)    O
.    O

Rifampin    B-Diol114835980

CYP2A6    O
is    O
known    O
to    O
be    O
inducible    O
by    O
phenobarbital    O
and    O
rifampicin    B-Diol114835980
,    O
and    O
it    O
is    O
suspected    O
that    O
other    O
antiepileptic    O
drugs    O
may    O
also    O
have    O
this    O
effect    O
.    O

rifampicin    B-Diol114835980
(    O
antibacterial    O
)    O

Amidophosphoribosyltransferase    O
(    O
ATase    O
)    O
,    O
also    O
known    O
as    O
glutamine    O
phosphoribosylpyrophosphate    O
amidotransferase    O
(    O
GPAT    O
)    O
,    O
is    O
an    O
enzyme    O
responsible    O
for    O
catalyzing    O
the    O
conversion    O
of    O
5-phosphoribosyl-1-pyrophosphate    B-Diol114835980
(    O
PRPP    O
)    O
into    O
5-phosphoribosyl-1-amine    O
(    O
PRA    O
)    O
,    O
using    O
the    O
ammonia    O
group    O
from    O
a    O
glutamine    O
side    O
-    O
chain    O
.    O

Image    O
:    O
Phosphoribosyl    O
PRPP    B-Diol114835980

The    O
inosinate    O
synthesis    O
is    O
complex    O
,    O
beginning    O
with    O
a    O
5-phosphoribosyl-1-pyrophosphate    B-Diol114835980
(    O
PRPP    O
)    O
.    O

Plants    O
and    O
microorganisms    O
commonly    O
synthesize    O
tryptophan    O
from    O
shikimic    O
acid    O
or    O
anthranilate    O
:    O
anthranilate    O
condenses    O
with    O
phosphoribosylpyrophosphate    B-Diol114835980
(    O
PRPP    O
)    O
,    O
generating    O
pyrophosphate    O
as    O
a    O
by    O
-    O
product    O
.    O

The    O
enzyme    O
ribose    O
-    O
phosphate    O
diphosphokinase    O
converts    O
ribose-5-phosphate    O
into    O
phosphoribosyl    B-Diol114835980
pyrophosphate    I-Diol114835980
.    O

Other    O
drugs    O
and    O
agents    O
include    O
diuretics    O
,    O
salicylates    O
,    O
pyrazinamide    O
,    O
ethambutol    B-Diol114835980
,    O
nicotinic    O
acid    O
,    O
ciclosporin    O
,    O
2-ethylamino-1,3,4-thiadiazole    O
,    O
and    O
cytotoxic    O
agents    O
.    O

The    O
treatment    O
of    O
TB    O
meningitis    O
is    O
isoniazid    O
,    O
rifampicin    B-Diol114835980
,    O
pyrazinamide    O
and    O
ethambutol    B-Diol114835980
for    O
two    O
months    O
,    O
followed    O
by    O
isoniazid    O
and    O
rifampicin    O
alone    O
for    O
a    O
further    O
ten    O
months    O
.    O

Ethambutol    B-Diol114835980

Its    O
potency    O
is    O
less    O
than    O
that    O
of    O
the    O
current    O
five    O
first    O
-    O
line    O
drugs    O
(    O
isoniazid    O
,    O
rifampicin    B-Diol114835980
,    O
ethambutol    B-Diol114835980
,    O
pyrazinamide    O
,    O
and    O
streptomycin    O
)    O
for    O
treating    O
tuberculosis    O
and    O
its    O
cost    O
is    O
higher    O
,    O
but    O
it    O
is    O
still    O
useful    O
in    O
the    O
treatment    O
of    O
multidrug    O
-    O
resistant    O
tuberculosis    O
.    O

These    O
drugs    O
include    O
all    O
diuretics    O
,    O
pyrazinoate    O
,    O
pyrazinamide    O
,    O
ethambutol    B-Diol114835980
,    O
and    O
aspirin    O
.    O

A    O
dermatologist    O
or    O
general    O
physician    O
usually    O
administers    O
combination    O
therapy    O
of    O
drugs    O
used    O
for    O
tuberculosis    O
,    O
such    O
as    O
Rifampicin    B-Diol114835980
,    O
Isoniazid    O
and    O
Pyrazinamide    O
(    O
possibly    O
with    O
either    O
streptomycin    O
or    O
ethambutol    B-Diol114835980
)    O
.    O

Ethambutol    B-Diol114835980

Among    O
these    O
are    O
:    O
ingestion    O
of    O
methanol    O
(    O
wood    O
alcohol    O
)    O
,    O
ethylene    O
glycol    O
(    O
automotive    O
antifreeze    O
)    O
,    O
disulfiram    O
(    O
used    O
to    O
treat    O
chronic    O
alcoholism    O
)    O
,    O
halogenated    O
hydroquinolones    O
(    O
amebicidal    O
medications    O
)    O
,    O
ethambutol    B-Diol114835980
and    O
isoniazid    O
(    O
tuberculosis    O
treatment    O
)    O
,    O
and    O
antibiotics    O
such    O
as    O
linezolid    O
and    O
chloramphenicol    O
.    O

Topoisomerase    O
II    O
inhibitors    O
:    O
etoposide    O
(    O
VP-16    O
)    O
,    O
teniposide    O
,    O
doxorubicin    O
,    O
daunorubicin    B-Diol114835980
,    O
mitoxantrone    B-Diol114835980
,    O
amsacrine    O
,    O
ellipticines    O
,    O
aurintricarboxylic    O
acid    O
,    O
and    O
HU-331    O
,    O
a    O
quinolone    O
synthesized    O
from    O
cannabidiol    O
.    O

mitoxantrone    B-Diol114835980
(    O
INN    O
)    O

Some    O
cancer    O
treatments    O
like    O
bexarotene    O
,    O
busulfan    O
,    O
chlorambucil    O
,    O
estramustine    O
,    O
etoposide    O
,    O
flutamide    O
,    O
idarubicin    B-Diol114835980
,    O
ifosfamide    O
,    O
irinotecan    O
,    O
ixabepilone    B-Diol114835980
,    O
letrozole    O
,    O
lomustine    O
,    O
megestrol    O
,    O
mitomycin    O
,    O
mitoxantrone    B-Diol114835980
,    O
paclitaxel    O
,    O
procarbazine    O
,    O
tamoxifen    O
,    O
topotecan    O

Losoxantrone    O
(    O
biantrazole    O
)    O
is    O
a    O
anthroquinone    O
anthrapyrazole    O
antineoplastic    O
agent    O
and    O
analog    O
of    O
mitoxantrone    B-Diol114835980
.    O

Mitoxantrone    B-Diol114835980

It    O
is    O
usually    O
lethal    O
,    O
but    O
it    O
has    O
been    O
found    O
to    O
be    O
responsive    O
to    O
Mitoxantrone    B-Diol114835980
and    O
Alemtuzumab    O
,    O
and    O
it    O
has    O
also    O
been    O
responsive    O
to    O
autologous    O
stem    O
cell    O
transplantation    O
.    O

These    O
hormones    O
and    O
medications    O
include    O
insulin    O
,    O
epinephrine    O
,    O
and    O
other    O
beta    O
agonists    O
(    O
e.g.    O
salbutamol    B-Diol114835980
or    O
salmeterol    B-Diol114835980
)    O
,    O
and    O
xanthines    O
(    O
e.g.    O
theophylline    O
)    O
.    O

Its    O
half    O
maximal    O
effective    O
concentration    O
(    O
EC50    O
)    O
is    O
0.1    O
nM.    O
It    O
has    O
a    O
higher    O
"    O
in    O
vitro    O
"    O
selectivity    O
for    O
β2    O
receptors    O
than    O
the    O
related    O
drugs    O
formoterol    O
and    O
salmeterol    B-Diol114835980
:    O
241-fold    O
versus    O
β1    O
and    O
2299-fold    O
versus    O
β3    O
adrenergic    O
receptors    O
.    O

The    O
pharmacologic    O
profile    O
of    O
this    O
medication    O
included    O
the    O
fact    O
its    O
potency    O
in    O
isolated    O
guinea    O
pig    O
trachea    O
is    O
greater    O
than    O
that    O
of    O
formoterol    O
and    O
salmeterol    B-Diol114835980
.    O

These    O
medications    O
include    O
short    O
-    O
acting    O
beta    O
agonists    O
(    O
SABAs    O
)    O
such    O
as    O
albuterol    B-Diol114835980
which    O
typically    O
last    O
4–6    O
hours    O
,    O
and    O
long    O
-    O
acting    O
beta    O
agonists    O
(    O
LABAs    O
)    O
such    O
as    O
salmeterol    B-Diol114835980
which    O
lasts    O
12    O
hours    O
.    O

Salmeterol    B-Diol114835980

Methanediol    B-Diol114835980
,    O
also    O
known    O
as    O
formaldehyde    B-Diol114835980
monohydrate    I-Diol114835980
or    O
methylene    B-Diol114835980
glycol    I-Diol114835980
,    O
is    O
an    O
organic    O
compound    O
with    O
chemical    O
formula    O
CH2(OH)2    O
.    O

It    O
is    O
joined    O
to    O
the    O
anthracycline    O
aglycone    O
and    O
further    O
modifications    O
are    O
done    O
to    O
produce    O
first    O
daunorubicin    B-Diol114835980
then    O
DXR    O
.    O

Initially    O
,    O
two    O
successive    O
oxidations    O
are    O
done    O
at    O
C-13    O
,    O
followed    O
by    O
a    O
single    O
oxidation    O
of    O
C-14    O
that    O
converts    O
daunorubicin    B-Diol114835980
to    O
doxorubicin    O
.    O

Daunorubicin    B-Diol114835980
(    O
Bedford    O
Labs    O
)    O

daunorubicin    B-Diol114835980
(    O
INN    O
)    O

Daunorubicin    B-Diol114835980

Also    O
,    O
the    O
intercalation    O
into    O
DNA    O
of    O
anthracyclines    O
such    O
as    O
daunorubicin    B-Diol114835980
and    O
doxorubicin    O
interferes    O
with    O
the    O
functioning    O
of    O
the    O
enzyme    O
topoisomerase    O
II    O
,    O
blocking    O
replication    O
as    O
well    O
as    O
causing    O
mitotic    O
homologous    O
recombination    O
.    O

Scientists    O
named    O
the    O
drug    O
daunorubicin    B-Diol114835980
and    O
further    O
development    O
identified    O
a    O
related    O
compound    O
doxorubicin    O
that    O
finds    O
use    O
as    O
a    O
chemotherapeutic    O
agent    O
used    O
to    O
treat    O
cancer    O
.    O

The    O
seeds    O
contain    O
leucodelphinidin    B-Diol114835980
,    O
a    O
colourless    O
chemical    O
compound    O
.    O

Antagonists    O
/    O
negative    O
allosteric    O
modulators    O
:    O
bicuculline    O
,    O
cicutoxin    B-Diol114835980
,    O
flumazenil    O
,    O
furosemide    O
,    O
gabazine    O
,    O
oenanthotoxin    B-Diol114835980
,    O
picrotoxin    B-Diol114835980
,    O
Ro15    O
-    O
4513    O
,    O
thujone    O
,    O
amentoflavone    O
.    O

Picrotoxin    B-Diol114835980

It    O
is    O
related    O
to    O
the    O
picrotoxin    B-Diol114835980
family    O
of    O
natural    O
products    O
.    O

While    O
structurally    O
related    O
to    O
picrotoxin    B-Diol114835980
,    O
dendrobine    O
is    O
not    O
an    O
antagonist    O
of    O
GABA    O
.    O

When    O
tested    O
in    O
mice    O
,    O
denatured    O
venom    O
from    O
"    O
P.    O
occidentalis    O
"    O
inhibited    O
convulsions    O
during    O
seizures    O
induced    O
by    O
bicuculline    O
,    O
picrotoxin    B-Diol114835980
,    O
and    O
kainic    O
acid    O
.    O

File    O
:    O
Clevudine    O
Clevudine    B-Diol114835980

Low    O
-    O
dosage    O
steroidal    O
eye    O
-    O
drops    O
,    O
such    O
as    O
prednisone    O
,    O
fluorometholone    B-Diol114835980
,    O
loteprednol    O
(    O
Lotemax    O
0.5%    O
)    O
or    O
rimexolone    O
.    O

FML    B-Diol114835980

Commonly    O
used    O
solutions    O
are    O
of    O
fluorometholone    B-Diol114835980
,    O
medrysone    O
,    O
betamethasone    O
or    O
dexamethasone    O
.    O

Floctafenine    B-Diol114835980
and    O
Glafenine    B-Diol114835980
are    O
a    O
pair    O
of    O
fenamate    O
NSAIDs    O
whose    O
synthesis    O
rely    O
on    O
the    O
Gould    O
–    O
Jacobs    O
reaction    O
.    O

Falcarindiol    B-Diol114835980
which    O
activates    O
the    O
nuclear    O
receptor    O
PPARgamma    O
,    O
and    O
induces    O
expression    O
of    O
antioxidant    O
enzymes    O
"    O
in    O
vitro    O
"    O
.    O

3D    O
structure    O
model    O
of    O
an    O
anticalin    O
(    O
ribbon    O
)    O
in    O
complex    O
with    O
digitoxigenin    B-Diol114835980
(    O
sticks    O
)    O
.    O

Gastrointestinal    O
-    O
protectant    O
drugs    O
,    O
such    O
as    O
misoprostol    B-Diol114835980
,    O
cimetidine    O
,    O
omeprazole    O
,    O
ranitidine    O
,    O
or    O
sucralfate    O
,    O
are    O
frequently    O
included    O
as    O
a    O
part    O
of    O
treatment    O
with    O
any    O
NSAID    O
.    O

Intravaginal    O
,    O
endocervical    O
or    O
extra    O
-    O
amniotic    O
administration    O
of    O
prostaglandin    O
,    O
such    O
as    O
dinoprostone    B-Diol114835980
or    O
misoprostol    B-Diol114835980
.    O

Misoprostol    B-Diol114835980
6    O
to    O
12    O
hrs    O
before    O
insertion    O
can    O
help    O
with    O
cervical    O
dilation    O
.    O

Misoprostol    B-Diol114835980
,    O
an    O
EP3    O
and    O
EP4    O
receptor    O
agonist    O
,    O
to    O
prevent    O
ulcers    O
;    O
to    O
induce    O
labor    O
in    O
pregnancy    O
,    O
medical    O
abortion    O
,    O
and    O
late    O
miscarriage    O
;    O
and    O
to    O
prevent    O
and    O
treat    O
postpartum    O
bleeding    O
.    O

Misoprostol    O
,    O
an    O
EP3    O
and    O
EP4    O
receptor    O
agonist    O
,    O
is    O
in    O
clinical    O
use    O
to    O
prevent    O
ulcers    O
,    O
to    O
induce    O
labor    O
in    O
pregnancy    O
,    O
medical    O
abortion    O
,    O
and    O
late    O
miscarriage    O
,    O
and    O
to    O
prevent    O
and    O
treat    O
postpartum    O
bleeding    O
(    O
see    O
Misoprostol    B-Diol114835980
)    O
.    O

In    O
recent    O
years    O
,    O
significant    O
reductions    O
in    O
maternal    O
death    O
and    O
injury    O
resulting    O
from    O
self    O
-    O
induced    O
abortions    O
have    O
been    O
attributed    O
to    O
the    O
growing    O
use    O
of    O
misoprostol    B-Diol114835980
(    O
known    O
commercially    O
at    O
"    O
Cytotec    O
"    O
)    O
,    O
an    O
inexpensive    O
,    O
widely    O
available    O
drug    O
with    O
multiple    O
uses    O
,    O
including    O
the    O
treatment    O
of    O
post    O
-    O
partum    O
hemorrhage    O
,    O
stomach    O
ulcers    O
,    O
and    O
induction    O
of    O
labor    O
.    O

The    O
prescription    O
synthetic    O
prostaglandin    O
drug    O
misoprostol    B-Diol114835980
–    O
used    O
in    O
the    O
U.S.    O
to    O
treat    O
gastric    O
ulcers    O
–    O
is    O
often    O
used    O
as    O
an    O
abortifacient    O
in    O
self    O
-    O
induced    O
abortion    O
in    O
Latin    O
American    O
countries    O
where    O
legal    O
abortions    O
are    O
unavailable    O
,    O
and    O
its    O
use    O
has    O
also    O
been    O
observed    O
in    O
immigrant    O
populations    O
in    O
New    O
York    O
.    O

She    O
had    O
induced    O
abortion    O
at    O
roughly    O
16    O
weeks    O
by    O
ingesting    O
misoprostol    B-Diol114835980
under    O
the    O
brand    O
name    O
Cytotec    O
,    O
an    O
ulcer    O
medication    O
with    O
abortifacient    O
potential    O
.    O

The    O
anti    O
-    O
estrogen    O
action    O
of    O
letrozole    O
has    O
been    O
shown    O
to    O
be    O
useful    O
in    O
pretreatment    O
for    O
termination    O
of    O
pregnancy    O
,    O
in    O
combination    O
with    O
misoprostol    B-Diol114835980
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
glycerone    B-Diol114835980
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
glycerone    O
phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
phosphoenolpyruvate    O
and    O
glycerone    B-Diol114835980
,    O
whereas    O
its    O
two    O
products    O
are    O
pyruvate    O
and    O
glycerone    O
phosphate    O
.    O

The    O
reaction    O
mechanism    O
is    O
similar    O
to    O
the    O
reverse    O
reaction    O
catalyzed    O
by    O
aldolase    O
:    O
The    O
bond    O
joining    O
carbons    O
3    O
and    O
4    O
is    O
broken    O
,    O
leaving    O
dihydroxyacetone    B-Diol114835980
joined    O
to    O
the    O
enzyme    O
via    O
a    O
Schiff    O
base    O
.    O

Then    O
transaldolase    O
catalyzes    O
the    O
condensation    O
of    O
glyceraldehyde-3-phosphate    O
with    O
the    O
Schiff    O
base    O
of    O
dihydroxyacetone    B-Diol114835980
,    O
yielding    O
enzyme    O
-    O
bound    O
fructose    O
6-phosphate    O
.    O

Idamycin    B-Diol114835980
(    O
Adria    O
Laboratories    O
)    O

idarubicin    B-Diol114835980
(    O
INN    O
)    O

Some    O
cancer    O
treatments    O
like    O
bexarotene    O
,    O
busulfan    O
,    O
chlorambucil    O
,    O
estramustine    O
,    O
etoposide    O
,    O
flutamide    O
,    O
idarubicin    B-Diol114835980
,    O
ifosfamide    O
,    O
irinotecan    O
,    O
ixabepilone    B-Diol114835980
,    O
letrozole    O
,    O
lomustine    O
,    O
megestrol    O
,    O
mitomycin    O
,    O
mitoxantrone    B-Diol114835980
,    O
paclitaxel    O
,    O
procarbazine    O
,    O
tamoxifen    O
,    O
topotecan    O

The    O
standard    O
treatment    O
is    O
chenodeoxycholic    B-Diol114835980
acid    I-Diol114835980
(    O
CDCA    O
)    O
replacement    O
therapy    O
.    O

The    O
balance    O
between    O
these    O
two    O
steroids    O
determines    O
the    O
relative    O
amounts    O
of    O
the    O
two    O
primary    O
bile    O
acids    O
,    O
cholic    O
acid    O
and    O
chenodeoxycholic    B-Diol114835980
acid    I-Diol114835980
,    O
both    O
of    O
which    O
are    O
secreted    O
in    O
the    O
bile    O
.    O

The    O
natural    O
bile    O
acid    O
,    O
chenodeoxycholic    B-Diol114835980
acid    I-Diol114835980
,    O
was    O
identified    O
in    O
1999    O
as    O
the    O
most    O
active    O
physiological    O
ligand    O
for    O
the    O
farnesoid    O
X    O
receptor    O
(    O
FXR    O
)    O
,    O
which    O
is    O
involved    O
in    O
many    O
physiological    O
and    O
pathological    O
processes    O
.    O

Muricholic    O
acids    O
differ    O
from    O
the    O
more    O
common    O
bile    O
acids    O
,    O
such    O
as    O
cholic    O
acid    O
or    O
chenodeoxycholic    B-Diol114835980
acid    I-Diol114835980
,    O
by    O
having    O
a    O
hydroxyl    O
group    O
at    O
the    O
6-position    O
.    O

Idoxuridine    B-Diol114835980
and    O
Trifluridine    B-Diol114835980
are    O
variants    O
of    O
deoxyuridine    O
used    O
as    O
antiviral    O
drugs    O
.    O

Pyrimidine    O
analogues    O
of    O
uridine    O
:    O
Idoxuridine    B-Diol114835980
,    O
Trifluridine    B-Diol114835980

Trifluridine    B-Diol114835980
,    O
a    O
antiviral    O
and    O
anticancer    O
medication    O

Molar    O
equivalents    O
of    O
synthetic    O
(    O
2R,3S,4R    O
or    O
leucocyanidin    B-Diol114835980
and    O
(    O
+    O
)    O
-catechin    O
condense    O
with    O
exceptional    O
rapidity    O
at    O
pH    O
5    O
under    O
ambient    O
conditions    O
to    O
give    O
the    O
all    O
-    O
trans-[4,8]-    O
and    O
[    O
4,6]-bi-[(+)-catechins    O
]    O
(    O
procyanidins    O
B3    O
and    O
B6    O
)    O
the    O
all    O
-    O
trans-[4,8:4,8]-    O
and    O
[    O
4,8:4,6]-tri-[(+)-catechins    O
]    O
(    O
procyanidin    O
C2    O
and    O
isomer    O
)    O
.    O

Leucocyanidin    O
reductase    O
(    O
LCR    O
)    O
uses    O
2,3-trans-3,4-cis    O
-    O
leucocyanidin    B-Diol114835980
to    O
produce    O
(    O
+    O
)    O
-catechin    O
and    O
is    O
the    O
first    O
enzyme    O
in    O
the    O
proanthocyanidins    O
(    O
PA)-specific    O
pathway    O
.    O

The    O
FP    O
receptor    O
is    O
the    O
least    O
selective    O
of    O
the    O
prostenoid    O
receptors    O
in    O
that    O
it    O
is    O
responsive    O
to    O
PGD2    O
and    O
to    O
a    O
lesser    O
extent    O
PGE2    O
at    O
concentrations    O
close    O
to    O
those    O
of    O
PGF2α.    O
Standard    O
prostanoids    O
have    O
the    O
following    O
relative    O
efficacies    O
as    O
receptor    O
ligands    O
in    O
binding    O
to    O
and    O
activating    O
FP    O
:    O
PGD2    B-Diol114835980
PGE2    B-Diol114835980
PGI2    B-Diol114835980
.    O

IP    O
binds    O
to    O
and    O
mediates    O
the    O
biological    O
actions    O
of    O
prostacyclin    B-Diol114835980
(    O
also    O
termed    O
Prostaglandin    O
I2    O
,    O
PGI2    O
,    O
or    O
when    O
used    O
as    O
a    O
drug    O
,    O
epoprostenol    O
)    O
.    O

Major    O
drugs    O
in    O
this    O
category    O
include    O
PGI2    O
itself    O
(    O
i.e.    O
epoprostenol    B-Diol114835980
)    O
,    O
iloprost    O
,    O
treprostinil    O
,    O
and    O
beraprost    O
with    O
epoprostenol    O
being    O
favored    O
in    O
some    O
studies    O
.    O

PGI2    B-Diol114835980

Iloprost    O
(    O
Prostacyclin    B-Diol114835980
)    O

Thrombus    O
formation    O
on    O
an    O
intact    O
endothelium    O
is    O
prevented    O
by    O
nitric    O
oxide    O
,    O
prostacyclin    B-Diol114835980
,    O
and    O
CD39    O
.    O

The    O
intact    O
endothelial    O
lining    O
"    O
inhibits    O
"    O
platelet    O
activation    O
by    O
producing    O
nitric    O
oxide    O
,    O
endothelial    O
-    O
ADPase    O
,    O
and    O
PGI2    B-Diol114835980
(    O
Prostacyclin    O
)    O
.    O

Endothelial    O
prostacyclin    B-Diol114835980
binds    O
to    O
prostanoid    O
receptors    O
on    O
the    O
surface    O
of    O
resting    O
platelets    O
.    O

Collagen    O
-    O
mediated    O
GPVI    O
signalling    O
increases    O
the    O
platelet    O
production    O
of    O
thromboxane    O
A2    O
(    O
TXA2    O
)    O
and    O
decreases    O
the    O
production    O
of    O
prostacyclin    B-Diol114835980
.    O

It    O
is    O
classified    O
as    O
a    O
prostacyclin    B-Diol114835980
analog    O
.    O

Thus    O
,    O
the    O
protective    O
anticoagulative    O
effect    O
of    O
PGI2    B-Diol114835980
is    O
removed    O
,    O
increasing    O
the    O
risk    O
of    O
thrombus    O
and    O
associated    O
heart    O
attacks    O
and    O
other    O
circulatory    O
problems    O
.    O

In    O
1976    O
,    O
he    O
was    O
involved    O
in    O
the    O
discovery    O
of    O
prostacyclin    B-Diol114835980
,    O
done    O
by    O
Salvador    O
Moncada    O
and    O
Ryszard    O
Gryglewski    O
.    O

The    O
older    O
antihistaminic    O
agent    O
terfenadine    B-Diol114835980
was    O
found    O
to    O
metabolize    O
into    O
the    O
related    O
carboxylic    O
acid    O
,    O
fexofenadine    O
.    O

Terfenadine    B-Diol114835980

And    O
in    O
those    O
being    O
treated    O
with    O
amiodarone    O
or    O
terfenadine    B-Diol114835980
.    O

Terfenadine    B-Diol114835980

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
monoterpenol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
monoterpenol    O
acetate    O
ester    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
N6-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N6-acetyl    O
-    O
N6-hydroxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
N    O
-    O
acetylneuraminate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N    O
-    O
acetyl-4-O    O
-    O
acetylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
N    O
-    O
acetylneuraminate    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    O
,    O
N    O
-    O
acetyl-7-O    O
-    O
acetylneuraminate    O
,    O
and    O
N    O
-    O
acetyl-9-O    O
-    O
acetylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
N    O
-    O
hydroxyarylamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N    O
-    O
acetoxyarylamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
peptide    O
,    O
whereas    O
its    O
two    O
products    O
are    O
Nalpha    O
-    O
acetylpeptide    O
and    O
CoA.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
L    O
-    O
phenylalanine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
phenylalanine    O
.    O

The    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
acetyl    O
phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
alpha-2,8-linked    O
polymer    O
of    O
sialic    O
acid    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    O
,    O
polysialic    O
acid    O
acetylated    O
on    O
O-7    O
,    O
and    O
polysialic    O
acid    O
acetylated    O
on    O
O-9    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
ribosomal    O
-    O
protein    O
L    O
-    O
alanine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
ribosomal    O
-    O
protein    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
alanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
salutaridinol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
7-O    O
-    O
acetylsalutaridinol    O
.    O

:    O
acetyl-CoA    B-Diol114835980
+    O
L    O
-    O
serine    O
CoA    O
+    O
O    O
-    O
acetyl    O
-    O
L    O
-    O
serine    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
L    O
-    O
serine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
O    O
-    O
acetyl    O
-    O
L    O
-    O
serine    O
.    O

More    O
specifically    O
,    O
its    O
role    O
is    O
to    O
catalyse    O
the    O
activation    O
of    O
L    O
-    O
serine    O
by    O
acetyl-CoA    B-Diol114835980
entry    O
refers    O
to    O
the    O
N    O
-    O
terminus    O
of    O
the    O
protein    O
which    O
has    O
a    O
sequence    O
that    O
is    O
conserved    O
in    O
plants    O
and    O
bacteria    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
taxa-4(20),11-dien-5alpha    O
-    O
ol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
taxa-4(20),11-dien-5alpha    O
-    O
yl    O
acetate    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
,    O
(    O
S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate    O
,    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
L-2-acetamido-6-oxoheptanedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
2-aminoethanethiol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
S-(2-aminoethyl)thioacetate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
and    O
16-epivellosimine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
vinorine    O
.    O

Arsenic    O
interferes    O
with    O
cellular    O
longevity    O
by    O
allosteric    O
inhibition    O
of    O
an    O
essential    O
metabolic    O
enzyme    O
pyruvate    O
dehydrogenase    O
(    O
PDH    O
)    O
complex    O
,    O
which    O
catalyzes    O
the    O
oxidation    O
of    O
pyruvate    O
to    O
acetyl-CoA    B-Diol114835980
by    O
NAD+    O
.    O

PDH    O
is    O
a    O
precursor    O
of    O
acetyl-CoA    B-Diol114835980
,    O
thus    O
the    O
inhibition    O
of    O
PDH    O
eventually    O
limits    O
the    O
production    O
of    O
ATP    O
in    O
electron    O
transport    O
chain    O
,    O
as    O
well    O
as    O
the    O
production    O
of    O
gluconeogenesis    O
intermediates    O
.    O

However    O
,    O
an    O
understanding    O
of    O
the    O
physiology    O
of    O
the    O
organism    O
would    O
have    O
revealed    O
that    O
due    O
to    O
an    O
incomplete    O
tricarboxylic    O
acid    O
pathway    O
,    O
"    O
Lactobacillus    O
plantarum    O
"    O
does    O
not    O
actually    O
produce    O
succinyl    O
-    O
CoA    O
,    O
and    O
the    O
correct    O
reactant    O
for    O
that    O
part    O
of    O
the    O
reaction    O
was    O
acetyl-CoA    B-Diol114835980

In    O
contrast    O
the    O
"    O
Rhizobium    O
etli    O
"    O
,    O
tetramer    O
in    O
complex    O
with    O
ethyl    O
-    O
CoA    O
,    O
a    O
non    O
-    O
hydrolyzable    O
analog    O
of    O
acetyl-CoA    B-Diol114835980
,    O
possesses    O
only    O
one    O
line    O
of    O
symmetry    O
.    O

In    O
most    O
species    O
,    O
this    O
reaction    O
requires    O
acetyl-CoA    B-Diol114835980
as    O
an    O
allosteric    O
activator    O
binding    O
to    O
the    O
PT    O
domain    O
.    O

Next    O
,    O
a    O
series    O
of    O
condensation    O
reactions    O
of    O
three    O
acetate    O
units    O
from    O
malonyl    O
-    O
CoA    O
occurs    O
,    O
each    O
proceeding    O
through    O
an    O
acetyl-CoA    B-Diol114835980
carbanion    O
derived    O
from    O
malonyl    O
-    O
CoA    O
decarboxylation    O
.    O

In    O
this    O
pathway    O
,    O
two    O
molecules    O
of    O
acetyl-CoA    B-Diol114835980
undergo    O
a    O
condensation    O
reaction    O
to    O
give    O
acetoacetyl    O
-    O
CoA.    O
This    O
product    O
then    O
condenses    O
with    O
third    O
molecule    O
of    O
acetyl    O
-    O
CoA    O
in    O
a    O
stereospecific    O
fashion    O
to    O
form    O
3-hydroxy-3-methylglutaryl    O
-    O
CoA    O
(    O
HMG    O
-    O
CoA    O
)    O
which    O
then    O
is    O
reduced    O
to    O
mevalonic    B-Diol114835980
acid    I-Diol114835980
(    O
MVA    O
)    O
.    O

The    O
backbone    O
is    O
synthesized    O
through    O
the    O
addition    O
of    O
two    O
carbon    O
units    O
via    O
addition    O
of    O
acetate    O
units    O
from    O
acetyl-CoA    B-Diol114835980
The    O
5    O
methyl    O
groups    O
are    O
added    O
via    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
(    O
SAM    O
)    O
methylation    O
,    O
as    O
opposed    O
to    O
incorporation    O
of    O
propionate    O
(    O
instead    O
of    O
acetate    O
)    O
to    O
the    O
growing    O
compound    O
during    O
biosynthesis    O
.    O

IPP    O
is    O
formed    O
from    O
acetyl-CoA    B-Diol114835980
via    O
the    O
intermediacy    O
of    O
mevalonic    B-Diol114835980
acid    I-Diol114835980
in    O
the    O
HMG    O
-    O
CoA    O
reductase    O
pathway    O
.    O

The    O
pyruvate    O
is    O
then    O
converted    O
into    O
acetyl-CoA    B-Diol114835980
so    O
that    O
it    O
can    O
enter    O
the    O
TCA    O
cycle    O
and    O
convert    O
the    O
original    O
pyruvate    O
molecules    O
into    O
ATP    O
,    O
or    O
usable    O
energy    O
for    O
the    O
organism    O
.    O

Each    O
pyruvate    O
goes    O
through    O
a    O
series    O
of    O
reactions    O
that    O
converts    O
it    O
to    O
acetyl    B-Diol114835980
coenzyme    I-Diol114835980
A    I-Diol114835980

In    O
the    O
presence    O
of    O
air    O
and    O
various    O
cofactors    O
and    O
enzymes    O
,    O
fatty    O
acids    O
are    O
degraded    O
to    O
acetyl-CoA    B-Diol114835980
The    O
pathway    O
is    O
called    O
beta    O
-    O
oxidation    O
.    O

Enoyl    O
-    O
CoA    O
hydratase    O
is    O
an    O
enzyme    O
that    O
hydrates    O
the    O
double    O
bond    O
between    O
the    O
second    O
and    O
third    O
carbons    O
on    O
acyl    O
-    O
CoA.    O
This    O
enzyme    O
,    O
also    O
known    O
as    O
crotonase    O
,    O
is    O
essential    O
to    O
metabolizing    O
fatty    O
acids    O
to    O
produce    O
both    O
acetyl    B-Diol114835980
CoA    I-Diol114835980
and    O
energy    O
.    O

ATP    O
citrate    O
lyase    O
is    O
the    O
primary    O
enzyme    O
responsible    O
for    O
the    O
synthesis    O
of    O
cytosolic    O
acetyl-CoA    B-Diol114835980
in    O
many    O
tissues    O
.    O

ATP    O
-    O
citrate    O
lyase    O
is    O
responsible    O
for    O
catalyzing    O
the    O
conversion    O
of    O
citrate    O
and    O
CoA    O
into    O
acetyl-CoA    B-Diol114835980
and    O
oxaloacetate    O
,    O
along    O
with    O
the    O
hydrolysis    O
of    O
ATP    O
.    O

In    O
the    O
presence    O
of    O
ATP    O
and    O
Coenzyme    O
A    O
,    O
citrate    O
lyase    O
catalyzes    O
the    O
cleavage    O
of    O
citrate    O
to    O
yield    O
acetyl    B-Diol114835980
CoA    I-Diol114835980
,    O
oxaloacetate    O
,    O
ADP    O
,    O
and    O
orthophosphate    O
:    O

:    O
citrate    O
+    O
ATP    O
+    O
CoA    O
+    O
H2O    O
→    O
oxaloacetate    O
+    O
Acetyl-CoA    B-Diol114835980
+    O
ADP    O
+    O
Pi    O

The    O
first    O
three    O
steps    O
of    O
the    O
reaction    O
pathways    O
lead    O
from    O
ethanol    O
to    O
acetaldehyde    O
to    O
acetic    O
acid    O
to    O
acetyl-CoA    B-Diol114835980
Once    O
acetyl    O
-    O
CoA    O
is    O
formed    O
,    O
it    O
is    O
free    O
to    O
enter    O
directly    O
into    O
the    O
citric    O
acid    O
cycle    O
.    O

Two    O
enzymes    O
are    O
associated    O
with    O
the    O
conversion    O
of    O
acetic    O
acid    O
to    O
acetyl-CoA    B-Diol114835980
The    O
first    O
is    O
acyl    O
-    O
CoA    O
synthetase    O
short    O
-    O
chain    O
family    O
member    O
2    O
ACSS2    O
(    O
EC    O
6.2.1.1    O
)    O
.    O

It    O
is    O
created    O
from    O
acetyl-CoA    B-Diol114835980
,    O
a    O
thioester    O
,    O
which    O
reacts    O
with    O
the    O
enolate    O
of    O
a    O
second    O
molecule    O
of    O
acetyl    O
-    O
CoA    O
in    O
a    O
Claisen    O
condensation    O
reaction    O
,    O
and    O
it    O
is    O
acted    O
upon    O
by    O
HMG    O
-    O
CoA    O
synthase    O
to    O
form    O
HMG    O
-    O
CoA.    O
During    O
the    O
metabolism    O
of    O
leucine    O
,    O
this    O
last    O
reaction    O
is    O
reversed    O
.    O

Thiolases    O
,    O
also    O
known    O
as    O
acetyl    O
-    O
coenzyme    O
A    O
acetyltransferases    O
(    O
ACAT    O
)    O
,    O
are    O
enzymes    O
which    O
convert    O
two    O
units    O
of    O
acetyl-CoA    B-Diol114835980
to    O
acetoacetyl    O
CoA    O
in    O
the    O
mevalonate    O
pathway    O
.    O

This    O
gene    O
encodes    O
a    O
mitochondrially    O
localized    O
enzyme    O
that    O
catalyzes    O
the    O
reversible    O
formation    O
of    O
acetoacetyl    O
-    O
CoA    O
from    O
two    O
molecules    O
of    O
acetyl-CoA    B-Diol114835980
The    O
ACAT1    O
enzyme    O
has    O
a    O
few    O
unique    O
properties    O
.    O

The    O
compound    O
undergoes    O
beta    O
oxidation    O
,    O
forming    O
one    O
or    O
more    O
molecules    O
of    O
acetyl-CoA    B-Diol114835980
This    O
,    O
in    O
turn    O
,    O
enters    O
the    O
citric    O
acid    O
cycle    O
,    O
eventually    O
forming    O
several    O
molecules    O
of    O
ATP    O
.    O

Acetyl-CoA    B-Diol114835980

The    O
complex    O
acts    O
to    O
convert    O
pyruvate    O
(    O
a    O
product    O
of    O
glycolysis    O
in    O
the    O
cytosol    O
)    O
to    O
acetyl-coA    B-Diol114835980
,    O
which    O
is    O
then    O
oxidized    O
in    O
the    O
mitochondria    O
to    O
produce    O
energy    O
,    O
in    O
the    O
citric    O
acid    O
cycle    O
.    O

Pyruvate    O
dehydrogenase    O
kinase    O
is    O
activated    O
by    O
ATP    O
,    O
NADH    O
and    O
acetyl-CoA    B-Diol114835980
It    O
is    O
inhibited    O
by    O
ADP    O
,    O
NAD+    O
,    O
CoA    O
-    O
SH    O
and    O
pyruvate    O
.    O

Processing    O
of    O
cholesterol    O
and    O
protein    O
gives    O
propionyl    O
-    O
CoA    O
that    O
is    O
converted    O
to    O
methylmalonyl-CoA    B-Diol114835980
,    O
which    O
is    O
used    O
by    O
MUT    O
enzyme    O
to    O
make    O
succinyl    O
-    O
CoA.    O
Vitamin    O
is    O
needed    O
to    O
prevent    O
anemia    O
,    O
since    O
making    O
porphyrin    O
and    O
heme    O
in    O
mitochondria    O
for    O
producing    O
hemoglobin    O
in    O
red    O
blood    O
cells    O
depends    O
on    O
succinyl    O
-    O
CoA    O
made    O
by    O
vitamin    O
.    O

The    O
4    O
substrates    O
of    O
this    O
enzyme    O
are    O
acyl    O
-    O
CoA    O
,    O
methylmalonyl-CoA    B-Diol114835980
,    O
NADPH    O
,    O
and    O
H+    O
,    O
whereas    O
its    O
4    O
products    O
are    O
multi    O
-    O
methyl    O
-    O
branched    O
acyl    O
-    O
CoA    O
,    O
CoA    O
,    O
CO2    O
,    O
and    O
NADP+    O
.    O

D.    O
propionicus    O
"    O
uses    O
the    O
methylmalony-CoA    B-Diol114835980
pathway    O
to    O
ferment    O
3    O
moles    O
of    O
pyruvate    O
to    O
2    O
moles    O
of    O
acetate    O
and    O
1    O
mole    O
of    O
propionate    O
.    O

Aminoshikimic    B-Diol114835980
acid    I-Diol114835980
is    O
a    O
synthetic    O
crystalline    O
carboxylic    O
acid    O
.    O

PAH    O
is    O
one    O
of    O
three    O
members    O
of    O
the    O
biopterin    B-Diol114835980
-    O
dependent    O
aromatic    O
amino    O
acid    O
hydroxylases    O
,    O
a    O
class    O
of    O
monooxygenase    O
that    O
uses    O
tetrahydrobiopterin    B-Diol114835980
(    O
BH4    O
,    O
a    O
pteridine    O
cofactor    O
)    O
and    O
a    O
non    O
-    O
heme    O
iron    O
for    O
catalysis    O
.    O

Defects    O
of    O
biopterin    B-Diol114835980
cofactor    O
biosynthesis    O

It    O
follows    O
that    O
an    O
increase    O
in    O
vitamin    O
D3    O
intake    O
should    O
lead    O
to    O
a    O
decrease    O
in    O
bone    O
resorption    O
—    O
it    O
has    O
been    O
shown    O
that    O
oral    O
administration    O
of    O
vitamin    O
D    O
does    O
not    O
linearly    O
correlate    O
to    O
increased    O
serum    O
levels    O
of    O
calcifediol    B-Diol114835980
,    O
the    O
precursor    O
to    O
calcitriol    O
.    O

T    O
-    O
cells    O
have    O
a    O
symbiotic    O
relationship    O
with    O
vitamin    O
D.    O
Not    O
only    O
does    O
the    O
T    O
-    O
cell    O
extend    O
a    O
vitamin    O
D    O
receptor    O
,    O
in    O
essence    O
asking    O
to    O
bind    O
to    O
the    O
steroid    O
hormone    O
version    O
of    O
vitamin    O
D    O
,    O
calcitriol    O
,    O
but    O
the    O
T    O
-    O
cell    O
expresses    O
the    O
gene    O
CYP27B1    O
,    O
which    O
is    O
the    O
gene    O
responsible    O
for    O
converting    O
the    O
pre    O
-    O
hormone    O
version    O
of    O
vitamin    O
D    O
,    O
calcidiol    B-Diol114835980
into    O
the    O
steroid    O
hormone    O
version    O
,    O
calcitriol    O
.    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Diol114835980
(    O
a    O
vitamin    O
D    O
)    O
-Standard    O
reference    O
range    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Diol114835980
-Therapeutic    O
target    O
range    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Diol114835980
(    O
a    O
vitamin    O
D    O
)    O

Third    O
generation    O
products    O
contain    O
brodifacoum    O
or    O
bromadiolone    B-Diol114835980
and    O
are    O
toxic    O
after    O
a    O
single    O
ingestion    O
.    O

Second    O
generation    O
:    O
difenacoum    O
,    O
brodifacoum    O
,    O
flocoumafen    O
and    O
bromadiolone    B-Diol114835980
.    O

Flavoxanthin    B-Diol114835980
is    O
a    O
natural    O
xanthophyll    O
pigment    O
with    O
a    O
golden    O
-    O
yellow    O
color    O
found    O
in    O
small    O
quantities    O
in    O
a    O
variety    O
of    O
plants    O
.    O

Cyclohexane-1,2-diol    B-Diol114835980
,    O
a    O
chemical    O
compound    O
found    O
in    O
castoreum    O

Cocamide    B-Diol114835980
DEA    I-Diol114835980
,    O
or    O
cocamide    B-Diol114835980
diethanolamine    I-Diol114835980
,    O
is    O
a    O
diethanolamide    O
made    O
by    O
reacting    O
the    O
mixture    O
of    O
fatty    O
acids    O
from    O
coconut    O
oils    O
with    O
diethanolamine    B-Diol114835980
.    O

A    O
neurotoxin    O
called    O
homobatrachotoxin    B-Diol114835980
found    O
in    O
the    O
birds    O
'    O
skin    O
and    O
feathers    O
causes    O
numbness    O
and    O
tingling    O
in    O
those    O
touching    O
the    O
bird    O
.    O

This    O
genus    O
of    O
beetle    O
is    O
known    O
to    O
have    O
high    O
levels    O
of    O
batrachotoxin    B-Diol114835980
and    O
is    O
believed    O
to    O
be    O
a    O
possible    O
toxin    O
source    O
for    O
Pitohui    O
and    O
Blue    O
-    O
capped    O
ifrit    O
birds    O
in    O
New    O
Guinea    O
.    O

The    O
combined    O
brachial    O
secretion    O
and    O
saliva    O
of    O
recently    O
captured    O
wild    O
lorises    O
was    O
shown    O
to    O
contain    O
batrachotoxin    B-Diol114835980
,    O
which    O
were    O
not    O
found    O
in    O
slow    O
lorises    O
held    O
in    O
captivity    O
for    O
more    O
than    O
a    O
year    O
.    O

Batrachotoxin    B-Diol114835980

batrachotoxin    B-Diol114835980

With    O
a    O
Schrock    O
catalyst    O
modified    O
with    O
a    O
BINOL    B-Diol114835980
ligand    O
in    O
a    O
norbornadiene    O
ROMP    O
leading    O
to    O
highly    O
stereoregular    O
cis    O
,    O
isotactic    O
polymer    O
.    O

Indole    O
reacts    O
with    O
an    O
enamide    O
catalyzed    O
by    O
a    O
chiral    O
BINOL    B-Diol114835980
derived    O
phosphoric    O
acid    O
:    O

In    O
2012    O
,    O
a    O
BINOL    B-Diol114835980
-    O
derived    O
catalyst    O
was    O
employed    O
to    O
generate    O
chiral    O
cyanide    O
anion    O
.    O

Other    O
phosphine    O
asymmetric    O
ligands    O
were    O
known    O
at    O
the    O
time    O
(    O
DIPAMP    O
,    O
BINOL    B-Diol114835980
,    O
CHIRAPHOS    O
)    O
but    O
the    O
new    O
ligand    O
was    O
found    O
to    O
be    O
more    O
effective    O
.    O

Ursodeoxycholic    B-Diol114835980
acid    I-Diol114835980
therapy    O
is    O
beneficial    O
,    O
but    O
the    O
disease    O
often    O
progresses    O
and    O
may    O
require    O
liver    O
transplantation    O
.    O

Urso    B-Diol114835980

Some    O
medication    O
,    O
such    O
as    O
ursodeoxycholic    B-Diol114835980
acid    I-Diol114835980
,    O
may    O
be    O
used    O
;    O
and    O
lithotripsy    O
,    O
a    O
procedure    O
used    O
to    O
break    O
down    O
the    O
stones    O
,    O
may    O
also    O
be    O
used    O
.    O

Disease    O
might    O
be    O
investigated    O
using    O
ultrasound    O
or    O
ERCP    O
,    O
and    O
might    O
be    O
treated    O
with    O
drugs    O
such    O
as    O
antibiotics    O
or    O
UDCA    B-Diol114835980
,    O
or    O
by    O
the    O
surgical    O
removal    O
of    O
the    O
gallbladder    O
.    O

Upon    O
diagnosis    O
,    O
many    O
providers    O
will    O
prescribe    O
Ursodeoxycholic    B-Diol114835980
Acid    I-Diol114835980
.    O

Her    O
internet    O
work    O
has    O
also    O
garnered    O
Web    O
Marketing    O
Association    O
's    O
best    O
education    O
website    O
,    O
numerous    O
CASE    O
awards    O
,    O
and    O
a    O
UCDA    B-Diol114835980
Gold    O
award    O
.    O

Dihydroxyphenylethylene    B-Diol114835980
glycol    I-Diol114835980
(    O
DOPEG    O
)    O
→    O
Methoxyhydroxyphenylglycol    O
(    O
MOPEG    O
)    O

Antagonists    O
/    O
negative    O
allosteric    O
modulators    O
:    O
bicuculline    O
,    O
cicutoxin    B-Diol114835980
,    O
flumazenil    O
,    O
furosemide    O
,    O
gabazine    O
,    O
oenanthotoxin    B-Diol114835980
,    O
picrotoxin    B-Diol114835980
,    O
Ro15    O
-    O
4513    O
,    O
thujone    O
,    O
amentoflavone    O
.    O

The    O
chief    O
poison    O
is    O
cicutoxin    B-Diol114835980
,    O
an    O
unsaturated    O
aliphatic    O
alcohol    O
that    O
is    O
most    O
concentrated    O
in    O
the    O
roots    O
.    O

The    O
company    O
's    O
products    O
include    O
Botox    O
,    O
Namenda    O
,    O
Restasis    O
,    O
Linzess    O
,    O
Bystolic    B-Diol114835980
,    O
Juvederm    O
,    O
Latisse    O
,    O
Lo    O
Loestrin    O
Fe    O
,    O
Estrace    O
,    O
Teflaro    O
,    O
Dalvance    O
,    O
Ozurdex    O
,    O
Optive    O
,    O
Natrelle    O
,    O
Viibryd    O
,    O
Liletta    O
,    O
Saphris    O
,    O
Enablex    O
,    O
Actonel    O
,    O
Androderm    O
,    O
Gelnique    O
and    O
others    O
.    O

Nebivolol    B-Diol114835980
(    O
in    O
hypertension    O
)    O

Nebivolol    B-Diol114835980

1,6-Hexanediol    B-Diol114835980

The    O
synthetic    O
analogs    O
that    O
like    O
PGF2α    O
act    O
as    O
selective    O
receptor    O
agonists    O
of    O
FP    O
viz    O
.    O
,    O
cloprostenol    O
,    O
flupostenol    O
,    O
latanoprost    O
,    O
and    O
tafluprost    O
(    O
acid    O
form    O
)    O
have    O
FP    O
binding    O
affinities    O
and    O
stimulating    O
potencies    O
similar    O
to    O
PGF2α    O
while    O
others    O
as    O
enprostil    O
,    O
sulprostone    B-Diol114835980
,    O
U46619    O
,    O
carbacyclin    O
,    O
and    O
iloprost    O
are    O
considerably    O
weaker    O
FP    O
agonists    O
.    O

As    O
with    O
dynemicin    O
A    O
,    O
neocarzinostatin    B-Diol114835980
also    O
interacts    O
with    O
DNA    O
.    O

Xylosan    B-Diol114835980

The    O
multiple    O
sclerosis    O
drug    O
fingolimod    B-Diol114835980
was    O
derived    O
from    O
myriocin    O
by    O
using    O
structure    O
–    O
activity    O
relationship    O
studies    O
to    O
determine    O
the    O
parts    O
of    O
the    O
molecule    O
important    O
to    O
its    O
activity    O
.    O

The    O
boxed    O
warning    O
had    O
been    O
included    O
for    O
the    O
drugs    O
Tecfidera    O
and    O
Gilenya    B-Diol114835980
,    O
both    O
of    O
which    O
have    O
had    O
incidences    O
of    O
PML    O
resulting    O
in    O
death    O
.    O

Siponimod    O
may    O
be    O
very    O
similar    O
to    O
fingolimod    B-Diol114835980
but    O
preventing    O
lymphopenia    O
,    O
one    O
of    O
its    O
main    O
side    O
effects    O
,    O
by    O
preventing    O
egress    O
of    O
lymphocytes    O
from    O
lymph    O
nodes    O
.    O

PRIMUS    O
has    O
been    O
used    O
to    O
assess    O
the    O
efficacy    O
of    O
fingolimod    B-Diol114835980
and    O
rivastigmine    O
.    O

Pinacol    B-Diol114835980

After    O
deprotection    O
(    O
pinacol    B-Diol114835980
)    O
to    O
diol    O
2.6    O
,    O
DIBAL    O
reduction    O
to    O
triol    O
2.7    O
and    O
TBS    O
reprotection    O
(    O
TBSOtf    O
,    O
lutidine    O
)    O
to    O
alcohol    O
2.8    O
it    O
was    O
possible    O
to    O
remove    O
the    O
phenylsulfide    O
group    O
in    O
a    O
with    O
tributyltin    O
hydride    O
and    O
AIBN(see    O
Barton    O
-    O
McCombie    O
deoxygenation    O
)    O
to    O
alcohol    O
2.9    O
.    O

These    O
thioesters    O
are    O
made    O
by    O
conjugating    O
the    O
fatty    O
acid    O
with    O
the    O
free    O
SH    O
group    O
of    O
the    O
pantetheine    B-Diol114835980
moiety    O
of    O
either    O
coenzyme    O
A    O
(    O
CoA    O
)    O
or    O
acyl    O
carrier    O
protein    O
(    O
ACP    O
)    O
.    O

Cyclobutanediol    B-Diol114835980
as    O
an    O
alternative    O
to    O
bisphenol    O
A    O

levosalbutamol    B-Diol114835980
(    O
INN    O
)    O
or    O
levalbuterol    O
(    O
USAN    O
)    O

Levalbuterol    B-Diol114835980

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
16-hydroxytabersonine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
16-methoxytabersonine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
5,8,13,13a    O
-    O
tetrahydrocolumbamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tetrahydropalmatine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
7-methylxanthine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
3,7-dimethylxanthine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
dimethyl    O
sulfide    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
trimethylsulfonium    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
thiol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
thioether    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
gamma    O
-    O
tocopherol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
alpha    O
-    O
tocopherol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
trans    O
-    O
aconitate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
(    O
E)-3-(methoxycarbonyl)pent-2-enedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
trans    O
-    O
aconitate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
(    O
E)-2-(methoxycarbonylmethyl)butenedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
5-methylaminomethyl-2-thiouridylic    O
acid    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
N1-methyladenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
N6-methyladenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
5-methylcytosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
N1-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
N2-Methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
N7-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
2'-O    O
-    O
methylguanosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tRNA    O
containing    O
uridine    O
at    O
position    O
54    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
tRNA    O
containing    O
ribothymidine    O
at    O
position    O
54    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
L    O
-    O
tryptophan    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
L-2-methyltryptophan    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
tyramine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
N    O
-    O
methyltyramine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
vitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
7-O    O
-    O
methylvitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
and    O
xanthotoxol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Diol114835980
and    O
O    O
-    O
methylxanthotoxol    O
.    O

DPD    O
is    O
produced    O
by    O
degradation    O
of    O
"S"-adenosylhomocysteine    B-Diol114835980
by    O
the    O
action    O
of    O
the    O
enzyme    O
"    O
S    O
"-    O
ribosylhomocysteinase    O
.    O

The    O
pathway    O
for    O
the    O
synthesis    O
of    O
creatineArg    O
-    O
Arginine    O
;    O
GATM    O
-    O
Glycine    O
amidinotransferase    O
;    O
GAMT    O
-    O
Guanidinoacetate    O
N    O
-    O
methyltransferase    O
;    O
Gly    O
-    O
Glycine    O
;    O
Met    O
-    O
Methionine    O
;    O
SAH    O
-    O
S-adenosyl    B-Diol114835980
homocysteine    I-Diol114835980
;    O
SAM    O
-    O
S-adenosyl    B-Diol114835980
methionine    I-Diol114835980
.    O

According    O
to    O
the    O
official    O
blog    O
of    O
Autism    O
Speaks    O
,    O
James    O
found    O
that    O
autistic    O
children    O
exhibit    O
abnormal    O
folate    O
metabolism    O
that    O
is    O
detectable    O
by    O
higher    O
levels    O
of    O
plasma    O
homocysteine    O
,    O
adenosine    O
,    O
and    O
S-adenosyl-L-homocysteine    B-Diol114835980
in    O
the    O
mothers    O
of    O
these    O
children    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-homocysteine    B-Diol114835980
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
inosyl    O
-    O
L    O
-    O
homocysteine    O
and    O
NH3    O
.    O

The    O
5    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Diol114835980
,    O
malonyl    O
-    O
CoA    O
,    O
NADPH    O
,    O
H+    O
,    O
and    O
S-adenosyl-L-methionine    B-Diol114835980
,    O
whereas    O
its    O
6    O
products    O
are    O
dihydromonacolin    O
L    O
,    O
CoA    O
,    O
CO2    O
,    O
NADP+    O
,    O
S-adenosyl-L-homocysteine    B-Diol114835980
,    O
and    O
H2O.    O

Abbreviations    O
:    O
S-Adenosyl-L-homocysteine    B-Diol114835980
(    O
SAH    O
)    O
,    O
S-adenosyl-L-methionine    B-Diol114835980
(    O
SAM    O
)    O
,    O
DNA    O
methyltransferase    O
(    O
DNA    O
MTase    O
)    O
,    O
Uracil    O
-    O
DNA    O
glycosylase    O
(    O
UNG    O
)    O
.    O

:    O
(    O
1    O
)    O
violaxanthin    B-Diol114835980
capsorubin    B-Diol114835980

:    O
(    O
2    O
)    O
antheraxanthin    O
capsanthin    B-Diol114835980

desoximetasone    B-Diol114835980
(    O
INN    O
)    O

Ointment    O
and    O
creams    O
containing    O
coal    O
tar    O
,    O
dithranol    O
,    O
corticosteroids    O
(    O
i.e.    O
desoximetasone    B-Diol114835980
)    O
,    O
fluocinonide    O
,    O
vitamin    O
D3    O
analogs    O
(    O
for    O
example    O
,    O
calcipotriol    O
)    O
,    O
and    O
retinoids    O
are    O
routinely    O
used    O
.    O

Ambroxide    O
is    O
synthesized    O
from    O
sclareol    B-Diol114835980
,    O
a    O
component    O
of    O
the    O
essential    O
oil    O
of    O
clary    O
sage    O
.    O

Methods    O
of    O
protection    O
against    O
contact    O
with    O
mosquitos    O
include    O
using    O
insect    O
repellents    O
with    O
substances    O
such    O
as    O
DEET    O
,    O
icaridin    O
,    O
PMD    O
(    O
p-menthane-3,8-diol    B-Diol114835980
,    O
a    O
substance    O
derived    O
from    O
the    O
lemon    O
eucalyptus    O
tree    O
)    O
,    O
or    O
IR3535    O
.    O

The    O
refined    O
oil    O
's    O
citronellal    O
content    O
is    O
turned    O
into    O
cis-    O
and    O
trans-    O
isomers    O
of    O
p-menthane-3,8-diol    B-Diol114835980
(    O
PMD    O
)    O
,    O
a    O
process    O
which    O
occurs    O
naturally    O
as    O
the    O
eucalyptus    O
leaves    O
age    O
.    O

Treosulfan    B-Diol114835980
is    O
a    O
substance    O
that    O
is    O
being    O
studied    O
in    O
the    O
treatment    O
of    O
cancer    O
.    O

He    O
named    O
the    O
newly    O
discovered    O
chemical    O
compound    O
as    O
"    O
Ajmaline    B-Diol114835980
"    O
,    O
after    O
his    O
mentor    O
Hakim    O
Ajmal    O
Khan    O
who    O
was    O
one    O
of    O
the    O
illustrious    O
practitioners    O
of    O
Unani    O
system    O
of    O
medicine    O
in    O
South    O
Asia    O
.    O

Vomilenine    O
is    O
an    O
intermediate    O
chemical    O
in    O
the    O
biosynthesis    O
of    O
ajmaline    B-Diol114835980
.    O

Class    O
Ia    O
—    O
Fast    O
sodium    O
channels    O
(    O
quinidine    O
,    O
ajmaline    B-Diol114835980
,    O
procainamide    O
,    O
disopyramide    O
)    O

Common    O
variants    O
replace    O
part    O
of    O
the    O
shrimp    O
or    O
peas    O
with    O
fish    O
meat    O
,    O
spinach    O
,    O
spirulina    O
,    O
or    O
mussel    O
meat    O
,    O
and    O
add    O
astaxanthin    B-Diol114835980
,    O
ascorbic    O
acid    O
,    O
or    O
garlic    O
.    O

Due    O
to    O
the    O
nature    O
of    O
canthaxanthin    O
,    O
relative    O
to    O
astaxanthin    B-Diol114835980
(    O
a    O
carotenoid    O
of    O
significant    O
commercial    O
value    O
)    O
these    O
beta    O
-    O
carotene    O
ketolase    O
proteins    O
have    O
been    O
studied    O
extensively    O
.    O

Canthaxanthin    O
is    O
used    O
in    O
combination    O
with    O
astaxanthin    B-Diol114835980
for    O
some    O
salmon    O
feeds    O
.    O

Astaxanthin    B-Diol114835980
-    O
found    O
naturally    O
in    O
red    O
algae    O
and    O
animals    O
higher    O
in    O
the    O
marine    O
food    O
chain    O
.    O

β-Crustacyanin    O
(    O
β-CR    O
)    O
,    O
is    O
composed    O
of    O
two    O
stacked    O
astaxanthin    B-Diol114835980
carotenoids    O
that    O
absorb    O
at    O
λ    O
=    O
580–590    O
nm    O
(    O
2.10–2.14    O
eV    O
)    O
.    O

Astaxanthin    B-Diol114835980
is    O
the    O
main    O
carotenoid    O
in    O
marine    O
crustaceans    O
(    O
and    O
fish    O
)    O
.    O

Astaxanthin    B-Diol114835980

FL3    B-Diol114835980
(flavagline)    I-Diol114835980

Lycorine    B-Diol114835980
is    O
toxic    O
in    O
sufficient    O
quantities    O
,    O
particularly    O
in    O
pets    O
and    O
small    O
children    O
.    O

Lycorine    B-Diol114835980
is    O
a    O
toxic    O
crystalline    O
alkaloid    O
found    O
in    O
various    O
Amaryllidaceae    O
species    O
,    O
such    O
as    O
the    O
cultivated    O
bush    O
lily    O
(    O
"    O
Clivia    O
miniata    O
"    O
)    O
,    O
surprise    O
lilies    O
(    O
"    O
Lycoris    O
"    O
)    O
,    O
and    O
daffodils    O
(    O
"    O
Narcissus    O
"    O
)    O
.    O

Melacacidin    B-Diol114835980
,    O
a    O
leucoanthocyanidin    O

Fenpentadiol    B-Diol114835980

The    O
protein    O
encoded    O
by    O
this    O
gene    O
is    O
a    O
bifunctional    O
enzyme    O
which    O
converts    O
leukotriene    O
A4    O
to    O
leukotriene    B-Diol114835980
B4    I-Diol114835980
and    O
acts    O
as    O
an    O
aminopeptidase    O
.    O

This    O
polyunsaturated    O
fatty    O
acid    O
is    O
metabolized    O
by    O
cyclooxygenases    O
to    O
various    O
prostaglandin    O
,    O
thromboxane    O
,    O
and    O
prostacyclin    B-Diol114835980
metabolites    O
in    O
what    O
has    O
been    O
termed    O
the    O
first    O
pathway    O
of    O
eicosanoid    O
production    O
;    O
it    O
is    O
also    O
metabolized    O
by    O
various    O
lipoxygenases    O
to    O
hydroxyeicosatetraenoic    O
acids    O
(    O
e.g.    O
5-Hydroxyeicosatetraenoic    O
acid    O
,    O
12-Hydroxyeicosatetraenoic    O
acid    O
,    O
15-hydroxyicosatetraenoic    O
acid    O
)    O
and    O
leukotrienes    O
(    O
e.g.    O
leukotriene    B-Diol114835980
B4    I-Diol114835980
,    O
leukotriene    O
C4    O
)    O
in    O
what    O
has    O
been    O
termed    O
the    O
second    O
pathway    O
of    O
eicosanoid    O
production    O
.    O

Leukotriene    O
B4    O
receptors    O
(    O
BLTRs    O
)    O
-    O
bind    O
to    O
and    O
are    O
activated    O
by    O
LTB4    B-Diol114835980
:    O

Leukotriene    B-Diol114835980
B4    I-Diol114835980

LTB4    B-Diol114835980

These    O
factors    O
include    O
most    O
particularly    O
chemokines    O
such    O
as    O
monocyte    O
chemotactic    O
protein-1    O
(    O
CCL2    O
)    O
and    O
monocyte    O
chemotactic    O
protein-3    O
(    O
CCL7    O
)    O
;    O
certain    O
arachidonic    O
acid    O
metabolites    O
such    O
as    O
Leukotriene    B-Diol114835980
B4    I-Diol114835980
and    O
members    O
of    O
the    O
5-Hydroxyicosatetraenoic    O
acid    O
and    O
5-oxo    O
-    O
eicosatetraenoic    O
acid    O
family    O
of    O
OXE1    O
receptor    O
agonists    O
(    O
e.g.    O
,    O
5-HETE    O
and    O
5-oxo    O
-    O
ETE    O
)    O
;    O
and    O
N    O
-    O
Formylmethionine    O
leucyl    O
-    O
phenylalanine    O
and    O
other    O
N    O
-    O
formylated    O
oligopeptides    O
which    O
are    O
made    O
by    O
bacteria    O
and    O
activate    O
the    O
formyl    O
peptide    O
receptor    O
1    O
.    O

All    O
of    O
the    O
prostanoid    O
receptors    O
are    O
G    O
-    O
protein    O
-    O
coupled    O
receptors    O
belonging    O
to    O
the    O
Subfamily    O
A14    O
of    O
the    O
rhodopsin    O
-    O
like    O
receptor    O
family    O
except    O
for    O
the    O
Prostaglandin    O
DP2    O
receptor    O
which    O
is    O
more    O
closely    O
related    O
in    O
amino    O
acid    O
sequence    O
and    O
functionality    O
to    O
chemotactic    O
factor    O
receptors    O
such    O
as    O
the    O
receptors    O
for    O
C5a    O
and    O
leukotriene    B-Diol114835980
B4    I-Diol114835980
.    O

This    O
metabolism    O
of    O
arachidonic    O
acid    O
produces    O
20-hydroxy    O
-    O
arachidonic    O
acid    O
(    O
i.e.    O
20-hydroxyeicosatetraeonic    O
acid    O
or    O
20-HETE    O
)    O
,    O
a    O
bioactive    O
product    O
involved    O
in    O
various    O
physiological    O
and    O
pathological    O
processes    O
(    O
see    O
20-Hydroxyeicosatetraenoic    O
acid    O
)    O
;    O
and    O
this    O
metabolism    O
of    O
certain    O
bioactive    O
arachidonic    O
acid    O
metabolites    O
such    O
as    O
leukotriene    B-Diol114835980
B4    I-Diol114835980
,    O
5-Hydroxyicosatetraenoic    O
acid    O
,    O
and    O
5-oxo    O
-    O
hydroxyeiocatetraenoic    O
acid    O
(    O
see    O
5-Hydroxyicosatetraenoic    O
acid    O
)    O
produces    O
20-hydroxylated    O
products    O
which    O
are    O
100-    O
to    O
1,000-fold    O
weaker    O
than    O
,    O
and    O
therefore    O
represents    O
the    O
inactivation    O
of    O
,    O
their    O
respective    O
precursors    O
.    O

"    O
Swertia    O
"    O
contains    O
the    O
chemicals    O
sawertiamarine    O
,    O
mangeferin    O
and    O
amarogenitine    O
1,5,8-trihydroxy-3-methoxyxanthone    O
,    O
1-hydroxy-2,3,5,7-tetramethoxyxanthone    O
,    O
1-hydroxy-3,5,8-trimethoxyxanthone    O
,    O
1-hydroxyl-2,3,4,6-tetramethoxyxanthone    O
,    O
1-hydroxy-2,3,4,7-tetramethoxyxanthone    O
,    O
1,8-dihydroxy-3,5-dimethoxyxanthone    O
,    O
1,7-dihydroxy-3,8-dimethoxyxanthone    O
,    O
1,3,5,8-tetrahydroxyxanthone    O
,    O
balanophonin    O
,    O
oleanolic    O
acid    O
,    O
maslinic    B-Diol114835980
acid    I-Diol114835980
,    O
and    O
sumaresinolic    O
acid    O

1,3-Butanediol    B-Diol114835980

PEG    B-Diol114835980
PABA    O
(    O
Uvinul    O
P    O
25    O
)    O

For    O
external    O
exposure    O
,    O
bathing    O
the    O
mucous    O
membrane    O
surfaces    O
that    O
have    O
contacted    O
capsaicin    O
with    O
oily    O
compounds    O
such    O
as    O
vegetable    O
oil    O
,    O
paraffin    O
oil    O
,    O
petroleum    O
jelly    O
(    O
Vaseline    O
)    O
,    O
creams    O
,    O
or    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
is    O
the    O
most    O
effective    O
way    O
to    O
attenuate    O
the    O
associated    O
discomfort    O
;    O
since    O
oil    O
and    O
capsaicin    O
are    O
both    O
hydrophobic    O
hydrocarbons    O
the    O
capsaicin    O
that    O
has    O
not    O
already    O
been    O
absorbed    O
into    O
tissues    O
will    O
be    O
picked    O
up    O
into    O
solution    O
and    O
easily    O
removed    O
.    O

Several    O
grades    O
of    O
this    O
material    O
are    O
available    O
depending    O
of    O
the    O
level    O
of    O
ethoxylation    O
performed    O
,    O
with    O
repeat    O
units    O
(    O
"    O
n    O
"    O
)    O
of    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
varying    O
between    O
2    O
and    O
20    O
.    O

Tocofersolan    O
is    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
derivative    O
of    O
α-tocopherol    O
that    O
enables    O
water    O
solubility    O
.    O

Paintballs    O
(    O
pellets    O
)    O
:    O
Paintballs    O
,    O
the    O
ammunition    O
used    O
in    O
the    O
marker    O
,    O
are    O
spherical    O
gelatin    O
capsules    O
containing    O
primarily    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
other    O
non    O
-    O
toxic    O
and    O
water    O
-    O
soluble    O
substances    O
,    O
and    O
dye    O
.    O

Polyethylene    B-Diol114835980
oxide    I-Diol114835980
,    O
a    O
polymer    O

This    O
molecule    O
consists    O
of    O
a    O
hydrophilic    O
PEG    B-Diol114835980
backbone    O
with    O
two    O
hydrophilic    O
terminal    O
groups    O
(    O
CnF2n+1-CH2CH2O    O
)    O
attached    O
via    O
isophorone    O
diurethane    O
.    O

Other    O
–    O
chemical    O
moieties    O
such    O
as    O
maleimide    O
,    O
click    O
residues    O
,    O
PEG    B-Diol114835980
,    O
charged    O
compounds    O

For    O
example    O
,    O
in    O
January    O
2001    O
,    O
the    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
approved    O
the    O
use    O
of    O
PEGylated    O
interferon    O
-    O
alpha    O
in    O
the    O
USA    O
;    O
in    O
this    O
formulation    O
,    O
PEGylated    O
interferon    O
-    O
alpha-2b    O
(    O
"    O
Pegintron    O
"    O
)    O
,    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
is    O
linked    O
to    O
the    O
interferon    O
molecule    O
to    O
make    O
the    O
interferon    O
last    O
longer    O
in    O
the    O
body    O
.    O

Pegvisomant    O
is    O
a    O
protein    O
containing    O
191    O
amino    O
acid    O
residues    O
to    O
which    O
several    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
polymers    O
have    O
been    O
covalently    O
bound    O
in    O
order    O
to    O
slow    O
clearance    O
from    O
the    O
blood    O
.    O

Polyoxyethylene    B-Diol114835980

The    O
substituent    O
can    O
also    O
be    O
a    O
small    O
molecule    O
(    O
such    O
as    O
biotin    O
,    O
a    O
fluorescent    O
dye    O
,    O
an    O
oligosaccharide    O
a    O
nucleic    O
acid    O
)    O
,    O
a    O
reactive    O
group    O
,    O
or    O
a    O
synthetic    O
polymer    O
such    O
as    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
.    O

Maleimides    O
linked    O
to    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
chains    O
are    O
often    O
used    O
as    O
flexible    O
linking    O
molecules    O
to    O
attach    O
proteins    O
to    O
surfaces    O
.    O

The    O
chemistry    O
is    O
based    O
upon    O
the    O
interaction    O
of    O
caesium    O
and    O
strontium    O
with    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
)    O
and    O
a    O
cobalt    O
carborane    O
anion    O
(    O
known    O
as    O
chlorinated    O
cobalt    O
dicarbollide    O
)    O
.    O

Polyethylene    B-Diol114835980
glycol    I-Diol114835980
are    O
more    O
commonly    O
used    O
in    O
practical    O
applications    O
.    O

Similar    O
to    O
coating    O
liposomes    O
with    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
polymersomes    O
can    O
be    O
made    O
invisible    O
to    O
the    O
immune    O
system    O
if    O
the    O
hydrophilic    O
block    O
consists    O
of    O
polyethylene    O
glycol    O
.    O

Poly(ethylene    B-Diol114835980
glycol)    I-Diol114835980
(    O
PEG    O
/    O
PEO    O
)    O

Other    O
block    O
copolymers    O
also    O
show    O
the    O
shape    O
-    O
memory    O
effect    O
,    O
such    O
as    O
,    O
block    O
copolymer    O
of    O
polyethylene    O
terephthalate    O
(    O
PET    O
)    O
and    O
polyethyleneoxide    B-Diol114835980
(    O
PEO    O
)    O
,    O
block    O
copolymers    O
containing    O
polystyrene    O
and    O
poly(1,4-butadiene    O
)    O
,    O
and    O
an    O
ABA    O
triblock    O
copolymer    O
made    O
from    O
poly(2-methyl-2-oxazoline    O
)    O
and    O
polytetrahydrofuran    B-Diol114835980
.    O

The    O
conservation    O
process    O
involved    O
keeping    O
the    O
wood    O
in    O
heated    O
tanks    O
in    O
a    O
solution    O
of    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
and    O
,    O
by    O
a    O
process    O
of    O
evaporation    O
,    O
gradually    O
replacing    O
the    O
water    O
in    O
the    O
wood    O
with    O
the    O
wax    O
over    O
a    O
period    O
of    O
about    O
nine    O
months    O
.    O

Poloxamers    O
are    O
nonionic    O
triblock    O
copolymers    O
composed    O
of    O
a    O
central    O
hydrophobic    O
chain    O
of    O
polyoxypropylene    O
(    O
poly(propylene    O
oxide    O
)    O
)    O
flanked    O
by    O
two    O
hydrophilic    O
chains    O
of    O
polyoxyethylene    B-Diol114835980
(    O
poly(ethylene    O
oxide    O
)    O
)    O
.    O

For    O
the    O
Pluronic    O
and    O
Synperonic    O
tradenames    O
,    O
coding    O
of    O
these    O
copolymers    O
starts    O
with    O
a    O
letter    O
to    O
define    O
its    O
physical    O
form    O
at    O
room    O
temperature    O
(    O
L    O
=    O
liquid    O
,    O
P    O
=    O
paste    O
,    O
F    O
=    O
flake    O
(    O
solid    O
)    O
)    O
followed    O
by    O
two    O
or    O
three    O
digits    O
,    O
The    O
first    O
digit    O
(    O
two    O
digits    O
in    O
a    O
three    O
-    O
digit    O
number    O
)    O
in    O
the    O
numerical    O
designation    O
,    O
multiplied    O
by    O
300    O
,    O
indicates    O
the    O
approximate    O
molecular    O
weight    O
of    O
the    O
hydrophobe    O
;    O
and    O
the    O
last    O
digit    O
x    O
10    O
gives    O
the    O
percentage    O
polyoxyethylene    O
content    O
(    O
e.g.    O
,    O
L61    O
indicates    O
a    O
polyoxypropylene    O
molecular    O
mass    O
of    O
1,800    O
g    O
/    O
mol    O
and    O
a    O
10%    O
polyoxyethylene    B-Diol114835980
content    O
)    O
.    O

Thus    O
,    O
the    O
core    O
of    O
the    O
aggregates    O
is    O
made    O
from    O
the    O
insoluble    O
blocks    O
(    O
polyoxypropylene    O
)    O
while    O
the    O
soluble    O
portion    O
(    O
polyoxyethylene    B-Diol114835980
)    O
forms    O
the    O
shell    O
of    O
the    O
micelles    O
.    O

Besides    O
spherical    O
micelles    O
,    O
elongated    O
or    O
worm    O
-    O
like    O
micelles    O
can    O
also    O
be    O
formed    O
.    O
The    O
final    O
geometry    O
will    O
depend    O
on    O
the    O
entropy    O
costs    O
of    O
stretching    O
the    O
blocks    O
,    O
which    O
is    O
directly    O
related    O
to    O
their    O
composition    O
(    O
size    O
and    O
polyoxypropylene    O
/    O
polyoxyethylene    B-Diol114835980
ratio    O
)    O
.    O

Eventually    O
,    O
a    O
complete    O
dehydration    O
of    O
the    O
polyoxypropylene    O
blocks    O
and    O
the    O
collapse    O
of    O
the    O
polyoxyethylene    B-Diol114835980
chains    O
will    O
lead    O
to    O
clouding    O
and/or    O
macroscopic    O
phase    O
separation    O
.    O

This    O
is    O
due    O
to    O
the    O
fact    O
that    O
hydrogen    O
bonding    O
between    O
the    O
polyoxyethylene    B-Diol114835980
and    O
the    O
water    O
molecules    O
breaks    O
down    O
at    O
high    O
temperature    O
and    O
polyoxyethylene    B-Diol114835980
becomes    O
also    O
insoluble    O
in    O
water    O
.    O

Some    O
more    O
perylene    O
based    O
organic    O
rectifiers    O
with    O
PEG    O
(    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
)    O
swallowtails    O
have    O
been    O
synthesized    O
in    O
Mattern    O
's    O
lab    O
by    O
Ramakrishna    O
Samudrala    O
.    O

PEGylation    O
(    O
often    O
styled    O
pegylation    O
)    O
is    O
the    O
process    O
of    O
both    O
covalent    O
and    O
non    O
-    O
covalent    O
attachment    O
or    O
amalgamation    O
of    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
(    O
PEG    O
,    O
in    O
pharmacy    O
called    O
macrogol    O
)    O
polymer    O
chains    O
to    O
molecules    O
and    O
macrostructures    O
,    O
such    O
as    O
a    O
drug    O
,    O
therapeutic    O
protein    O
or    O
vesicle    O
,    O
which    O
is    O
then    O
described    O
as    O
PEGylated    O
(    O
pegylated    O
)    O
.    O

Polyethylene    B-Diol114835980
glycol    I-Diol114835980
(    O
in    O
pharmacy    O
called    O
macrogol    O
)    O
.    O

Examples    O
of    O
potentiators    O
include    O
albumin    O
,    O
LISS    O
(    O
low    O
ionic    O
-    O
strength    O
saline    O
)    O
and    O
PEG    O
(    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
)    O
.    O

Paintball    O
is    O
a    O
sport    O
in    O
which    O
participants    O
eliminate    O
opponents    O
from    O
play    O
by    O
hitting    O
them    O
with    O
paintballs    O
,    O
spherical    O
gelatin    O
capsules    O
containing    O
primarily    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
other    O
non    O
-    O
toxic    O
and    O
water    O
-    O
soluble    O
substances    O
,    O
and    O
dye    O
,    O
shot    O
from    O
a    O
compressed    O
-    O
gas    O
-    O
powered    O
gun    O
,    O
commonly    O
called    O
a    O
marker    O
.    O

Thickening    O
agents    O
used    O
in    O
cosmetics    O
or    O
personal    O
hygiene    O
products    O
include    O
viscous    O
liquids    O
such    O
as    O
polyethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
synthetic    O
polymers    O
such    O
as    O
carbomer    O
(    O
a    O
trade    O
name    O
for    O
polyacrylic    O
acid    O
)    O
and    O
vegetable    O
gums    O
.    O

1,8-Octanediol    B-Diol114835980
,    O
also    O
known    O
as    O
octamethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
is    O
a    O
diol    O
with    O
the    O
molecular    O
formula    O
HO(CH2)8OH    O
.    O

decitabine    B-Diol114835980
(    O
INN    O
)    O

In    O
a    O
methotrexate    O
resistant    O
breast    O
cancer    O
cell    O
line    O
lacking    O
drug    O
uptake    O
and    O
folate    O
carrier    O
expression    O
,    O
administration    O
of    O
DAC    B-Diol114835980
,    O
a    O
DNA    O
methylation    O
inhibitor    O
,    O
effectively    O
improved    O
drug    O
uptake    O
and    O
folate    O
carrier    O
expression    O
.    O

However    O
,    O
when    O
rats    O
were    O
treated    O
with    O
the    O
DNMT    O
inhibitors    O
zebularine    O
or    O
5-aza-2′-deoxycytidine    B-Diol114835980
immediately    O
after    O
fear    O
-    O
conditioning    O
,    O
they    O
demonstrated    O
reduced    O
learning    O
(    O
freezing    O
behavior    O
)    O
.    O

5-Aza-2'-deoxycytidine    O
(    O
decitabine    B-Diol114835980
)    O
is    O
a    O
nucleoside    O
analog    O
that    O
inhibits    O
DNMTs    O
by    O
trapping    O
them    O
in    O
a    O
covalent    O
complex    O
on    O
DNA    O
by    O
preventing    O
the    O
β-elimination    O
step    O
of    O
catalysis    O
,    O
thus    O
resulting    O
in    O
the    O
enzymes    O
'    O
degradation    O
.    O

Isosorbide    O
and    O
its    O
two    O
isomers    O
,    O
namely    O
isoidide    O
and    O
isomannide    O
,    O
are    O
dianhydrohexitol    B-Diol114835980
.    O

Naloxegol    B-Diol114835980

Naloxegol    B-Diol114835980
(    O
Movantik    O
)    O
–    O
PEGylated    O
naloxol    O
for    O
the    O
treatment    O
of    O
opioid    O
-    O
induced    O
constipation    O
in    O
adults    O
patients    O
with    O
chronic    O
non    O
-    O
cancer    O
pain    O
(    O
un    O
-    O
pegylated    O
methadone    O
can    O
cause    O
adverse    O
gastrointestinal    O
reactions    O
)    O
.    O

Disodium    O
guanylate    O
,    O
also    O
known    O
as    O
sodium    O
5'-guanylate    O
and    O
disodium    O
5'-guanylate    O
,    O
is    O
a    O
natural    O
sodium    O
salt    O
of    O
the    O
flavor    O
enhancing    O
nucleotide    O
guanosine    B-Diol114835980
monophosphate    I-Diol114835980
(    O
GMP    O
)    O
.    O

It    O
is    O
produced    O
by    O
combining    O
the    O
sodium    O
salts    O
of    O
the    O
natural    O
compounds    O
guanylic    B-Diol114835980
acid    I-Diol114835980
(    O
E626    O
)    O
and    O
inosinic    B-Diol114835980
acid    I-Diol114835980
(    O
E630    O
)    O
.    O

It    O
reversibly    O
inhibits    O
inosine    O
monophosphate    O
dehydrogenase    O
,    O
the    O
enzyme    O
that    O
controls    O
the    O
rate    O
of    O
synthesis    O
of    O
guanine    B-Diol114835980
monophosphate    I-Diol114835980
in    O
the    O
"    O
de    O
novo    O
"    O
pathway    O
of    O
purine    O
synthesis    O
used    O
in    O
the    O
proliferation    O
of    O
B    O
and    O
T    O
lymphocytes    O
.    O

Guanosine    B-Diol114835980
monophosphate    I-Diol114835980

:    O
ATP    O
+    O
GMP    B-Diol114835980
ADP    O
+    O
GDP    B-Diol114835980

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GMP    B-Diol114835980
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
GDP    B-Diol114835980
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    O
-    O
mannose    O
and    O
(    O
phosphomannan)n    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GMP    B-Diol114835980
and    O
(    O
phosphomannan)n+1    O
.    O

The    O
OMEGA    B-Diol114835980
process    I-Diol114835980
(    O
"    O
Only    O
MEG    O
Advantage    O
"    O
)    O
is    O
a    O
process    O
by    O
Shell    O
Global    O
Solutions    O
that    O
is    O
used    O
to    O
produce    O
ethylene    O
glycol    O
from    O
ethylene    O
.    O

Recent    O
clinical    O
studies    O
have    O
verified    O
that    O
red    O
alder    O
contains    O
betulin    B-Diol114835980
and    O
lupeol    O
,    O
compounds    O
shown    O
to    O
be    O
effective    O
against    O
a    O
variety    O
of    O
tumors    O
.    O

It    O
also    O
contains    O
glaucarubol    O
,    O
a    O
compound    O
characteristic    O
of    O
the    O
family    O
,    O
ellagic    O
acid    O
,    O
betulin    B-Diol114835980
and    O
(    O
—)-syringaresinol    O
.    O

The    O
hydrophilic    O
diethylene    B-Diol114835980
glycol    I-Diol114835980
stopper    O
on    O
the    O
left    O
(    O
gray    O
)    O
is    O
specifically    O
designed    O
to    O
anchor    O
to    O
the    O
silicon    O
wire    O
(    O
made    O
hydrophilic    O
by    O
phosphorus    O
doping    O
)    O
while    O
the    O
hydrophobic    O
tetraarylmethane    O
stopper    O
on    O
the    O
right    O
does    O
the    O
same    O
to    O
the    O
likewise    O
hydrophobic    O
titanium    O
wire    O
.    O

In    O
1937    O
,    O
S.    O
E.    O
Massengill    O
Company    O
,    O
a    O
pharmaceutical    O
manufacturer    O
,    O
created    O
a    O
preparation    O
of    O
sulfanilamide    O
using    O
diethylene    B-Diol114835980
glycol    I-Diol114835980
(    O
DEG    O
)    O
as    O
a    O
solvent    O
,    O
and    O
called    O
the    O
preparation    O
"    O
Elixir    O
Sulfanilamide    O
"    O
.    O

Shin    O
,    O
et    O
al    O
.    O
,    O
reported    O
in    O
2008    O
that    O
salivary    O
detection    O
of    O
ethanol    O
and    O
three    O
of    O
its    O
metabolites    O
(    O
methanol    O
,    O
ethylene    O
glycol    O
,    O
and    O
diethylene    B-Diol114835980
glycol    I-Diol114835980
)    O
had    O
“    O
relatively    O
high    O
sensitivity    O
and    O
specificity    O
”    O
and    O
that    O
such    O
testing    O
facilitates    O
rapid    O
diagnosis    O
of    O
alcohol    O
intoxication    O
.    O

Diethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
used    O
dangerously    O
by    O
some    O
winemakers    O
in    O
sweet    O
wines    O

Includes    O
mono-    O
and    O
di-    O
ethers    O
of    O
ethylene    O
glycol    O
,    O
diethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
and    O
triethylene    B-Diol114835980
glycol    I-Diol114835980
R-(OCH2CH2)n    O
-OR    O
'    O
where    O

An    O
outbreak    O
of    O
deaths    O
in    O
1937    O
due    O
to    O
a    O
medication    O
mixed    O
in    O
a    O
similar    O
compound    O
,    O
diethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
resulted    O
in    O
the    O
Food    O
,    O
Drug    O
,    O
and    O
Cosmetic    O
Act    O
of    O
1938    O
in    O
the    O
United    O
States    O
which    O
mandated    O
evidence    O
of    O
safety    O
before    O
new    O
medications    O
could    O
be    O
sold    O
.    O

He    O
investigated    O
Pharval    O
Laboratories    O
,    O
a    O
pharmaceutical    O
company    O
,    O
for    O
selling    O
cough    O
syrup    O
contaminated    O
with    O
diethylene    B-Diol114835980
glycol    I-Diol114835980
that    O
was    O
responsible    O
for    O
the    O
poisoning    O
of    O
two    O
hundred    O
children    O
,    O
of    O
whom    O
sixty    O
died    O
.    O

For    O
example    O
,    O
in    O
dry    O
dibutyl    O
ether    O
of    O
diethylene    B-Diol114835980
glycol    I-Diol114835980
,    O
the    O
solubility    O
exceeds    O
1    O
mol    O
/    O
L.    O
Saturated    O
solutions    O
in    O
the    O
organic    O
solvents    O
often    O
are    O
the    O
liquid    O
solvates    O
of    O
specific    O
stoichiometry    O
.    O

In    O
Austria    O
,    O
which    O
largely    O
abandoned    O
the    O
semi    O
-    O
sweet    O
wine    O
category    O
in    O
the    O
wake    O
of    O
the    O
1985    O
diethylene    B-Diol114835980
glycol    I-Diol114835980
scandal    O
in    O
order    O
to    O
concentrate    O
more    O
on    O
dry    O
wines    O
,    O
Spätlese    O
wines    O
are    O
much    O
less    O
common    O
than    O
in    O
Germany    O
.    O

This    O
reaction    O
is    O
used    O
in    O
the    O
production    O
of    O
various    O
antibiotics    O
including    O
chloramphenicol    O
,    O
dihydrostreptomycin    O
,    O
and    O
thiophenicol    B-Diol114835980
.    O

Sodium    O
borohydride    O
is    O
also    O
used    O
to    O
reduce    O
aldehydes    O
and    O
ketones    O
in    O
the    O
production    O
of    O
pharmaceuticals    O
including    O
chloramphenicol    O
,    O
thiophenicol    B-Diol114835980
,    O
vitamin    O
A    O
,    O
atropine    O
,    O
and    O
scopolamine    O
,    O
as    O
well    O
as    O
many    O
flavorings    O
and    O
aromas    O
.    O

Halotestin    B-Diol114835980

Fluoxymesterone    B-Diol114835980

Fluoxymesterone    B-Diol114835980

Selamectin    B-Diol114835980
(    O
Revolution    B-Diol114835980
)    O
is    O
a    O
topical    O
preventive    O
likewise    O
administered    O
monthly    O
;    O
it    O
also    O
controls    O
fleas    O
,    O
ticks    O
,    O
and    O
mites    O
.    O

Selamectin    B-Diol114835980
is    O
also    O
recommended    O
for    O
treatment    O
.    O

Selamectin    B-Diol114835980
(    O
trade    O
names    O
Revolution    B-Diol114835980
,    O
Stronghold    B-Diol114835980
)    O
is    O
a    O
topical    O
parasiticide    O
and    O
anthelminthic    O
used    O
on    O
dogs    O
and    O
cats    O
,    O
distributed    O
by    O
Zoetis    O
,    O
a    O
former    O
Pfizer    O
subsidiary    O
.    O

Allopumiliotoxin    B-Diol114835980
267A    I-Diol114835980

:    O
1,4-Butynediol    B-Diol114835980
is    O
produced    O
industrially    O
in    O
this    O
way    O
from    O
formaldehyde    O
and    O
acetylene    O
.    O

JZL184    O
is    O
an    O
irreversible    O
inhibitor    O
for    O
monoacylglycerol    O
lipase    O
(    O
MAGL    O
)    O
,    O
the    O
primary    O
enzyme    O
responsible    O
for    O
degrading    O
the    O
endocannabinoid    O
2-arachidonoylglycerol    B-Diol114835980
(    O
2-AG    O
)    O
.    O

It    O
displays    O
high    O
selectivity    O
for    O
MAGL    O
over    O
other    O
brain    O
serine    O
hydrolases    O
,    O
including    O
the    O
anandamide    O
-    O
degrading    O
enzyme    O
fatty    O
acid    O
amide    O
hydrolase    O
(    O
FAAH    O
)    O
,    O
thereby    O
making    O
it    O
a    O
useful    O
tool    O
for    O
studying    O
the    O
effects    O
of    O
endogenous    O
2-AG    B-Diol114835980
signaling    O
,    O
"    O
in    O
vivo    O
"    O
.    O

Administration    O
of    O
JZL184    O
to    O
mice    O
was    O
reported    O
to    O
cause    O
dramatic    O
elevation    O
of    O
brain    O
2-AG    B-Diol114835980
leading    O
to    O
several    O
cannabinoid    O
-    O
related    O
behavioral    O
effects    O
.    O

However    O
,    O
it    O
is    O
also    O
found    O
that    O
consumption    O
of    O
food    O
for    O
pleasure    O
increased    O
peripheral    O
levels    O
of    O
both    O
ghrelin    O
and    O
the    O
endocannabinoid    O
2-arachidonoyl-glycerol    B-Diol114835980
(    O
2-AG    O
)    O
in    O
healthy    O
humans    O
,    O
and    O
this    O
hedonic    O
eating    O
influences    O
food    O
intake    O
and    O
,    O
ultimately    O
,    O
body    O
mass    O
.    O

Insulin    O
is    O
a    O
major    O
regulator    O
of    O
endocannabinoid    O
(    O
EC    O
)    O
metabolism    O
and    O
insulin    O
treatment    O
has    O
been    O
shown    O
to    O
reduce    O
intracellular    O
ECs    O
,    O
the    O
2-arachidonylglycerol    B-Diol114835980
(    O
2-AG    O
)    O
and    O
anandamide    O
(    O
AEA    O
)    O
,    O
which    O
correspond    O
with    O
insulin    O
-    O
sensitive    O
expression    O
changes    O
in    O
enzymes    O
of    O
EC    O
metabolism    O
.    O

The    O
endocannabinoids    O
(    O
anandamide    O
,    O
AEA    O
,    O
and    O
2-arachidonoylglycerol    B-Diol114835980
,    O
2-AG    O
)    O
on    O
the    O
other    O
hand    O
,    O
are    O
non    O
-    O
charged    O
lipids    O
that    O
readily    O
cross    O
lipid    O
membranes    O
.    O

Glycerol    B-Diol114835980
monostearate    I-Diol114835980
,    O
a    O
type    O
of    O
emulsifier    O

Glycerol    B-Diol114835980
monostearate    I-Diol114835980
,    O
commonly    O
known    O
as    O
GMS    B-Diol114835980
,    O
is    O
an    O
organic    O
molecule    O
used    O
as    O
an    O
emulsifier    O
.    O

Hederagenin    B-Diol114835980

Squarate    O
and    O
related    O
anions    O
such    O
deltate    O
and    O
acetylenediolate    B-Diol114835980
have    O
been    O
obtained    O
from    O
carbon    O
monoxide    O
under    O
mild    O
conditions    O
by    O
reductive    O
coupling    O
of    O
CO    O
ligands    O
in    O
organouranium    O
complexes    O
.    O

Acetylenediol    B-Diol114835980

It    O
is    O
the    O
simplest    O
geminal    B-Diol114835980
diol    I-Diol114835980
,    O
and    O
formally    O
the    O
second    O
simplest    O
carbohydrate    O
(    O
after    O
formaldehyde    O
)    O
.    O

It    O
is    O
typically    O
hydrated    O
,    O
i.e.    O
,    O
one    O
keto    O
group    O
has    O
added    O
water    O
to    O
give    O
the    O
geminal    B-Diol114835980
diol    I-Diol114835980
.    O

:    O
C10AX03    O
Tiadenol    B-Diol114835980

Hydromorphinol    B-Diol114835980

hydromorphinol    B-Diol114835980
(    O
INN    O
)    O

#    O
Hydromorphinol    B-Diol114835980

This    O
includes    O
studies    O
looking    O
into    O
educational    O
intervention    O
,    O
topical    O
corticosteroids    O
and    O
pimecrolimus    B-Diol114835980
.    O

Fourteen    O
patients    O
with    O
hypopigmented    O
in    O
their    O
scarreed    O
tissues    O
were    O
treated    O
with    O
the    O
FP    O
receptor    O
agonist    O
,    O
bimatoprost    O
,    O
applied    O
topically    O
plus    O
laser    O
therapy    O
and    O
topical    O
tretinoin    O
or    O
pimecrolimus    B-Diol114835980
.    O

If    O
topical    O
corticosteroids    O
and    O
moisturisers    O
fail    O
,    O
short    O
-    O
term    O
treatment    O
with    O
topical    O
calcineurin    O
inhibitors    O
like    O
tacrolimus    O
or    O
pimecrolimus    B-Diol114835980
may    O
be    O
tried    O
,    O
although    O
they    O
are    O
usually    O
avoided    O
as    O
they    O
can    O
increase    O
the    O
risk    O
of    O
developing    O
skin    O
cancer    O
or    O
lymphoma    O
.    O

These    O
amino    O
acid    O
standards    O
can    O
be    O
visualized    O
on    O
the    O
TLC    O
substrate    O
by    O
exposure    O
to    O
ninhydrin    B-Diol114835980
,    O
which    O
colors    O
the    O
amino    O
acids    O
a    O
visible    O
purple    O
when    O
heated    O
at    O
~100    O
°C    O
.    O

Its    O
peptide    O
-    O
like    O
structure    O
,    O
including    O
the    O
presence    O
of    O
glycine    O
and    O
valine    O
,    O
was    O
first    O
suggested    O
by    O
a    O
combination    O
of    O
acidic    O
hydrolysis    O
,    O
acetylation    O
,    O
ninhydrin    B-Diol114835980
staining    O
,    O
and    O
paper    O
chromatography    O
,    O
among    O
other    O
experiments    O
.    O

At    O
the    O
bottom    O
end    O
of    O
the    O
separation    O
tube    O
,    O
the    O
effluent    O
is    O
mixed    O
with    O
ninhydrin    B-Diol114835980
,    O
a    O
chemical    O
that    O
changes    O
color    O
in    O
the    O
presence    O
of    O
amines    O
,    O
a    O
component    O
part    O
of    O
amino    O
acids    O
.    O

#    O
the    O
volume    O
of    O
ninhydrin    B-Diol114835980
added    O
to    O
the    O
effluent    O

2,3-Dihydroxy-3-methylpentanoic    B-Diol114835980
acid    I-Diol114835980
is    O
an    O
intermediate    O
in    O
the    O
metabolism    O
of    O
isoleucine    O
.    O

Nifurquinazol    B-Diol114835980

17α-Dihydroequilin    O
,    O
or    O
α-dihydroequilin    O
,    O
also    O
known    O
as    O
7-dehydro-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),7-tetraen-3,17α-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
,    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    O
,    O
equilenin    O
,    O
and    O
17α-estradiol    B-Diol114835980
.    O

17α-Dihydroequilenin    O
,    O
or    O
α-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17α-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    O
,    O
equilenin    O
,    O
and    O
17α-estradiol    B-Diol114835980
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
1.2%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    O
)    O
.    O

16β,17α-Epiestriol    O
,    O
or    O
16,17-epiestriol    O
,    O
also    O
known    O
as    O
16β-hydroxy-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10)-triene-3,16β,17α-triol    O
,    O
is    O
a    O
minor    O
and    O
weak    O
endogenous    O
steroidal    O
estrogen    O
that    O
is    O
related    O
to    O
17α-estradiol    B-Diol114835980
and    O
estriol    O
.    O

The    O
compound    O
is    O
then    O
treated    O
with    O
NADPH    O
and    O
dihydroflavinol    O
4-reductase    O
to    O
form    O
leucopelargonidin    B-Diol114835980
,    O
which    O
is    O
further    O
oxidized    O
with    O
oxygen    O
gas    O
,    O
"    O
alpha    O
"-    O
Ketogluteratic    O
acid    O
,    O
and    O
anthocyanidin    O
synthase    O
.    O

Levodropropizine    B-Diol114835980

Evoxine    B-Diol114835980

For    O
instance    O
,    O
squaraine    O
dyes    O
are    O
also    O
formed    O
via    O
reaction    O
of    O
squaric    B-Diol114835980
acid    I-Diol114835980
or    O
its    O
derivatives    O
with    O
so    O
-    O
called    O
"    O
methylene    O
bases    O
"    O
like    O
2-methyl    O
-    O
indolenines    O
,    O
2-methyl    O
-    O
benzthiazoles    O
or    O
2-methyl    O
-    O
benzo    O
-    O
selenazoles    O
.    O

Squaric    B-Diol114835980
acid    I-Diol114835980

Other    O
more    O
exotic    O
carbon    O
–    O
oxygen    O
anions    O
exist    O
,    O
such    O
as    O
acetylenedicarboxylate    O
(    O
O2C    O
–    O
C≡C    O
–    O
CO22−    O
)    O
,    O
mellitate    O
(    O
C12O96−    O
)    O
,    O
squarate    B-Diol114835980
(    O
C4O42−    O
)    O
,    O
and    O
rhodizonate    O
(    O
C6O62−    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
2-lysophosphatidylcholine    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
glycerophosphocholine    B-Diol114835980
and    O
carboxylate    O
.    O

Croconic    B-Diol114835980
acid    I-Diol114835980
also    O
has    O
hydroxy    O
groups    O
.    O

Croconic    B-Diol114835980
acid    I-Diol114835980
,    O

Many    O
other    O
different    O
structures    O
have    O
been    O
used    O
for    O
their    O
muscle    O
relaxant    O
effect    O
such    O
as    O
alcuronium    B-Diol114835980
(    O
alloferin    O
)    O
,    O
anatruxonium    O
,    O
diadonium    O
,    O
fazadinium    O
(    O
AH8165    O
)    O
and    O
tropeinium    O
.    O

Alcuronium    B-Diol114835980

Aqueous    O
monoethanolamine    O
(    O
MEA    O
)    O
,    O
diglycolamine    O
(    O
DGA    O
)    O
,    O
diethanolamine    B-Diol114835980
(    O
DEA    O
)    O
,    O
diisopropanolamine    O
(    O
DIPA    O
)    O
and    O
methyldiethanolamine    B-Diol114835980
(    O
MDEA    O
)    O
are    O
widely    O
used    O
industrially    O
for    O
removing    O
carbon    O
dioxide    O
(    O
CO2    O
)    O
and    O
hydrogen    O
sulfide    O
(    O
H2S    O
)    O
from    O
natural    O
gas    O
and    O
refinery    O
process    O
streams    O
.    O

Fexofenadine    B-Diol114835980

Allergy    O
medications    O
containing    O
antihistamines    O
such    O
as    O
diphenhydramine    O
(    O
Benadryl    O
)    O
,    O
cetirizine    O
(    O
Zyrtec    O
)    O
,    O
loratidine    O
(    O
Claritin    O
)    O
,    O
cyproheptadine    O
(    O
Periactin    O
)    O
,    O
and    O
fexofenadine    B-Diol114835980
(    O
Allegra    O
)    O
may    O
be    O
taken    O
orally    O
to    O
prevent    O
and    O
relieve    O
some    O
of    O
the    O
hives    O
(    O
depending    O
on    O
the    O
severity    O
of    O
the    O
allergy    O
)    O
.    O

Fexofenadine    B-Diol114835980

Unlike    O
loratadine    O
or    O
fexofenadine    B-Diol114835980
,    O
clemastine    O
is    O
a    O
sedating    O
antihistamine    O
;    O
however    O
,    O
it    O
exhibits    O
fewer    O
other    O
side    O
effects    O
than    O
most    O
of    O
the    O
widely    O
used    O
antihistamines    O
.    O

Fexofenadine    B-Diol114835980
,    O
sold    O
under    O
the    O
trade    O
name    O
Allegra    B-Diol114835980
among    O
others    O
is    O
an    O
antihistamine    O
pharmaceutical    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
allergy    O
symptoms    O
,    O
such    O
as    O
hay    O
fever    O
,    O
nasal    O
congestion    O
,    O
and    O
urticaria    O
.    O

A.    O
flavus    O
"    O
also    O
produces    O
other    O
toxic    O
compounds    O
including    O
sterigmatocystin    O
,    O
cyclopiazonic    O
acid    O
,    O
kojic    O
acid    O
,    O
β-nitropropionic    O
acid    O
,    O
aspertoxin    O
,    O
aflatrem    O
,    O
gliotoxin    B-Diol114835980
,    O
and    O
aspergillic    O
acid    O
.    O

Gliotoxin    B-Diol114835980
is    O
a    O
sulfur    O
-    O
containing    O
mycotoxin    O
produced    O
by    O
several    O
species    O
of    O
fungi    O
under    O
investigation    O
as    O
an    O
antiviral    O
agent    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Diol114835980
and    O
sn-glycerol    B-Diol114835980
3-phosphate    I-Diol114835980
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CDP    O
-    O
glycerol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Diol114835980
and    O
N    O
-    O
acylneuraminate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CMP    O
-    O
N    O
-    O
acylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Diol114835980
and    O
N    O
-    O
methylethanolamine    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CDP    O
-    O
N    O
-    O
methylethanolamine    O
.    O

Phosphatidate    O
cytidylyltransferase    O
(    O
also    O
known    O
as    O
CDP-    O
diacylglycerol    O
synthase    O
)    O
(    O
CDS    O
)    O
is    O
the    O
enzyme    O
that    O
catalyzes    O
the    O
synthesis    O
of    O
CDP    O
-    O
diacylglycerol    O
from    O
cytidine    B-Diol114835980
triphosphate    I-Diol114835980
and    O
phosphatidate    O
.    O

However    O
,    O
archaeal    O
riboflavin    O
kinases    O
in    O
general    O
utilize    O
CTP    B-Diol114835980
rather    O
than    O
ATP    O
as    O
the    O
donor    O
nucleotide    O
,    O
catalyzing    O
the    O
reaction    O

Bis(2-Hydroxyethyl)    B-Diol114835980
terephthalate    I-Diol114835980
is    O
an    O
organic    O
compound    O
;    O
it    O
is    O
the    O
ester    O
of    O
ethylene    O
glycol    O
and    O
terephthalic    O
acid    O
.    O

In    O
addition    O
,    O
it    O
is    O
also    O
the    O
distributor    O
of    O
"    O
Yingtaiqing    O
"-    O
branded    O
generic    O
diclofenac    O
sodium    O
sustained    O
-    O
release    O
capsules    O
,    O
the    O
"    O
Faneng    O
"-    O
branded    O
generic    O
alfacalcidol    B-Diol114835980
soft    O
capsules    O
and    O
the    O
"    O
Yineng    O
"-    O
branded    O
generic    O
lentinan    O
injection    O
,    O
all    O
of    O
which    O
are    O
prescription    O
pharmaceuticals    O
manufactured    O
by    O
independent    O
third    O
parties    O
.    O

GMP    O
is    O
formed    O
by    O
the    O
inosinate    O
oxidation    O
to    O
xanthylate    B-Diol114835980
(    O
XMP    O
)    O
,    O
and    O
afterwards    O
adds    O
an    O
amino    O
group    O
on    O
carbon    O
2    O
.    O

Xanthosine    B-Diol114835980
monophosphate    I-Diol114835980

Xanthosine    B-Diol114835980
monophosphate    I-Diol114835980

It    O
is    O
restored    O
to    O
the    O
required    O
cofactor    O
tetrahydrobiopterin    B-Diol114835980
by    O
dihydrobiopterin    O
reductase    O
.    O

Tetrahydrobiopterin    B-Diol114835980

If    O
tetrahydrobiopterin    B-Diol114835980
deficiency    O
is    O
not    O
treated    O
,    O
excess    O
phenylalanine    O
can    O
build    O
up    O
to    O
harmful    O
levels    O
in    O
the    O
body    O
,    O
causing    O
intellectual    O
disability    O
and    O
other    O
serious    O
health    O
problems    O
.    O

High    O
levels    O
of    O
phenylalanine    O
are    O
present    O
from    O
infancy    O
in    O
people    O
with    O
untreated    O
tetrahydrobiopterin    B-Diol114835980
(    O
THB    O
,    O
BH4    O
)    O
deficiency    O
.    O

Tetrahydrobiopterin    B-Diol114835980
(    O
THB    O
,    O
BH4    O
)    O

PAH    O
is    O
one    O
of    O
three    O
members    O
of    O
the    O
biopterin    B-Diol114835980
-    O
dependent    O
aromatic    O
amino    O
acid    O
hydroxylases    O
,    O
a    O
class    O
of    O
monooxygenase    O
that    O
uses    O
tetrahydrobiopterin    B-Diol114835980
(    O
BH4    O
,    O
a    O
pteridine    O
cofactor    O
)    O
and    O
a    O
non    O
-    O
heme    O
iron    O
for    O
catalysis    O
.    O

From    O
2000–2010    O
,    O
Stevens    O
has    O
worked    O
with    O
BioMarin    O
Pharmaceutical    O
to    O
develop    O
KuvanTM    O
(    O
tetrahydrobiopterin    B-Diol114835980
)    O
and    O
assisted    O
in    O
the    O
design    O
and    O
development    O
of    O
PEG    O
-    O
PAL    O
(    O
pegylated    O
Phenylalanine    O
ammonia    O
-    O
lyase    O
)    O
as    O
treatments    O
for    O
mild    O
and    O
classical    O
phenylketonuria    O
(    O
PKU    O
)    O
.    O

Several    O
hydroxylase    O
enzymes    O
are    O
believed    O
to    O
incorporate    O
an    O
NIH    O
shift    O
in    O
their    O
mechanism    O
,    O
including    O
4-hydroxyphenylpyruvate    O
dioxygenase    O
and    O
the    O
tetrahydrobiopterin    B-Diol114835980
dependent    O
hydroxylases    O
.    O

Employing    O
intravascular    O
ultrasound    O
(    O
IVUS    O
)    O
,    O
they    O
showed    O
regression    O
of    O
the    O
atherosclerotic    O
plaques    O
in    O
response    O
to    O
a    O
high    O
dose    O
of    O
rosuvastatin    B-Diol114835980

Also    O
,    O
co    O
-    O
administration    O
of    O
eluxadoline    O
with    O
rosuvastatin    B-Diol114835980
may    O
increase    O
the    O
risk    O
of    O
rhabdomyolysis    O
.    O

The    O
AURORA    O
trial    O
(    O
A    O
Study    O
to    O
Evaluate    O
the    O
Use    O
of    O
Rosuvastatin    B-Diol114835980
in    O
Subjects    O
on    O
Regular    O
Hemodialysis    O
:    O
An    O
Assessment    O
of    O
Survival    O
and    O
Cardiovascular    O
Events    O
)    O
was    O
a    O
randomized    O
,    O
double    O
-    O
blind    O
,    O
placebo    O
-    O
controlled    O
study    O
investigating    O
the    O
use    O
of    O
rosuvastatin    B-Diol114835980
in    O
the    O
prevention    O
of    O
cardiovascular    O
disease    O
among    O
patients    O
undergoing    O
chronic    O
hemodialysis    O
.    O

The    O
trial    O
was    O
sponsored    O
,    O
in    O
part    O
,    O
by    O
AstraZeneca    O
,    O
the    O
marketer    O
of    O
Crestor    B-Diol114835980
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
4-diphosphocytidyl-2-C    O
-    O
methyl    O
-    O
D    O
-    O
erythritol    O
2-phosphate    O
(    O
CDP    O
-    O
MEP    O
)    O
,    O
and    O
two    O
products    O
,    O
2-C-methyl-D-erythritol    B-Diol114835980
2,4-cyclodiphosphate    I-Diol114835980
(    O
MEcPP    O
)    O
and    O
CMP    O
.    O

It    O
contains    O
large    O
quantities    O
of    O
the    O
extremely    O
toxic    O
alkaloid    O
pseudaconitine    B-Diol114835980
(    O
also    O
known    O
as    O
nepaline    O
,    O
after    O
Nepal    O
)    O
and    O
is    O
considered    O
to    O
be    O
the    O
most    O
poisonous    O
plant    O
found    O
in    O
the    O
Himalaya    O
and    O
one    O
of    O
the    O
most    O
poisonous    O
in    O
the    O
world    O
.    O

This    O
reaction    O
is    O
a    O
key    O
step    O
in    O
the    O
biosynthesis    O
of    O
sphingosine    B-Diol114835980
which    O
is    O
a    O
precursor    O
of    O
many    O
other    O
sphingolipids    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acyl    O
-    O
CoA    O
and    O
sphingosine    B-Diol114835980
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N    O
-    O
acylsphingosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP-choline    B-Diol114835980
and    O
sphingosine    B-Diol114835980
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    O
and    O
sphingosyl    O
-    O
phosphocholine    O
.    O

PAP    O
is    O
downregulated    O
by    O
sphingosine    B-Diol114835980
and    O
dihydrosphingosine    B-Diol114835980
.    O

The    O
lipid    O
complex    O
most    O
often    O
comprises    O
either    O
a    O
glycerol    O
or    O
a    O
sphingosine    B-Diol114835980
backbone    O
,    O
which    O
engenders    O
glyceroglycolipids    O
and    O
sphingolipids    O
,    O
the    O
two    O
main    O
categories    O
of    O
glycolipids    O
.    O

The    O
heads    O
of    O
glycolipids    O
(    O
glyco-    O
stands    O
for    O
sugar    O
)    O
contain    O
a    O
sphingosine    B-Diol114835980
with    O
one    O
or    O
several    O
sugar    O
units    O
attached    O
to    O
it    O
.    O

Sphingosine    B-Diol114835980
is    O
an    O
amino    O
alcohol    O
that    O
contains    O
a    O
long    O
,    O
unsaturated    O
hydrocarbon    O
chain    O
.    O

Lead    O
styphnate    O
(    O
lead    O
2,4,6-trinitroresorcinate    O
,    O
C6HN3O8Pb    O
)    O
,    O
whose    O
name    O
is    O
derived    O
from    O
styphnic    B-Diol114835980
acid    I-Diol114835980
,    O
is    O
an    O
explosive    O
used    O
as    O
a    O
component    O
in    O
primer    O
and    O
detonator    O
mixtures    O
for    O
less    O
sensitive    O
secondary    O
explosives    O
.    O

Two    O
formylation    O
reactions    O
are    O
required    O
in    O
the    O
eleven    O
step    O
de    O
novo    O
synthesis    O
of    O
inosine    B-Diol114835980
monophosphate    I-Diol114835980
(IMP)    I-Diol114835980
,    O
the    O
precursor    O
of    O
the    O
purine    O
ribonucleotides    O
AMP    O
and    O
GMP    O
.    O

Inosinic    B-Diol114835980
acid    I-Diol114835980
or    O
inosine    B-Diol114835980
monophosphate    I-Diol114835980
(    O
IMP    B-Diol114835980
)    O
is    O
a    O
nucleoside    O
monophosphate    O
.    O

The    O
umami    O
taste    O
is    O
most    O
frequently    O
associated    O
with    O
the    O
food    O
additive    O
monosodium    O
glutamate    O
(    O
MSG    O
)    O
and    O
can    O
be    O
enhanced    O
through    O
the    O
binding    O
of    O
inosine    B-Diol114835980
monophosphate    I-Diol114835980
(    O
IMP    O
)    O
and    O
guanosine    B-Diol114835980
monophosphate    I-Diol114835980
(    O
GMP    O
)    O
molecules    O
.    O

Poly    O
I    O
:    O
C    O
is    O
a    O
mismatched    O
double    O
-    O
stranded    O
RNA    O
with    O
one    O
strand    O
being    O
a    O
polymer    O
of    O
inosinic    B-Diol114835980
acid    I-Diol114835980
,    O
the    O
other    O
a    O
polymer    O
of    O
cytidylic    O
acid    O
.    O

It    O
is    O
produced    O
by    O
combining    O
the    O
sodium    O
salts    O
of    O
the    O
natural    O
compounds    O
guanylic    B-Diol114835980
acid    I-Diol114835980
(    O
E626    O
)    O
and    O
inosinic    B-Diol114835980
acid    I-Diol114835980
(    O
E630    O
)    O
.    O

Disodium    O
inosinate    O
(    O
E631    O
)    O
is    O
the    O
disodium    O
salt    O
of    O
inosinic    B-Diol114835980
acid    I-Diol114835980
with    O
the    O
chemical    O
formula    O
C10H11N4Na2O8P.    O
It    O
is    O
used    O
as    O
a    O
food    O
additive    O
and    O
often    O
found    O
in    O
instant    O
noodles    O
,    O
potato    O
chips    O
,    O
and    O
a    O
variety    O
of    O
other    O
snacks    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
inosine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
IMP    B-Diol114835980
.    O

Addressing    O
principle    O
#    O
7    O
is    O
a    O
green    O
route    O
to    O
1,3-propanediol    B-Diol114835980
,    O
which    O
is    O
traditionally    O
generated    O
from    O
petrochemical    O
precursors    O
.    O

In    O
2004    O
,    O
it    O
established    O
a    O
joint    O
venture    O
with    O
DuPont    O
to    O
manufacture    O
a    O
renewable    O
1,3-Propanediol    B-Diol114835980
that    O
can    O
be    O
used    O
to    O
make    O
Sorona    O
(    O
a    O
substitute    O
for    O
nylon    O
)    O
.    O

At    O
least    O
one    O
FAA    O
approved    O
deicing    O
fluid    O
(    O
Kilfrost    O
DF    O
Sustain    O
)    O
is    O
now    O
using    O
1,3-propanediol    B-Diol114835980
(    O
a    O
fermentation    O
product    O
of    O
corn    O
)    O
as    O
a    O
freezing    O
point    O
depressant    O
instead    O
of    O
ethylene    O
glycol    O
or    O
propylene    O
glycol    O
.    O

The    O
defect    O
in    O
red    O
cell    O
DNA    O
synthesis    O
is    O
most    O
often    O
due    O
to    O
hypovitaminosis    O
,    O
specifically    O
a    O
deficiency    O
of    O
vitamin    B-Diol114835980
B    I-Diol114835980
and/or    O
folic    O
acid    O
.    O

Selective    O
vitamin    B-Diol114835980
B12    I-Diol114835980
malabsorption    O
(    O
congenital    O
—    O
juvenile    O
megaloblastic    O
anemia    O
1—and    O
drug    O
-    O
induced    O
)    O

A    O
,    O
D3    O
,    O
E    O
,    O
B6    O
,    O
B12    B-Diol114835980
,    O
folic    O
acid    O
(    O
B9    O
)    O
,    O
ascorbic    O
acid    O
(    O
vitamin    O
C    O
)    O
,    O
along    O
with    O
a    O
vitamin    O
K    O
derivative    O
,    O
menadione    O
sodium    O
bisulfite    O
DVL    O
adds    O
these    O
vitamins    O
to    O
an    O
electrolyte    O
premix    O
that    O
has    O
7    O
mineral    O
salts    O
:    O
magnesium    O
acetate    O
,    O
sodium    O
acetate    O
,    O
calcium    O
acetate    O
,    O
potassium    O
chloride    O
,    O
calcium    O
chloride    O
,    O
sodium    O
chloride    O
and    O
sodium    O
diacetate    O
.    O

vitamins    O
(    O
folic    O
acid    O
,    O
nicotinamide    O
,    O
riboflavin    O
,    O
B12    B-Diol114835980
)    O

Patients    O
should    O
take    O
folic    O
acid    O
and    O
vitamin    B-Diol114835980
B12    I-Diol114835980
supplement    O
even    O
if    O
levels    O
are    O
normal    O
when    O
they    O
are    O
on    O
pemetrexed    O
therapy    O
.    O

Vitamin    B-Diol114835980
B12    I-Diol114835980
,    O
folic    O
acid    O
and    O
other    O
anti    O
-    O
megaloblastic    O
-    O
anaemia    O
preparations    O

Vitamin    B-Diol114835980
B12    I-Diol114835980
deficiency    O
anaemia    O

Vitamin    B-Diol114835980
B12    I-Diol114835980
deficiency    O
anaemia    O
due    O
to    O
intrinsic    O
factor    O
deficiency    O

Vitamin    B-Diol114835980
B    I-Diol114835980
12    I-Diol114835980
deficiency    O
anaemia    O
due    O
to    O
selective    O
vitamin    B-Diol114835980
B    I-Diol114835980
12    I-Diol114835980
malabsorption    O
with    O
proteinuria    O

Other    O
dietary    O
vitamin    B-Diol114835980
B    I-Diol114835980
12    I-Diol114835980
deficiency    O
anaemia    O

Other    O
vitamin    B-Diol114835980
B    I-Diol114835980
12    I-Diol114835980
deficiency    O
anaemias    O

Vitamin    B-Diol114835980
B    I-Diol114835980
12    I-Diol114835980
deficiency    O
anaemia    O
,    O
unspecified    O

It    O
has    O
3    O
cofactors    O
:    O
pyridoxal    O
phosphate    O
,    O
Cobamide    B-Diol114835980
coenzyme    I-Diol114835980
,    O
and    O
Dithiothreitol    B-Diol114835980
.    O

Vitamin    B-Diol114835980
B12    I-Diol114835980

Vitamin    B-Diol114835980
B12    I-Diol114835980

One    O
study    O
in    O
2014    O
pointed    O
to    O
certain    O
species    O
of    O
seaweed    O
as    O
being    O
a    O
possible    O
vegan    O
source    O
of    O
biologically    O
-    O
active    O
Vitamin    B-Diol114835980
B-12    I-Diol114835980
.    O

Diseases    O
that    O
may    O
present    O
similar    O
to    O
an    O
anxiety    O
disorder    O
,    O
including    O
certain    O
endocrine    O
diseases    O
(    O
hypo-    O
and    O
hyperthyroidism    O
,    O
hyperprolactinemia    O
)    O
,    O
metabolic    O
disorders    O
(    O
diabetes    O
)    O
,    O
deficiency    O
states    O
(    O
low    O
levels    O
of    O
vitamin    O
D    O
,    O
B2    O
,    O
B12    B-Diol114835980
,    O
folic    O
acid    O
)    O
,    O
gastrointestinal    O
diseases    O
(    O
celiac    O
disease    O
,    O
non    O
-    O
celiac    O
gluten    O
sensitivity    O
,    O
inflammatory    O
bowel    O
disease    O
)    O
,    O
heart    O
diseases    O
,    O
blood    O
diseases    O
(    O
anemia    O
)    O
,    O
and    O
brain    O
degenerative    O
diseases    O
(    O
Parkinson    O
's    O
disease    O
,    O
dementia    O
,    O
multiple    O
sclerosis    O
,    O
Huntington    O
's    O
disease    O
)    O
.    O

Vitamin    B-Diol114835980
B12    I-Diol114835980
,    O
or    O
cobalamin    O
,    O
acts    O
as    O
a    O
cofactor    O
for    O
the    O
enzyme    O
methionine    O
synthase    O
(    O
which    O
forms    O
part    O
of    O
the    O
S-adenosylmethionine    B-Diol114835980
(    O
SAMe    O
)    O
biosynthesis    O
and    O
regeneration    O
cycle    O
)    O
.    O

The    O
"    O
FIGLU    O
"    O
test    O
is    O
used    O
to    O
identify    O
deficiency    O
of    O
vitamin    B-Diol114835980
B12    I-Diol114835980
or    O
folate    O
deficiency    O
or    O
liver    O
disease    O
.    O

Indomie    O
is    O
made    O
from    O
flour    O
supplied    O
by    O
Bogasari    O
flour    O
mills    O
,    O
and    O
fortified    O
with    O
vitamin    O
A    O
,    O
B1    O
,    O
B6    O
,    O
B12    B-Diol114835980
,    O
niacin    O
,    O
folic    O
acid    O
and    O
iron    O
.    O

He    O
is    O
best    O
known    O
for    O
his    O
development    O
of    O
rapid    O
-    O
reaction    O
techniques    O
,    O
including    O
stopped    O
flow    O
and    O
rapid    O
freeze    O
-    O
quench    O
EPR    O
methods    O
,    O
as    O
tools    O
to    O
study    O
the    O
mechanisms    O
of    O
enzymes    O
containing    O
flavin    O
,    O
iron    O
,    O
cobalamin    B-Diol114835980
,    O
or    O
pyridoxal    O
phosphate    O
cofactors    O
.    O

Vitamin    B-Diol114835980
B12    I-Diol114835980
,    O
vitamin    O
C    O
and    O
thiamin    O

Vitamin    B-Diol114835980
B12    I-Diol114835980
deficiency    O
can    O
cause    O
demyelination    O
.    O

Hyperhomocysteine    O
,    O
a    O
condition    O
known    O
to    O
promote    O
clots    O
,    O
can    O
be    O
caused    O
by    O
a    O
combination    O
of    O
genetic    O
factors    O
and    O
vitamin    O
B6    O
,    O
vitamin    B-Diol114835980
b12    I-Diol114835980
and    O
folic    O
acid    O
deficiency    O
.    O

This    O
vitamin    B-Diol114835980
B12    I-Diol114835980
enzyme    O
catalyzes    O
the    O
isomerization    O
of    O
methylmalonyl    O
-    O
CoA    O
to    O
succinyl    O
-    O
CoA    O
in    O
humans    O
.    O

Regarding    O
autism    O
,    O
James    O
'    O
view    O
is    O
that    O
the    O
transsulfuration    O
pathway    O
is    O
disrupted    O
in    O
autistic    O
children    O
,    O
resulting    O
in    O
these    O
children    O
being    O
deficient    O
in    O
glutathione    O
,    O
as    O
well    O
as    O
vitamins    O
such    O
as    O
vitamin    O
B6    O
and    O
vitamin    B-Diol114835980
B12    I-Diol114835980
,    O
and    O
that    O
maternal    O
glutathione    O
deficiency    O
may    O
also    O
be    O
a    O
risk    O
factor    O
for    O
autism    O
.    O

Nitrous    O
oxide    O
is    O
thought    O
to    O
be    O
particularly    O
non    O
-    O
toxic    O
,    O
though    O
heavy    O
long    O
-    O
term    O
use    O
can    O
lead    O
to    O
a    O
variety    O
of    O
serious    O
health    O
problems    O
linked    O
to    O
destruction    O
of    O
vitamin    B-Diol114835980
B12    I-Diol114835980
and    O
folic    O
acid    O
.    O

Vitamin    B-Diol114835980
B12    I-Diol114835980

The    O
rings    O
of    O
porphyrin    O
are    O
components    O
of    O
hemoglobin    O
,    O
myoglobin    O
,    O
vitamin    B-Diol114835980
B12    I-Diol114835980
,    O
chlorophyll    O
,    O
and    O
cytochromes    O
.    O

H.    O
Boyd    O
Woodruff    O
(    O
1917    O
-    O
2017    O
)    O
,    O
soil    O
microbiologist    O
who    O
discovered    O
actinomycin    O
and    O
developed    O
industrial    O
production    O
by    O
fermentation    O
of    O
many    O
natural    O
products    O
,    O
including    O
cyanocobalamin    O
(    O
a    O
synthetic    O
form    O
of    O
Vitamin    B-Diol114835980
B12    I-Diol114835980
)    O
,    O
the    O
avermectins    O
and    O
other    O
important    O
antibiotics    O
.    O

In    O
nature    O
,    O
vitamin    B-Diol114835980
B12    I-Diol114835980
and    O
its    O
many    O
derivatives    O
contain    O
reactive    O
Co    O
-    O
alkyl    O
bonds    O
.    O

|rowspan=2|    O
Vitamin    B-Diol114835980
B12    I-Diol114835980
(    O
Cobalamin    O
)    O

Vitamin    B-Diol114835980
B12    I-Diol114835980
,    O
also    O
called    O
cobalamin    O
,    O
is    O
a    O
water    O
-    O
soluble    O
vitamin    O
that    O
has    O
a    O
key    O
role    O
in    O
the    O
normal    O
functioning    O
of    O
the    O
brain    O
and    O
nervous    O
system    O
via    O
the    O
synthesis    O
of    O
myelin    O
(    O
myelinogenesis    O
)    O
,    O
and    O
the    O
formation    O
of    O
red    O
blood    O
cells    O
.    O

Cyanocobalamin    O
is    O
a    O
synthetic    O
form    O
of    O
vitamin    B-Diol114835980
.    O
Vitamin    O
is    O
the    O
"    O
generic    O
descriptor    O
"    O
name    O
for    O
any    O
vitamers    O
of    O
vitamin    O
.    O

Vitamin    B-Diol114835980
B12    I-Diol114835980

A    O
corrole    O
is    O
an    O
aromatic    O
organic    O
chemical    O
tetrapyrrole    O
,    O
the    O
structure    O
of    O
which    O
is    O
similar    O
to    O
the    O
corrin    O
ring    O
,    O
which    O
is    O
also    O
present    O
in    O
cobalamin    O
(    O
vitamin    B-Diol114835980
B12    I-Diol114835980
)    O
.    O

Insects    O
such    O
as    O
crickets    O
and    O
meal    O
worms    O
have    O
high    O
concentrations    O
of    O
amino    O
acids    O
,    O
vitamin    B-Diol114835980
B12    I-Diol114835980
,    O
riboflavin    O
and    O
vitamin    O
A.    O
Insect    O
farming    O
is    O
cheaper    O
than    O
other    O
livestock    O
farming    O
and    O
requires    O
much    O
less    O
energy    O
and    O
space    O
.    O

Mary    O
Shaw    O
Shorb    O
,    O
research    O
scientist    O
,    O
invented    O
first    O
method    O
to    O
assay    O
Vitamin    B-Diol114835980
B-12    I-Diol114835980

A    O
small    O
serving    O
of    O
sardines    O
once    O
a    O
day    O
can    O
provide    O
up    O
to    O
13%    O
of    O
the    O
RDA    O
(    O
recommended    O
daily    O
allowance    O
)    O
value    O
of    O
vitamin    O
B2    O
;    O
roughly    O
one    O
-    O
quarter    O
of    O
the    O
RDA    O
of    O
niacin    O
,    O
and    O
about    O
150%    O
of    O
the    O
RDA    O
of    O
vitamin    B-Diol114835980
B12    I-Diol114835980
.    O

Before    O
this    O
procedure    O
is    O
undertaken    O
,    O
a    O
patient    O
will    O
generally    O
have    O
had    O
other    O
blood    O
tests    O
to    O
find    O
diagnostic    O
clues    O
,    O
including    O
a    O
complete    O
blood    O
count    O
,    O
renal    O
function    O
and    O
electrolytes    O
,    O
liver    O
enzymes    O
,    O
thyroid    O
function    O
tests    O
,    O
vitamin    B-Diol114835980
B12    I-Diol114835980
and    O
folic    O
acid    O
levels    O
.    O

He    O
made    O
significant    O
contributions    O
to    O
developing    O
a    O
therapy    O
for    O
vitamin    B-Diol114835980
B-12    I-Diol114835980
deficiency    O
.    O

Individual    O
fruits    O
weigh    O
between    O
270    O
and    O
480    O
mg    O
and    O
contain    O
high    O
amounts    O
of    O
vitamin    O
C    O
,    O
vitamin    O
E    O
,    O
carotenoids    O
,    O
flavonoids    O
and    O
health    O
-    O
beneficial    O
fatty    O
acids    O
,    O
as    O
well    O
as    O
higher    O
amounts    O
of    O
vitamin    B-Diol114835980
B12    I-Diol114835980
than    O
other    O
fruits    O
.    O

He    O
would    O
later    O
claim    O
to    O
have    O
received    O
a    O
tainted    O
Vitamin    B-Diol114835980
B12    I-Diol114835980
shot    O
from    O
teammate    O
Miguel    O
Tejada    O
.    O

The    O
failure    O
of    O
the    O
electrical    O
insulation    O
surrounding    O
nerves    O
,    O
the    O
myelin    O
,    O
is    O
seen    O
in    O
certain    O
deficiency    O
diseases    O
,    O
such    O
as    O
the    O
failure    O
of    O
the    O
body    O
's    O
system    O
for    O
absorbing    O
vitamin    B-Diol114835980
B-12    I-Diol114835980

Vitamin    B-Diol114835980
B12    I-Diol114835980
is    O
depleted    O
by    O
recreational    O
use    O
of    O
nitrous    O
oxide    O
,    O
and    O
is    O
thereby    O
useful    O
.    O

Haptocorrin    O
(    O
also    O
known    O
as    O
R    O
-    O
factor    O
)    O
:    O
Helps    O
with    O
the    O
absorption    O
of    O
vitamin    B-Diol114835980
B12    I-Diol114835980
.    O

Congenital    O
disorders    O
of    O
the    O
stomach    O
include    O
pernicious    O
anaemia    O
,    O
in    O
which    O
a    O
targeted    O
immune    O
response    O
against    O
parietal    O
cells    O
results    O
in    O
an    O
inability    O
to    O
absorb    O
vitamin    O
B12    B-Diol114835980
.    O

The    O
claims    O
of    O
Metabolite    O
's    O
patent    O
include    O
the    O
correlation    O
between    O
levels    O
of    O
homocysteine    O
and    O
vitamins    O
B6    O
and    O
B12    B-Diol114835980
.    O

Carbohydrates    O
,    O
fat    O
,    O
protein    O
,    O
niacin    O
,    O
pantothenic    O
acid    O
,    O
vitamin    O
B2    O
,    O
vitamin    O
B6    O
,    O
vitamin    B-Diol114835980
B12    I-Diol114835980
,    O
caffeine    O
,    O
taurine    O
.    O

It    O
contains    O
no    O
lactose    O
or    O
cholesterol    O
,    O
and    O
is    O
usually    O
sold    O
with    O
added    O
calcium    O
and    O
vitamins    O
,    O
especially    O
B12    B-Diol114835980
.    O

Budesonide    B-Diol114835980
,    O
by    O
its    O
trade    O
name    O
"    O
Giona    O
"    O

Amcinonide    O
,    O
budesonide    B-Diol114835980
,    O
desonide    O
,    O
fluocinolone    O
acetonide    O
,    O
fluocinonide    O
,    O
halcinonide    O
,    O
and    O
triamcinolone    B-Diol114835980
acetonide    I-Diol114835980
.    O

Budesonide    B-Diol114835980

Corticosteroids    O
:    O
Inhaled    O
corticosteroids    O
(    O
i.e.    O
fluticasone    O
,    O
budesonide    B-Diol114835980
)    O
are    O
typically    O
used    O
when    O
bronchoconstrictive    O
disease    O
has    O
advanced    O
to    O
a    O
persistent    O
inflammatory    O
state    O
,    O
more    O
specifically    O
in    O
persistent    O
or    O
severe    O
asthma    O
and    O
chronic    O
obstructive    O
pulmonary    O
disease    O
(    O
COPD    O
)    O
.    O

Budesonide    B-Diol114835980

In    O
this    O
case    O
,    O
the    O
main    O
compounds    O
used    O
are    O
beclometasone    O
,    O
budesonide    B-Diol114835980
,    O
fluticasone    O
,    O
mometasone    O
and    O
ciclesonide    O
.    O

Oenanthotoxin    B-Diol114835980

Antagonists    O
/    O
negative    O
allosteric    O
modulators    O
:    O
bicuculline    O
,    O
cicutoxin    B-Diol114835980
,    O
flumazenil    O
,    O
furosemide    O
,    O
gabazine    O
,    O
oenanthotoxin    B-Diol114835980
,    O
picrotoxin    B-Diol114835980
,    O
Ro15    O
-    O
4513    O
,    O
thujone    O
,    O
amentoflavone    O
.    O

16-"O    O
"-    O
Methylcafestol    O
,    O
a    O
derivative    O
of    O
cafestol    B-Diol114835980
,    O
is    O
an    O
isolate    O
of    O
green    O
coffee    O
beans    O
.    O

Examples    O
of    O
diterpenes    O
and    O
diterpenoids    O
are    O
cafestol    B-Diol114835980
,    O
kahweol    B-Diol114835980
,    O
cembrene    O
and    O
taxadiene    O
(    O
precursor    O
of    O
taxol    O
)    O
.    O

Common    O
matrices    O
include    O
glycerol    O
,    O
thioglycerol    B-Diol114835980
,    O
3-nitrobenzyl    O
alcohol    O
(    O
3-NBA    O
)    O
,    O
18-crown-6    O
ether    O
,    O
2-nitrophenyloctyl    O
ether    O
,    O
sulfolane    O
,    O
diethanolamine    B-Diol114835980
,    O
and    O
triethanolamine    O
.    O

Bronopol    B-Diol114835980

Tracheal    O
tubes    O
may    O
also    O
be    O
used    O
as    O
a    O
route    O
for    O
administration    O
of    O
certain    O
medications    O
such    O
as    O
salbutamol    B-Diol114835980
,    O
atropine    O
,    O
epinephrine    O
,    O
ipratropium    O
,    O
and    O
lidocaine    O
.    O

Salbutamol    B-Diol114835980
(    O
albuterol    O
)    O

In    O
the    O
normal    O
eye    O
,    O
beta-2    O
stimulation    O
by    O
salbutamol    B-Diol114835980
increases    O
intraocular    O
pressure    O
via    O
net    O
:    O

salbutamol    B-Diol114835980
(    O
INN    O
)    O
or    O
albuterol    O
(    O
USAN    O
)    O

salbutamol    B-Diol114835980
(    O
INN    O
)    O
or    O
albuterol    O
(    O
USAN    O
)    O

This    O
detail    O
is    O
not    O
lost    O
in    O
the    O
2006    O
film    O
remake    O
of    O
the    O
same    O
name    O
in    O
which    O
Le    O
Chiffre    O
played    O
by    O
Danish    O
actor    O
,    O
Mads    O
Mikkelsen    O
,    O
uses    O
a    O
platinum    O
cased    O
Salbutamol    B-Diol114835980
inhaler    O
.    O

Corticosteroids    O
and    O
bronchodilators    O
such    O
as    O
salbutamol    B-Diol114835980
(    O
"    O
albuterol    O
"    O
USAN    O
)    O
are    O
often    O
used    O
,    O
and    O
sometimes    O
in    O
combination    O
with    O
ipratropium    O
.    O

A    O
vial    O
of    O
0.5%    O
albuterol    B-Diol114835980
sulfate    O
as    O
inhalation    O
solution    O
for    O
nebulizing    O
.    O

These    O
hormones    O
and    O
medications    O
include    O
insulin    O
,    O
epinephrine    O
,    O
and    O
other    O
beta    O
agonists    O
(    O
e.g.    O
salbutamol    B-Diol114835980
or    O
salmeterol    B-Diol114835980
)    O
,    O
and    O
xanthines    O
(    O
e.g.    O
theophylline    O
)    O
.    O

Salbutamol    B-Diol114835980
(    O
albuterol    O
)    O
—    O
a    O
β2    O
agonist    O
.    O

Substances    O
that    O
may    O
cause    O
this    O
toxidrome    O
include    O
salbutamol    B-Diol114835980
,    O
amphetamines    O
,    O
cocaine    O
,    O
ephedrine    O
(    O
Ma    O
Huang    O
)    O
,    O
methamphetamine    O
,    O
phenylpropanolamine    O
(    O
PPA    O
's    O
)    O
,    O
and    O
pseudoephedrine    O
.    O

Still    O
others    O
(    O
e.    O
g.    O
salbutamol/аlbuterol    B-Diol114835980
,    O
fenoterol    O
)    O
have    O
to    O
be    O
applied    O
three    O
or    O
four    O
times    O
a    O
day    O
for    O
continuous    O
action    O
,    O
which    O
can    O
also    O
be    O
an    O
advantage    O
for    O
patients    O
who    O
need    O
to    O
apply    O
β2    O
agonists    O
only    O
occasionally    O
,    O
for    O
example    O
in    O
an    O
asthma    O
attack    O
.    O

An    O
in    O
-    O
competition    O
drug    O
test    O
at    O
the    O
2009    O
IPC    O
Swimming    O
European    O
Championships    O
found    O
high    O
levels    O
of    O
Salbutamol    B-Diol114835980
in    O
Frederiksen    O
's    O
bloodstream    O
.    O

These    O
medications    O
include    O
short    O
-    O
acting    O
beta    O
agonists    O
(    O
SABAs    O
)    O
such    O
as    O
albuterol    B-Diol114835980
which    O
typically    O
last    O
4–6    O
hours    O
,    O
and    O
long    O
-    O
acting    O
beta    O
agonists    O
(    O
LABAs    O
)    O
such    O
as    O
salmeterol    B-Diol114835980
which    O
lasts    O
12    O
hours    O
.    O

Salbutamol    B-Diol114835980

On    O
February    O
25    O
Pliușchins    O
Synergy    O
Baku    O
Cycling    O
Project    O
announced    O
it    O
had    O
suspended    O
him    O
for    O
a    O
non    O
-    O
negative    O
test    O
for    O
Salbutamol    B-Diol114835980
at    O
the    O
Sharjah    O
Cycling    O
Tour    O
(    O
a    O
race    O
he    O
won    O
)    O
whilst    O
riding    O
for    O
.    O

He    O
tested    O
positive    O
for    O
the    O
asthma    O
drug    O
salbutamol    B-Diol114835980
,    O
which    O
is    O
found    O
in    O
Ventolin    B-Diol114835980
.    O

In    O
December    O
2006    O
Trentin    O
tested    O
positive    O
for    O
salbutamol    B-Diol114835980
and    O
was    O
subsequently    O
handed    O
a    O
two    O
-    O
month    O
suspension    O
for    O
the    O
anti    O
-    O
doping    O
rule    O
violation    O
.    O

Both    O
vehicles    O
carry    O
a    O
variety    O
of    O
medical    O
supplies    O
and    O
equipment    O
including    O
oxygen    O
,    O
defibrillators    O
,    O
albuterol    B-Diol114835980
,    O
aspirin    O
,    O
naloxone    O
,    O
and    O
epinephrine    O
which    O
allow    O
life    O
saving    O
response    O
to    O
emergencies    O
.    O

A    O
dose    O
of    O
bronchodilator    O
medication    O
is    O
administered    O
by    O
means    O
of    O
inhaler    O
or    O
nebulizer    O
(    O
such    O
as    O
400mcg    O
of    O
salbutamol    B-Diol114835980
(    O
also    O
known    O
as    O
albuterol    O
)    O
)    O
.    O

They    O
additionally    O
contain    O
water    O
-    O
soluble    O
protein    O
-    O
pigment    O
complexes    O
that    O
exploit    O
carotenoids    O
such    O
as    O
peridinin    B-Diol114835980
to    O
extend    O
their    O
photosynthetic    O
capacity    O
.    O

SureLight    O
Dyes    O
(    O
APC    O
,    O
PerCP    B-Diol114835980
,    O
Phycobilisomes)(Columbia    O
Biosciences    O
)    O

Thiodiglycol    B-Diol114835980
,    O
or    O
bis(2-hydroxyethyl)sulfide    B-Diol114835980
(    O
also    O
known    O
as    O
2,2-thiodiethanol    B-Diol114835980
or    O
TDE    O
)    O
,    O
is    O
a    O
viscous    O
,    O
clear    O
to    O
pale    O
-    O
yellow    O
liquid    O
used    O
as    O
a    O
solvent    O
.    O

It    O
is    O
also    O
used    O
for    O
manufacture    O
of    O
thiodiglycol    B-Diol114835980
.    O

It    O
is    O
the    O
drug    O
in    O
the    O
feed    O
additives    O
called    O
Bovatec    B-Diol114835980
and    O
Avatec    B-Diol114835980
.    O

The    O
reaction    O
of    O
ammonia    O
produces    O
important    O
bulk    O
chemicals    O
such    O
as    O
ethanolamine    O
,    O
diethanolamine    B-Diol114835980
,    O
and    O
triethanolamine    O
.    O

Ethanolamine    O
is    O
prepared    O
by    O
a    O
ring    O
-    O
opening    O
reaction    O
with    O
ethylene    O
oxide    O
:    O
the    O
reaction    O
is    O
sometimes    O
allowed    O
to    O
go    O
further    O
to    O
produce    O
diethanolamine    B-Diol114835980
and    O
triethanolamine    O
.    O

Aqueous    O
monoethanolamine    O
(    O
MEA    O
)    O
,    O
diglycolamine    O
(    O
DGA    O
)    O
,    O
diethanolamine    B-Diol114835980
(    O
DEA    O
)    O
,    O
diisopropanolamine    O
(    O
DIPA    O
)    O
and    O
methyldiethanolamine    B-Diol114835980
(    O
MDEA    O
)    O
are    O
widely    O
used    O
industrially    O
for    O
removing    O
carbon    O
dioxide    O
(    O
CO2    O
)    O
and    O
hydrogen    O
sulfide    O
(    O
H2S    O
)    O
from    O
natural    O
gas    O
and    O
refinery    O
process    O
streams    O
.    O

Dithioerythritol    B-Diol114835980
(DTE)    I-Diol114835980
is    O
a    O
sulfur    O
containing    O
sugar    O
derived    O
from    O
the    O
corresponding    O
4-carbon    O
monosaccharide    O
erythrose    O
.    O

Hectorol    B-Diol114835980

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Diol114835980
and    O
RNAn    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
RNAn+1    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Diol114835980
and[N    O
-    O
acetyl    O
-    O
alpha    O
-    O
D    O
-    O
glucosamine    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Diol114835980
and    O
alpha    O
-    O
D    O
-    O
galactose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
galactose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Diol114835980
and    O
monosaccharide    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
monosaccharide    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Diol114835980
and    O
alpha    O
-    O
D    O
-    O
xylose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
xylose    O
.    O

Nalbuphine    B-Diol114835980

Nalbuphine    B-Diol114835980

A    O
variety    O
of    O
partial    O
agonists    O
or    O
mixed    O
agonists    O
-    O
antagonists    O
of    O
the    O
MOR    O
and    O
KOR    O
are    O
also    O
marketed    O
,    O
and    O
include    O
butorphanol    O
,    O
levorphanol    O
,    O
nalbuphine    B-Diol114835980
,    O
pentazocine    O
,    O
and    O
phenazocine    O
.    O

Synthesis    O
of    O
morphine    O
-    O
like    O
alkaloids    O
in    O
chemistry    O
describes    O
the    O
total    O
synthesis    O
of    O
the    O
natural    O
morphinan    O
class    O
of    O
alkaloids    O
that    O
includes    O
codeine    O
,    O
morphine    O
,    O
oripavine    O
,    O
and    O
thebaine    O
and    O
the    O
closely    O
related    O
semisynthetic    O
analogs    O
buprenorphine    O
,    O
hydrocodone    O
,    O
isocodeine    O
,    O
naltrexone    O
,    O
naloxone    O
,    O
nalbuphine    B-Diol114835980
,    O
and    O
oxycodone    O
.    O

Other    O
drugs    O
of    O
the    O
partial    O
mu    O
-    O
opioid    O
agonist    O
/    O
antagonist    O
type    O
include    O
meptazinol    O
,    O
buprenorphine    O
,    O
butorphanol    O
,    O
phenazocine    O
,    O
nalbuphine    B-Diol114835980
,    O
pentazocine    O
,    O
dezocine    O
and    O
its    O
relatives    O
.    O


